
<html lang="en"     class="pb-page"  data-request-id="07e73621-2097-45dd-90de-9e83c617fe03"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.8b01531;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-6;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects" /></meta><meta name="dc.Creator" content="Xiaoyun  Lu" /></meta><meta name="dc.Creator" content="Hao  Chen" /></meta><meta name="dc.Creator" content="Adam V.  Patterson" /></meta><meta name="dc.Creator" content="Jeff B.  Smaill" /></meta><meta name="dc.Creator" content="Ke  Ding" /></meta><meta name="dc.Description" content="Hepatocellular carcinoma (HCC) is a lethal disease with limited therapeutic options and a particularly poor prognosis. Aberrant fibroblast growth factor 19 (FGF19) signaling through fibroblast grow..." /></meta><meta name="Description" content="Hepatocellular carcinoma (HCC) is a lethal disease with limited therapeutic options and a particularly poor prognosis. Aberrant fibroblast growth factor 19 (FGF19) signaling through fibroblast grow..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 7, 2018" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01531" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01531" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01531" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01531" /></link>
        
    
    

<title>Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01531" /></meta><meta property="og:title" content="Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0017.jpeg" /></meta><meta property="og:description" content="Hepatocellular carcinoma (HCC) is a lethal disease with limited therapeutic options and a particularly poor prognosis. Aberrant fibroblast growth factor 19 (FGF19) signaling through fibroblast growth factor receptor 4 (FGFR4) has been identified as an oncogenic driver for a subset of patients with HCC. FGFR4 is therefore a promising target for the treatment of HCC harboring aberrant FGF19-FGFR4 signaling, and several FGFR4 inhibitors have advanced to clinical trial. In this review, we summarize the latest developments in FGFR4 inhibitors, including the known pharmacophores, their binding mode, selectivity, and clinical implications, as well as the optimization strategy of introducing an acrylamide into a known pan-FGFR inhibitor targeting Cys552 of FGFR4 to provide selective covalent FGFR4 inhibitors." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01531"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01531">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01531&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01531&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01531&amp;href=/doi/10.1021/acs.jmedchem.8b01531" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 2905-2915</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01105" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.8b01216" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects</span></h1><h2 class="article_header-subtitle"><span class="hlFld-SubTitle">Miniperspective</span></h2><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xiaoyun Lu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaoyun Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou 510632, China</div></div><span class="conrtib-corresp"><strong>*</strong>X. L.: e-mail, <a href="/cdn-cgi/l/email-protection#3c504944450e0c0d0a7c56524912595849125f52"><span class="__cf_email__" data-cfemail="cca0b9b4b5fefcfdfa8ca6a2b9e2a9a8b9e2afa2">[email protected]</span></a>; phone, +86-20-85223259; fax, +86-20-85224766.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoyun++Lu">Xiaoyun Lu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7931-6873" title="Orcid link">http://orcid.org/0000-0001-7931-6873</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hao Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hao Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou 510632, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hao++Chen">Hao Chen</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Adam V. Patterson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Adam V. Patterson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</div><div class="loa-info-affiliations-info">Translational Therapeutics Team, Auckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Adam+V.++Patterson">Adam V. Patterson</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeff B. Smaill</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeff B. Smaill</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</div><div class="loa-info-affiliations-info">Translational Therapeutics Team, Auckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</div></div><span class="conrtib-corresp"><strong>*</strong>J.B.S.: e-mail, <a href="/cdn-cgi/l/email-protection#6e04401d030f0702022e0f1b0d05020f000a400f0d400014"><span class="__cf_email__" data-cfemail="bcd692cfd1ddd5d0d0fcddc9dfd7d0ddd2d892dddf92d2c6">[email protected]</span></a>; phone, +64-9-9236798.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeff+B.++Smaill">Jeff B. Smaill</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Ke Ding</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ke Ding</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou 510632, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ke++Ding">Ke Ding</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9016-812X" title="Orcid link">http://orcid.org/0000-0001-9016-812X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01531&amp;href=/doi/10.1021%2Facs.jmedchem.8b01531" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 2905–2915</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 7, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 October 2018</li><li><span class="item_label"><b>Published</b> online</span>7 November 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 March 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01531" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01531</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2905%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXiaoyun%2BLu%252C%2BHao%2BChen%252C%2BAdam%2BV.%2BPatterson%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D6%26contentID%3Dacs.jmedchem.8b01531%26title%3DFibroblast%2BGrowth%2BFactor%2BReceptor%2B4%2B%2528FGFR4%2529%2BSelective%2BInhibitors%2Bas%2BHepatocellular%2BCarcinoma%2BTherapy%253A%2BAdvances%2Band%2BProspects%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2915%26publicationDate%3DMarch%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01531"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3619</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">24</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01531" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xiaoyun&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Hao&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Adam&quot;,&quot;last_name&quot;:&quot;V. Patterson&quot;},{&quot;first_name&quot;:&quot;Jeff&quot;,&quot;last_name&quot;:&quot;B. Smaill&quot;},{&quot;first_name&quot;:&quot;Ke&quot;,&quot;last_name&quot;:&quot;Ding&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;2905-2915&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01531&quot;},&quot;abstract&quot;:&quot;Hepatocellular carcinoma (HCC) is a lethal disease with limited therapeutic options and a particularly poor prognosis. Aberrant fibroblast growth factor 19 (FGF19) signaling through fibroblast growth factor receptor 4 (FGFR4) has been identified as an oncogenic driver for a subset of patients with HCC. FGFR4 is therefore a promising target for the treatment of HCC harboring aberrant FGF19-FGFR4 signaling, and several FGFR4 inhibitors have advanced to clinical trial. In this review, we summarize the latest developments in FGFR4 inhibitors, including the known pharmacophores, their binding mode, selectivity, and clinical implications, as well as the optimization strategy of introducing an acrylamide into a known pan-FGFR inhibitor targeting Cys552 of FGFR4 to provide selective covalent FGFR4 inhibitors.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01531&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01531" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01531&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01531" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01531&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01531" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01531&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01531&amp;href=/doi/10.1021/acs.jmedchem.8b01531" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01531" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01531" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01531%26sid%3Dliteratum%253Aachs%26pmid%3D30403487%26genre%3Darticle%26aulast%3DLu%26date%3D2019%26atitle%3DFibroblast%2BGrowth%2BFactor%2BReceptor%2B4%2B%2528FGFR4%2529%2BSelective%2BInhibitors%2Bas%2BHepatocellular%2BCarcinoma%2BTherapy%253A%2BAdvances%2Band%2BProspects%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D6%26spage%3D2905%26epage%3D2915%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291763" title="Noncovalent interactions">Noncovalent interactions</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/jmcmar.2019.62.issue-6/20190328/jmcmar.2019.62.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Hepatocellular carcinoma (HCC) is a lethal disease with limited therapeutic options and a particularly poor prognosis. Aberrant fibroblast growth factor 19 (FGF19) signaling through fibroblast growth factor receptor 4 (FGFR4) has been identified as an oncogenic driver for a subset of patients with HCC. FGFR4 is therefore a promising target for the treatment of HCC harboring aberrant FGF19-FGFR4 signaling, and several FGFR4 inhibitors have advanced to clinical trial. In this review, we summarize the latest developments in FGFR4 inhibitors, including the known pharmacophores, their binding mode, selectivity, and clinical implications, as well as the optimization strategy of introducing an acrylamide into a known pan-FGFR inhibitor targeting Cys552 of FGFR4 to provide selective covalent FGFR4 inhibitors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76541" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76541" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Hepatocellular carcinoma (HCC), accounting for 85–90% of primary liver cancer, is commonly associated with underlying chronic liver disease arising from viral infection, metabolic disorders, or alcohol abuse.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> HCC has become the sixth most common cancer worldwide with over 780 000 new cases diagnosed each year.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> HCC is refractory to conventional chemotherapy, and there has been minimal progress in the standard of care for the treatment of this disease in the past 20 years. The multikinase inhibitor sorafenib was approved for use in advanced HCC in 2007 based on a 3 month improvement in median survival and time to progression.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In 2017, another multikinase inhibitor regorafenib was approved for the treatment of patients with HCC in Japan and the EU who have previously been treated with sorafenib.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In the same year nivolumab was granted accelerated approval by the FDA for HCC patients previously treated with sorafenib, following reports of a 14.3% response rate in a 154-patient subgroup of the CHECKMATE-040 clinical trial (NCT01658878). Despite this encouraging progresses, there remains an urgent need to develop new therapies for HCC.</div><div class="NLM_p last">Fibroblast growth factor receptor 4 (FGFR4) is a tyrosine kinase receptor that selectively binds fibroblast growth factor 19 (FGF19) to stimulate autophosphorylation in trans and mediates cellular effects via downstream MAP kinase and AKT signaling pathways.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> Aberrant signaling through the FGF19-FGFR4 complex has been validated as an oncogenic driver of HCC.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> FGFR4 has therefore been considered as a novel potential target for the treatment of FGFR4-dependent diseases, and in particular HCC. Several small molecule FGFR4 inhibitors with different selectivity profiles and binding modes have been developed and advanced to clinical trial for the treatment of HCC and other solid tumors harboring aberrant FGFR4 signaling.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> In this review, we focus on current developments in our understanding of the pharmacophores utilized, their binding modes and the kinome selectivity of current FGFR4 inhibitors. We further detail their clinical implications, with special attention paid to reversible covalent FGFR4 inhibitors. We also describe the medicinal chemistry optimization strategy utilizing the introduction of an acrylamide into a known pan-FGFR inhibitor targeting Cys552 of FGFR4 to provide selective covalent FGFR4 inhibitors.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  FGF19/FGFR4 and HCC</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05708" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05708" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">FGFR4 is highly expressed in liver tissue and specifically utilizes endocrine FGF19 as its intracellular ligand.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> First, FGF19 binds to a binary complex formed by FGFR4 and β-Klotho, a single-pass transmembrane co-receptor, leading to FGFR4 dimerization and autophosphorylation in trans.<a onclick="showRef(event, 'ref6 ref11'); return false;" href="javascript:void(0);" class="ref ref6 ref11">(6,11)</a> Subsequently, activated FGFR4 engages in the phosphorylation of FGF receptor substrate 2 (FRS2), leading to the recruitment of growth factor receptor-bound protein 2 (GRB2). By docking of adaptor proteins, the subsequent FGFR4 signaling complex may lead to the activation of four signaling branches PI3K/AKT, PLCγ/DAG/PKC, RAS/RAF/MAPK, and GSK3β/β-catenin, which are involved in proliferation, antiapoptosis, angiogenesis, drug resistance, invasion, and epithelial-to-mesenchymal transition (EMT) in HCC cells (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a><b>)</b>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. FGF19-FGFR4 mediated signaling pathway. FGF19 regulates cell functions by binding with its receptor FGFR4 and co-receptor β-Klotho, leading to the activation of four signaling branches PI3K/AKT (depicted in yellow), PLCγ/DAG/PKC (green), RAS/RAF/MAPK (gray), and GSK3β/β-catenin (orange), which are involved in proliferation, antiapoptosis, angiogenesis, drug resistance, invasion, and epithelial-to-mesenchymal transition (EMT) in HCC cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Nicholes et al. first demonstrated that overexpression of FGF19 at an ectopic site led to liver dysplasia and HCC in transgenic mice.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Later, Wu et al. revealed that FGF19 increased hepatocyte proliferation by activating FGFR4 to induce HCC.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> In addition, FGF19 and its receptor FGFR4 have been shown to be involved in EMT in HCC cells through modulating the GSK3β/β-catenin signaling cascade.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Moreover, it was found that downregulation of the FGFR4/FGF19 signaling pathway by small interfering RNA or by an autoinhibitory soluble domain (solFGFR4) led to decreased viability, invasion, and tumor formation of HCC in SCID mice.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> These data suggested that targeting FGF19/FGFR4-mediated signaling provided a new promising strategy in HCC therapy.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">3.  Structure of FGFR4</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32314" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32314" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">FGFR4 contains 802 amino acids composed of three immunoglobulin-like domains (D1–D3), a single-pass transmembrane domain, and a cytoplasmic intracellular split domain with tyrosine kinase function (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>),<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> which is conserved in the four FGFR subtypes. D1 and the acidic box, a unique sequence in the linker between D1 and D2, function as a receptor autoinhibition motif, while the D2 and D3 domains are vital for ligand binding and specificity (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The intracellular kinase domain acts as an activator of downstream pathways by direct phosphorylation or recruitment of adaptor proteins.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic structure overview of FGFR4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">FGFR4 kinase domain has a typical protein kinase structure with two canonical domains: a smaller N-terminal domain composed of a five-stranded β sheet and the αC-helix, and a larger C-terminal domain composed of several α-helixes (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The nonphosphorylated FGFR4 kinase is in an autoinhibited state, which is maintained by a hydrogen bond network termed a “molecular brake”.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Sequence alignment of human FGFR4 and FGFR1/2/3 demonstrated that they share 74–92% sequence identity in the kinase domain;<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> thus development of ATP-competitive FGFR4 isoform-selective inhibitors is challenging. However, one poorly conserved cysteine located at position 552 (Cys552) in the middle-hinge region of the ATP binding site of FGFR4 (corresponding tyrosine in FGFR1/2/3) has been exploited as a potential site to develop selective inhibitors of FGFR4 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> In addition, another cysteine at position 477 of the P-loop of FGFR4 can also be a potential site for developing covalent pan-FGFR inhibitors due to its presence in all four FGFR subtypes.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structural overview of a cocrystal structure of FGFR4 with BLU9931 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4xcu">4xcu</a>). Expanded view is comparison of Cys552 in FGFR4 and Tyr 563 in FGFR1 (PD code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4v04">4v04</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">4.  Small Molecule Inhibitors of FGFR4</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11847" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11847" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Given the contribution of FGFR4 signaling in HCC progression, clinical therapies are urgently needed to target the FGFR4 pathway. Several FGFR4 inhibitors have been evaluated in early phase clinical trials for the treatment of HCC and other cancers (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Classification and Representative FGFR4 Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">classification</th><th class="colsep0 rowsep0" align="center">name</th><th class="colsep0 rowsep0" align="center">organization</th><th class="colsep0 rowsep0" align="center">research status</th><th class="colsep0 rowsep0" align="center">clinical trial number</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pan-FGFR inhibitors</td><td class="colsep0 rowsep0" align="left">LY2874455</td><td class="colsep0 rowsep0" align="left">Eli Lilly</td><td class="colsep0 rowsep0" align="left">Phase II</td><td class="colsep0 rowsep0" align="left">NCT01212107</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">JNJ42756493</td><td class="colsep0 rowsep0" align="left">Janssen</td><td class="colsep0 rowsep0" align="left">Phase II</td><td class="colsep0 rowsep0" align="left">NCT02365597</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT02699606</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PRN1371</td><td class="colsep0 rowsep0" align="left">Principia Biopharma</td><td class="colsep0 rowsep0" align="left">Phase I</td><td class="colsep0 rowsep0" align="left">NCT02608125</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AZD4547</td><td class="colsep0 rowsep0" align="left">AstraZeneca</td><td class="colsep0 rowsep0" align="left">Phase II</td><td class="colsep0 rowsep0" align="left">NCT00979134</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BGJ398</td><td class="colsep0 rowsep0" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">Phase II</td><td class="colsep0 rowsep0" align="left">NCT01697605</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT01975701</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Aminopyrazole</td><td class="colsep0 rowsep0" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">Discovery</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR4 selective inhibitors</td><td class="colsep0 rowsep0" align="left">BLU9931</td><td class="colsep0 rowsep0" align="left">Blueprint</td><td class="colsep0 rowsep0" align="left">Preclincal</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BLU554</td><td class="colsep0 rowsep0" align="left">Blueprint</td><td class="colsep0 rowsep0" align="left">Phase I</td><td class="colsep0 rowsep0" align="left">NCT02508467</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">H3B-6527</td><td class="colsep0 rowsep0" align="left">H3 Biomedicine</td><td class="colsep0 rowsep0" align="left">Phase I</td><td class="colsep0 rowsep0" align="left">NCT02834780</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">FGF401</td><td class="colsep0 rowsep0" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">Phase I/II</td><td class="colsep0 rowsep0" align="left">NCT02325739</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Aminopyrimidine</td><td class="colsep0 rowsep0" align="left">GIBH and WuXi AppTec</td><td class="colsep0 rowsep0" align="left">Candidate selected</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Dipyridylamine</td><td class="colsep0 rowsep0" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">Discovery</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div></div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">4.1.  Nonselective FGFR4 Inhibitors</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8">4.1.1.  Multitargeted Kinase Inhibitors</h4><div class="NLM_p">Receptor tyrosine kinases (RTKs) possess a high sequence and structural homology in the kinase domain. To date, several known multitargeted RTK inhibitors have been studied for the suppression of FGFR signaling, such as ponatinib,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> nintedanib,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> dovitinib,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and lucitanib.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The multikinase inhibitor ponatinib by way of an example (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A) has been approved for the treatment of patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) by virtue of targeting ABL kinase.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> In 2012, ARIAD Pharmaceuticals also reported ponatinib inhibited the in vitro kinase activity of FGFR1/2/3/4 with IC<sub>50</sub> values of 2, 2, 18, and 8 nM, respectively.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> X-ray structural analysis of a ponatinib/FGFR4 complex confirmed ponatinib bound to FGFR4 with a type II binding mode and maintained a network of protein contacts similar to those observed when binding ABL kinase (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B).<a onclick="showRef(event, 'ref19 ref27'); return false;" href="javascript:void(0);" class="ref ref19 ref27">(19,27)</a> The imidazo[1,2-<i>b</i>]pyridazine core makes a hydrogen bond with Ala553, the amide linker forms two hydrogen bonds with Glu520 and Asp630, and the trifluoromethylphenyl group binds deeply into the hydrophobic pocket. Further cellular assays and in vivo studies suggested that ponatinib may serve as a potential treatment for FGFR-driven solid tumors.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> However, the toxicity profile of ponatinib related to on-target activity against the VEGF receptors restricts its further development for the treatment of HCC.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> In this regard, it has been suggested that more selective FGFR inhibitors may have the potential to display an improved therapeutic margin relative to multitargeted RTK inhibitors.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Chemical structure and pharmacophore of ponatinib. (B) Binding mode of ponatinib with FGFR4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4uxq">4uxq</a>). Hydrogen bonds are indicated by yellow dashed lines to key amino acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9">4.1.2.  Pan-FGFR Inhibitors</h4><div class="NLM_p">The reported clinical pan-FGFR inhibitors with potent FGFR4 inhibitory activity (LY2874455, JNJ-42756463 and PRN1371) are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Some others with relatively weak FGFR4 inhibitory activity (AZD4547and BGJ398) are not described here.</div><div id="sec4_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i10" class="anchor-spacer"></div><h5 class="article-section__title" id="_i10">4.1.2.1.  LY2874455</h5><div class="NLM_p">LY2874455 (<b>2</b>) is a pan-FGFR inhibitor with low nanomolar potency in biochemical assays against all four FGFR isoforms (IC<sub>50</sub> values of 2.8, 2.6, 6.4, and 6 nM for FGFR1/2/3/4, respectively) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A), whereas is about 6- to 9-fold less potent against VEGFR2.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> LY2874455 discovery was based on a novel indazole scaffold, but the detailed SAR studies have not yet been reported. It exhibits potent inhibition of multiple cancer cell lines mediated by FGF/FGFR signaling (IC<sub>50</sub> = 0.57–290.7 nM). Further, LY2874455 displays potent in vivo anticancer activity in several tumor xenograft models without evidence of off-target VEGFR2-mediated toxicities. An X-ray crystal structure of LY2874455 with FGFR4 demonstrated LY2874455 is a type I inhibitor that binds to the DFG-in active conformation of FGFR4 with conserved interactions as for FGFR1/2/3 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Briefly, the indazolyl ring forms two hydrogen bonds with hinge residues Glu551 and Ala553, while the dichloropyridinyl ring occupies a hydrophobic pocket with the pyridyl nitrogen forming a hydrogen bond with Asn557. In addition, the ethoxyl substituted 2-vinylpyrazolyl group is directed toward solvent accessible space. LY2874455 is being evaluated in phase II clinical trial by Eli Lilly for the treatment of patients with advanced cancer (NCT01212107).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Structure and pharmacophore of LY2874455. (B) Binding mode of LY2874455 with FGFR4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JKG">5JKG</a>). Hydrogen bonds are indicated by yellow dashed lines to key amino acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_1_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i11" class="anchor-spacer"></div><h5 class="article-section__title" id="_i11">4.1.2.2.  JNJ-42756463</h5><div class="NLM_p">Like LY2874455, JNJ-42756493 (<b>3</b>, erdafitinib) is also a potent inhibitor of the FGFR1/2/3/4 isoforms with similar IC<sub>50</sub> values of 1.2, 2.5, 3.0, and 5.7 nM, respectively (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A),<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> while it also inhibited VEGFR2 with an IC<sub>50</sub> value of 36.8 nM. Publication of an FGFR1/JNJ-42756493 X-ray cocrystal structure provided a detailed binding interaction conserved across the other FGFR isoforms (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Counterscreening against 451 kinases (KINOMEscan) indicated the low selectivity of JNJ-42756493 might lead to side effects due to off-target action. Nevertheless, JNJ-42756493 exhibited potent in vitro and in vivo anticancer activity against tumors with activating FGFR alterations. JNJ-42756463 is now in phase II trial for the treatment of metastatic or surgically unresectable urothelial cancer (NCT02365597) and non-small cell lung cancer, gastric cancer, esophageal cancer, and cholangiocarcinoma (NCT02699606). Janssen Pharmaceuticals has recently announced that JNJ-42756493 has been granted breakthrough therapy designation by FDA for the treatment of metastatic urothelial cancer.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Structure and pharmacophore of JNJ-42756493. (B) Binding mode of JNJ-42756493 with FGFR1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EW8">5EW8</a>). Hydrogen bonds are indicated by yellow dashed lines to key amino acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_1_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i12" class="anchor-spacer"></div><h5 class="article-section__title" id="_i12">4.1.2.3.  PRN1371</h5><div class="NLM_p">Unlike LY2874455 and JNJ-42756493, PRN1371 (<b>4</b>) is an irreversible (or covalent) pan-FGFR inhibitor designed to covalently bind a conserved cysteine located on the p-loop of FGFR1–4 (numbered Cys477 in FGFR4) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> PRN1371 exhibited strong potency against FGFR1/2/3/4 with IC<sub>50</sub> values of 0.7, 1.3, 4.1, and 19.3 nM, respectively, while sparing VEGFR2 (IC<sub>50</sub> = 705 nM). PRN1371 also displayed excellent kinome-wide selectivity and potency against cancer cells harboring FGFR alterations.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Moreover, PRN1371 had favorable PK characteristics and sustained FGFR inhibition in vivo following clearance of drug from circulation. Thus, PRN1371 exhibited strong activity in multiple tumor xenografts and patient-derived tumor xenograft (PDX) models driven by FGFR alterations. PRN1371 is in phase I clinical development under sponsorship of Principia Biopharma for the treatment of solid tumors (NCT02608125).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structure and pharmacophore of PRN1371.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_1_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i13" class="anchor-spacer"></div><h5 class="article-section__title" id="_i13">4.1.2.4.  Aminopyrazole</h5><div class="NLM_p">Novartis reported an optimization strategy directed toward improved FGFR4-selectivity involving introduction of an acrylamide into the pan-FGFR inhibitor scaffold of AZD4547 (<b>5</b>).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Aminopyrazole <b>6</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), designed to target Cys552 unique to FGFR4, unfortunately lacked the FGFR4-selectivity sought, instead displaying potent inhibitory activity against FGFR1/2/3/4 (IC<sub>50</sub> = 1.5, 4.5, 2.2, and 1.7 nM, respectively). Further biochemical analysis demonstrated that compound <b>6</b> was 400-fold less active against FGFR4<sup>C477A</sup> when compared to FGFR4 wild type, whereas a loss of only 5-fold in activity was observed with FGFR4<sup>C552A</sup>, which strongly supports Cys447 (common to all four isoforms) as the primary site of covalent reaction of <b>6</b> with FGFR4.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> An X-ray crystal structure of compound <b>6</b> with FGFR4 was determined to further clarify its binding mode. The aminopyrazole core was found to form three hydrogen bonds with the hinge residues Ala553 and Glu551 in the proximity of Cys552. The acrylamide moiety was determined to form a covalent bond with Cys477. In addition, the dimethoxyphenyl group occupied the hydrophobic pocket with an additional hydrogen bond to Asp630. The positioning of the aminopyrazole core in the hinge region and the formation of an intramolecular hydrogen bond between the N–H of the acrylamide and carbonyl group of the inhibitor phenyl carboxamide support formation of two hydrogen bonds between the acrylamide carbonyl and Asn557, features of the binding mode that all serve to position the acrylamide Michael acceptor toward Cys477.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Optimization strategy of compound <b>6</b>. (B) Binding mode of <b>6</b> with FGFR4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5nwz">5nwz</a>). Hydrogen bonds are indicated by yellow dashed lines to key amino acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">4.2.  Selective FGFR4 Inhibitors</h3><div class="NLM_p">Collectively, early trials of several pan-FGFR inhibitors have proven encouraging for the treatment of patients with various FGFR fusions, including muscle-invasive urothelial carcinoma, glioma, and biliary tract cancers including cholangiocarcinomas.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> However, hyperphosphatemia is a commonly observed adverse effect for pan-FGFR inhibitors such as JNJ-42756493<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> and BGJ398.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> This serious toxicity, requiring strategies that mitigate plasma phosphate increases, has been attributed to on-target systemic inhibition of FGFR1 and FGFR3, leading to blockade of FGF23 mediated signaling disrupting normal phosphate homeostasis.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Hence, compounds that are able to selectively target FGFR4 while sparing its isoforms (FGFR1/2/3) may demonstrate an improved therapeutic margin and may therefore be of significant promise. However, given the high sequence homology between the ATP-binding pockets of the FGFR family, developing FGFR4 selective inhibitors represents a major challenge in oncology. To this end, several classes of FGFR4 selective inhibitors that target the unique cysteine 552 have been reported (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15">4.2.1.  Irreversible Inhibitors</h4><div id="sec4_2_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i16" class="anchor-spacer"></div><h5 class="article-section__title" id="_i16">4.2.1.1.  BLU9931 and BLU554</h5><div class="NLM_p">With the aim of discovering FGFR4 selective inhibitors, Blueprint Medicines developed a series of compounds based on an anilinoquinazoline scaffold utilizing structure-based design methods to covalently target Cys552 in the hinge region of FGFR4 (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Briefly, inspired by the high potency and good selectivity of the pan-FGFR inhibitor PD173074 (<b>7</b>), a 2,6-dichloro-3,5-dimethoxyphenyl group (<b>8</b>) was introduced instead of the dimethoxyphenyl moiety of <b>7</b> to occupy the hydrophobic back pocket. Further optimization of the aniline ring included introduction of an electrophilic acrylamide at the <i>ortho</i>-position (<b>9</b>) that was capable of forming a covalent bond with Cys552 in FGFR4. However, possibly due to the undesirable rotational angle between the aniline group and the quinazoline core, compound <b>9</b> did not exhibit the desired selectivity for FGFR4. Thus, a methyl group was introduced at the remaining <i>ortho</i>-position of the aniline ring to increase the rotation of this ring out of plane with the quinazoline core, leading to BLU9931 (<b>10</b>). An X-ray crystal structure of FGFR4 and BLU9931 revealed that the aminoquinazoline core formed two hydrogen bonds with the hinge region Ala553 while the acrylamide successfully formed a covalent bond with Cys552 to achieve potent FGFR4 activity and the desired selectivity over FGFR1/2/3 (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). In addition, the dichlorodimethoxyphenyl group occupied the hydrophobic pocket in a similar manner to the known pan-FGFR inhibitors.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Optimization process of BLU9931 and BLU554.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Binding mode of BLU9931with FGFR4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4xcu">4xcu</a>). Hydrogen bonds are indicated by yellow dashed lines to key amino acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">BLU9931 demonstrated potent FGFR4 activity (IC<sub>50</sub> = 3 nM) with good selectivity over FGFR1/2/3 (IC<sub>50</sub> = 591, 493, and 150 nM, respectively). BLU9931 also displayed excellent kinome-wide selectivity and inhibited the proliferation of HCC cell lines with an activated FGFR4 signaling pathway. BLU9931 induced apoptosis in Hep3B human liver cancer cells and significantly inhibited growth of Hep3B tumor xenografts in nude mice at 100 and 300 mg/kg po b.i.d. with no significant changes in body weight. BLU9931 represents a first-in-class irreversible selective FGFR4 inhibitor for the treatment of HCC patients with aberrant FGFR4 signaling. However, BLU9931 has not entered clinical study.</div><div class="NLM_p last">Further optimization of BLU9931 with the aim of improving its physicochemical properties afforded the clinical candidate BLU554 (<b>11</b>).<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> BLU554 is currently in phase I clinical trials for the treatment of hepatocellular carcinoma (NCT02508467) and has also been granted orphan drug designation by FDA in 2015. An interim analysis of the phase I study reports that BLU554 is efficacious in HCC patients with an overall response rate (ORR) of 16% and a disease control rate of 68%.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The most common and more serious grade 3–4 side effects are anemia, diarrhea, and elevations in liver enzymes (ALT and AST).</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i17" class="anchor-spacer"></div><h5 class="article-section__title" id="_i17">4.2.1.2.  H3B-6527</h5><div class="NLM_p">H3 Biomedicine has developed the FGFR4 selective irreversible inhibitor H3B-6527 (<b>13</b>)<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> by incorporating an acrylamide into the <i>ortho</i>-position of the aniline group of the Novartis pan-FGFR inhibitor BGJ398 (<b>12</b>) to target Cys552 of FGFR4 (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>A). The acrylamide moiety not only increased the binding affinity to FGFR4 but also induced a steric clash with the corresponding Tyr residue of FGFR1–3, improving FGFR4 selectivity. H3B-6527 selectively inhibits FGFR4 (IC<sub>50</sub> < 1.2 nM) while sparing FGFR1/2/3 (IC<sub>50</sub> = 0.32, 1.29, and 1.06 μM, respectively) and other kinases. Subsequently, both FGFR4 mass spectrometry and FGFR1-Y563C protein X-ray crystallography studies confirmed the covalent binding of H3B-6527 to the target cysteine. In this instance an FGFR1 surrogate crystallization system in which the key Tyr563 of FGFR1 is mutated to cysteine (Cys563) was used to mirror the ATP-binding pocket of FGFR4 and interrogate the binding mode of H3B-6527 by X-ray crystallography (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>B). The aminopyrimidine core forms two hydrogen bonds with the hinge residue Ala564, and the dichlorodimethoxyphenyl group occupies the hydrophobic pocket forming an additional hydrogen bond with Asp641.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) Optimization strategy of H3B-6527. (B) Binding mode of H3B-6527 with FGFR1-Y563C (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5vnd">5vnd</a>). Hydrogen bonds are indicated by yellow dashed lines to key amino acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">H3B-6527 exhibited excellent antitumor activity against FGF19-amplified HCC cell lines and HCC PDX models.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Preclinical studies also revealed that FGF19 expression was a predictive biomarker for H3B-6527 response. Moreover, administration of H3B-6527 combined with palbociclib synergistically suppressed tumor growth in a xenograft model of HCC. H3B-6527 is currently in phase I clinical trial for advanced HCC and intrahepatic cholangiocarcinoma (NCT02834780), having been granted an orphan drug designation by the U.S. FDA for the treatment of HCC in 2017. Thus, we conclude that structure-based design of selective FGFR4 inhibitors by incorporating a Michael acceptor on a pan-FGFR inhibitor scaffold is of significant interest.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i18" class="anchor-spacer"></div><h5 class="article-section__title" id="_i18">4.2.1.3.  Aminopyrimidine</h5><div class="NLM_p">Our group recently reported a series of 2-aminopyrimidine compounds as selective FGFR4 inhibitors based on a ring opening strategy designed to eliminate the benzene ring of BLU9931 (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Replacing the benzene ring of BLU9931 by a methyl ether linker to yield an aminopyrimidine scaffold was predicted to maintain FGFR4 selective inhibitory activity while improving the drug-like physicochemical properties of the compound class. Further optimization of the substituents on the aniline group resulted in compound <b>14</b> as one of the most promising examples with an FGFR4 biochemical IC<sub>50</sub> value of 2.6 nM and complete selectivity over FGFR1/2/3 (IC<sub>50</sub> > 10 μM). Compound <b>14</b> also exhibited extraordinary target specificity in a kinome-wide screen and selectively suppressed proliferation of breast cancer cells harboring an FGFR4Y367C mutation. However, the poor pharmacokinetic (PK) properties of compound <b>14</b> limited its potential for in vivo studies.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Optimization strategy of 2-aminopyrimidine <b>14</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">WuXi AppTec also reported a series of aminopyrimidine compounds deriving from the structure-based drug design strategy of adding a phenylacrylamide moiety to the core structure of pan-FGFR inhibitor ASP5878 (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The first hybrid compound <b>16</b> showed ideal FGFR isoform selectivity with an IC<sub>50</sub> of 3 nM against FGFR4 and >8 μM against FGFR1. Compound <b>16</b> displayed better physicochemical properties than BLU9931 but unfortunately suffered from poor plasma and microsomal stability with a high Cl<sub>int(liver)</sub> value of 9643 mL min<sup>–1</sup> kg<sup>–1</sup> in mouse liver microsomes. Further optimization of <b>16</b> with the aim of improving plasma stability afforded compound <b>17</b>, which maintained both FGFR4 inhibitory potency and selectivity. Unfortunately, compound <b>17</b> still displayed a low volume of distribution and high plasma clearance in an in vivo PK study. Further optimization of the 2-aminopyrimidine series is ongoing.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Optimization process of 2-aminopyrimidine <b>17</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i19" class="anchor-spacer"></div><h5 class="article-section__title" id="_i19">4.2.1.4.  Dipyridylamine</h5><div class="NLM_p">Novartis have reported another electrophile variation designed to achieve covalent binding with Cys522 of FGFR4, a 3-nitro-6-chloropyridyl moiety, in which the 6-chloro substituent is positioned for attack by the Cys552 thiomethyl group through a S<sub>N</sub>Ar nucleophilic aromatic substitution (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). The dipyridylamine <b>18</b> was identified by high throughput screening (HTS), demonstrating high potency against FGFR4 (IC<sub>50</sub> = 53 nM) while sparing the FGFR1–3 isoforms (IC<sub>50</sub> > 10 μM) (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>A).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Subsequent mass spectrometry and protein X-ray crystallography confirmed covalent interaction with FGFR4. In addition, it was found that each pyridyl ring nitrogen atom formed a hydrogen bond with hinge residue Ala553. The relatively low molecular weight and novel mechanism of covalent binding of dipyridylamine <b>18</b> suggest potential as a promising lead compound for further discovery of FGFR4 selective inhibitors.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. (A) Chemical structure of dipyridylamine <b>18</b>. (B) Binding mode of <b>18</b> with FGFR4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5nud">5nud</a>). Hydrogen bonds are indicated by yellow dashed lines to key amino acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20">4.2.2.  Reversible Inhibitors</h4><div id="sec4_2_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i21" class="anchor-spacer"></div><h5 class="article-section__title" id="_i21">4.2.2.1.  Reversible Covalent Inhibitors</h5><div class="NLM_p">Concerns about potentially undesirable side effects from irreversible-covalent inhibition due to nonspecific reactivity with off-target proteins and the immunogenic nature of small molecule/protein adducts, together with the observation that HCC cell lines demonstrate a relatively fast FGFR4 resynthesis rate (<2 h) and require complete and continuous inhibition to reach maximum antitumor efficacy, have led to the investigation of reversible covalent FGFR4 inhibitors for the treatment of HCC.</div><div class="NLM_p">Recently, Fairhurst et al. from Novartis discovered a 2-formylquinoline amide scaffold <b>19</b> as a reversible covalent inhibitor of FGFR4 by high throughput screening (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).<a onclick="showRef(event, 'ref34 ref46'); return false;" href="javascript:void(0);" class="ref ref34 ref46">(34,46)</a> Molecular modeling indicated that a covalent bond was formed between the 2-formyl quinoline group and Cys552 by an addition reaction to generate a hemithioacetal adduct, considered a reversible-covalent interaction (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). Further medicinal chemistry optimization of hit <b>19</b> yielded a more potent tetrahydronaphthyridine urea <b>20</b> to improve the solubility of the compound by reducing the aromatic planar nature of <b>19</b> without disrupting the intramolecular hydrogen bond between the amide/urea N–H and the quinoline nitrogen.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Molecular modeling indicated that <b>20</b> covalently bound the FGFR4 ATP binding pocket with the aminopyridyl moiety forming two hydrogen bonds with hinge residues Glu551 and Ala553. FGFR4 kinetic binding studies showed compound <b>20</b> possessed a long target residence time (4.5 h). Systematic SAR investigations at the aminopyridyl moiety and the tetrahydronaphthyridine scaffold led to the drug candidate FGF401 (<b>22</b>) with high potency and ideal physical properties.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Optimization process of FGF401 and its analogue <b>23</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">FGF401 displayed at least 1000-fold selectivity for FGFR4 over FGFR1/2/3 and other kinases,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> with an IC<sub>50</sub> value of 1.9 nM against FGFR4. Moreover, FGF401 has remarkable antitumor activity in mice bearing HCC tumor xenografts and PDX models as well as excellent pharmacokinetic/pharmacodynamics (PK/PD) properties.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> FGF401 has entered phase I/II clinical trial to evaluate its safety and efficacy in HCC and other solid tumors characterized by positive FGFR4 and β-klotho expression (NCT02325739). Recently, researchers at Novartis found that FGF401 led to up-regulation of bile acid synthesis correlated to a subsequent increase in ALT expression in preclinical safety studies, which can be prevented by combination with the bile acid sequestrant cholestyramine.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> In 2018, HANSOH Pharma also patented a series of 2-formylpyridyl ureas with a similar structure to FGF401 (example as <b>23</b>).<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div></div><div id="sec4_2_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i22" class="anchor-spacer"></div><h5 class="article-section__title" id="_i22">4.2.2.2.  Reversible Inhibitors</h5><div class="NLM_p">The smaller residue volume of Cys552 in FGFR4 when compared to the corresponding tyrosine of FGFR1/2/3 provides an opportunity for designing selective inhibitors of FGFR4. Analysis of the Novartis internal kinase panel revealed that an isopropoxy substituted diaminopyrimidine compound (<b>24</b>) displayed more than 100-fold selectivity for FGFR4 over FGFR1/2/3 (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Binding mode analysis indicated that the isopropoxy group filled a small hydrophobic pocket formed by Cys552 in FGFR4; however this substituent could not be accommodated by FGFR1/2/3 due to the larger tyrosine residue size. Subsequent replacement of the isopropoxy group with the smaller methoxy group led to compound <b>25</b>, which lost FGFR4 selectivity due to this substituent being well accommodated in the hinge region of FGFR1/2/3/4. Further medicinal chemistry optimization of substituents on the phenyl ring coupled with variations in structure predicted to occupy the aromatic ring binding back pocket provided an improved derivative <b>26</b>, which maintained FGFR4 potency and selectivity. Similar to <b>24</b>, the isobutoxy group formed key hydrophobic interactions with Cys552 while the aminopyrimidine core made the specific hydrogen bond contacts with the hinge residue Ala553. In addition to these interactions the introduced bicyclic moiety extended into the hydrophobic back pocket created by Val481 and Gly474.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Optimization of the reversible selective FGFR4 inhibitors <b>24</b> and <b>26</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">5.  Perspective and Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80706" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80706" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">FGF19/FGFR4 mediated signaling plays a functional role in hepatocellular carcinoma (HCC) progression and metastasis, making FGFR4 a promising target for discovery of new drugs for the treatment of HCC. Numerous classes of small molecule FGFR4 inhibitors with differing selectivity profiles have been discovered, and several have been advanced to clinical trial. However, some of the early clinical candidates discussed herein were originally developed to target FGFR1/2/3 and lack FGFR4 isoform selectivity (pan-FGFR inhibitors). These agents have demonstrated on-target FGFR1/3 dose-related limiting toxicities, such as hyperphosphatemia, which required strict phosphate management protocols and limited their clinical utility. Encouragingly, several classes of highly selective FGFR4 inhibitors have recently been designed by targeting a poorly conserved cysteine found in the ATP-binding domain of FGFR4 (Cys552). Both BLU554 and H3B-6527 that utilize this approach are in phase I clinical trials for the treatment of HCC. Interim results indicate the promising potential for FGFR4-based HCC therapy.</div><div class="NLM_p">However, recent studies also demonstrate that the fast resynthesis rate of FGFR4 in HCC cells will require an inhibitor with a toxicity profile that allows for frequent dosing to achieve complete and continuous target inhibition to reach maximum antitumor efficacy. Reversible-covalent inhibitors of FGFR4 may theoretically have the necessary properties required. The recently disclosed FGFR4 reversible-covalent inhibitor FGF401, which binds to Cys552 through an aldehyde group to generate a hemithioacetal adduct, shows remarkable antitumor activity in preclinical studies and has now entered phase I/II clinical evaluation.</div><div class="NLM_p last">Despite the significant progress made in the design and development of selective FGFR4 inhibitors, two major limitations and challenges remain. (1) As with other tyrosine kinase inhibitors, a growing challenge for FGFR4 inhibitor efficacy is the development of acquired resistance. The gatekeeper mutations FGFR4<sup>V550L</sup> and FGFR4<sup>V550M</sup> have been identified.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The pan-FGFR inhibitor FIIN-2 has been reported to have activity against the FGFR4<sup>V550L</sup> mutation, but this agent has low or no selectivity for FGFR4 relative to the other FGFR isoforms.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> With this recognized mechanism of resistance and other induced acquired resistance mutations expected, development of FGFR4 inhibitors with high selectivity and potency for predicted mutants is critical. (2) The reported irreversible or reversible-covalent inhibitors are capable of selectively inhibiting FGFR4 but are still in early clinical trials. The evaluation of more chemotypes in comprehensive clinical studies with a clear focus on selection of appropriate patients and predictive biomarkers of response is needed to fully validate the use of FGFR4 selective inhibitors for the treatment of HCC with aberrant FGFR4 signaling.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b01531" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68554" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68554" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoyun Lu</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou 510632, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7931-6873" title="Orcid link">http://orcid.org/0000-0001-7931-6873</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c8a4bdb0b1faf8f9fe88a2a6bde6adacbde6aba6"><span class="__cf_email__" data-cfemail="a0ccd5d8d992909196e0caced58ec5c4d58ec3ce">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeff B. Smaill</span> - <span class="hlFld-Affiliation affiliation">Maurice
Wilkins Centre for Molecular Biodiscovery, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</span>; 
    <span class="hlFld-Affiliation affiliation">Translational
Therapeutics Team, Auckland Cancer Society Research Centre, School
of Medical Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a7cd89d4cac6cecbcbe7c6d2c4cccbc6c9c389c6c489c9dd"><span class="__cf_email__" data-cfemail="7a105409171b1316163a1b0f1911161b141e541b19541400">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hao Chen</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou 510632, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adam V. Patterson</span> - <span class="hlFld-Affiliation affiliation">Maurice
Wilkins Centre for Molecular Biodiscovery, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</span>; 
    <span class="hlFld-Affiliation affiliation">Translational
Therapeutics Team, Auckland Cancer Society Research Centre, School
of Medical Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ke Ding</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou 510632, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9016-812X" title="Orcid link">http://orcid.org/0000-0001-9016-812X</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>X.L. and H.C. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11488" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11488" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Xiaoyun Lu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=BIO-d7e1184-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Xiaoyun Lu</b> is Professor of Medicinal Chemistry at Jinan University. She received her Ph.D. from China Pharmaceutical University in 2010 and then worked at Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences during 2010–2016. Dr Lu’s research is mainly focused on discovering novel small molecule kinase inhibitors for anticancer and anti-inflammatory therapy using synthetic medicinal chemistry and combined computational methods for lead optimization.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Hao Chen</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=BIO-d7e1189-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hao Chen</b> received his Bachelor degree at Shenyang Pharmaceutical University, China. He is currently study for his Master degree at Jinan University. His recent academic work is focused on synthesis kinase inhibitors as anticancer drugs.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Adam V. Patterson</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=BIO-d7e1194-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Adam V. Patterson</b> was educated at Oxford University where he completed his Bachelor of Biochemistry degree. He undertook his doctoral training jointly at the MRC Radiobiology unit and Institute of Molecular Medicine, Oxford, where he researched various prodrug therapies. After completing a postdoctoral fellowship at the University of Manchester he joined the Faculty of Medical and Health Sciences at the University of Auckland. He is currently an Associate Professor and leads the Translational Therapeutics Team, a talented group of scientists within the Auckland Cancer Society Research Centre. His core interests are focused on translational cancer therapeutics, including drug discovery and development, specializing in the tumour microenvironment as a therapeutic target.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Jeff B. Smaill</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=BIO-d7e1199-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jeff B. Smaill</b> received his Ph.D. in Organic Chemistry from the University of Otago and did his postdoctoral training at the University of Cambridge. He is currently an Associate Professor at the University of Auckland where he leads a medicinal chemistry group at the Auckland Cancer Society Research Centre in the Faculty of Medical and Health Sciences. He is an Associate Investigator of the Maurice Wilkins Centre for Molecular Biodiscovery, one of New Zealand’s 10 Centres of Research Excellence. He has had 25 years of experience leading drug discovery programs in collaboration with industry partners. His research interests include the discovery of novel small molecule irreversible kinase inhibitors and hypoxia-activated prodrugs. He has been involved in the development of canertinib, dacomitinib, tarloxotinib, and CP-506.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Ke Ding</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=BIO-d7e1204-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ke Ding</b> is Professor of Medicinal Chemistry at Jinan University. He obtained his Ph.D. from Fudan University in 2001 and did his postdoctoral trainings at University of Michigan, Ann Arbor. Dr Ding worked as a professor at Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences during 2006–2016. Dr. Ding’s research interests mainly focus on design and synthesis of novel bioactive lead compounds for drug discovery. He has published more than 160 publications and is co-inventor of over 50 international patents, some of which have been licensed to international pharmaceutical companies.</p></figure></div><div class="ack" id="ACK-d7e1217-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00466" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00466" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors appreciate the financial support from National Natural Science Foundation of China (Grants 81874285 and 81673285), Outstanding Youth Fund of Guangdong (Grant 2015A030312014), Cancer Society Auckland Northland, and Jinan University.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">FGFR4</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor 4</p></td></tr><tr><td class="NLM_term">FGF19</td><td class="NLM_def"><p class="first last">fibroblast growth factor 19</p></td></tr><tr><td class="NLM_term">HCC</td><td class="NLM_def"><p class="first last">hepatocellular carcinoma</p></td></tr><tr><td class="NLM_term">Cys</td><td class="NLM_def"><p class="first last">cysteine</p></td></tr><tr><td class="NLM_term">EU</td><td class="NLM_def"><p class="first last">European Union</p></td></tr><tr><td class="NLM_term">EMT</td><td class="NLM_def"><p class="first last">epithelial–mesenchymal transition</p></td></tr><tr><td class="NLM_term">GSK3β</td><td class="NLM_def"><p class="first last">glycogen synthase kinase 3β</p></td></tr><tr><td class="NLM_term">FRS2</td><td class="NLM_def"><p class="first last">FGFR substrate 2</p></td></tr><tr><td class="NLM_term">GRB2</td><td class="NLM_def"><p class="first last">growth factor receptor-bound 2</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositol 4,5-bisphosphate 3-kinase</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">PLCγ</td><td class="NLM_def"><p class="first last">phospholipase C-γ</p></td></tr><tr><td class="NLM_term">DAG</td><td class="NLM_def"><p class="first last">diacylglycerol</p></td></tr><tr><td class="NLM_term">PKC</td><td class="NLM_def"><p class="first last">protein kinase C</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">CML</td><td class="NLM_def"><p class="first last">chronic myeloid leukemia</p></td></tr><tr><td class="NLM_term">ALL</td><td class="NLM_def"><p class="first last">acute lymphoblastic leukemia</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">PDX</td><td class="NLM_def"><p class="first last">patient-derived tumor xenograft</p></td></tr><tr><td class="NLM_term">ORR</td><td class="NLM_def"><p class="first last">overall response rate</p></td></tr><tr><td class="NLM_term">ALT</td><td class="NLM_def"><p class="first last">alanine aminotransferase</p></td></tr><tr><td class="NLM_term">AST</td><td class="NLM_def"><p class="first last">aspartate aminotransferase</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high throughput screening</p></td></tr><tr><td class="NLM_term">GIBH</td><td class="NLM_def"><p class="first last">Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77875" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77875" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 53 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Best, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schotten, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerken, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechêne, A.</span></span> <span> </span><span class="NLM_article-title">Tivantinib for the Treatment of Hepatocellular Carcinoma</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">733</span>, <span class="refDoi"> DOI: 10.1080/14656566.2017.1316376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1080%2F14656566.2017.1316376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=28414564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlOgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=727-733&issue=7&author=J.+Bestauthor=C.+Schottenauthor=G.+Lohmannauthor=G.+Gerkenauthor=A.+Dech%C3%AAne&title=Tivantinib+for+the+Treatment+of+Hepatocellular+Carcinoma&doi=10.1080%2F14656566.2017.1316376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Tivantinib for the treatment of hepatocellular carcinoma</span></div><div class="casAuthors">Best, Jan; Schotten, Clemens; Lohmann, Gregor; Gerken, Guido; Dechene, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">727-733</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide with a poor prognosis due to late diagnosis in the majority of cases.  Physicians are frequently confronted with patients who are not eligible for curative or locoregional treatments any more.  In this scenario, the multi-tyrosine kinase inhibitor sorafenib remains the only systemic first-line treatment option providing modest survival benefit compared to placebo with significant but for most patients acceptable adverse effects.  Areas covered: Tivantinib was the first antiproliferative agent to be been applied in a phase III trial based on receptor overexpression analyses after disease progression on sorafenib.  While phase I and II trials with tivantinib in second line showed encouraging results, a recent press release announced that the METIV-HCC phase III study of tivantinib in HCC did not meet its primary endpoint of improving overall survival.  Expert commentary: Evidence for antiangiogenetic therapy inducing tumor hypoxia leading to overexpression of proliferative genes, including cMET, underlines the potential of tivantinib as second-line treatment.  However, as the mechanism of action of tivantinib through cMET inhibition has recently been questioned by several groups, identification of alternative proliferative markers or targets is mandatory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotJjBNgdYxY7Vg90H21EOLACvtfcHk0lj2kIdnqLo7dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlOgsL0%253D&md5=038cad92d2a175d2ec0c8860c54c1784</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1080%2F14656566.2017.1316376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2017.1316376%26sid%3Dliteratum%253Aachs%26aulast%3DBest%26aufirst%3DJ.%26aulast%3DSchotten%26aufirst%3DC.%26aulast%3DLohmann%26aufirst%3DG.%26aulast%3DGerken%26aufirst%3DG.%26aulast%3DDech%25C3%25AAne%26aufirst%3DA.%26atitle%3DTivantinib%2520for%2520the%2520Treatment%2520of%2520Hepatocellular%2520Carcinoma%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2017%26volume%3D18%26issue%3D7%26spage%3D727%26epage%3D733%26doi%3D10.1080%2F14656566.2017.1316376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilgour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. D.</span></span> <span> </span><span class="NLM_article-title">Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1855</span>– <span class="NLM_lpage">1862</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-0699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F1078-0432.CCR-11-0699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=22388515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFOmurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1855-1862&issue=7&author=A.+N.+Brooksauthor=E.+Kilgourauthor=P.+D.+Smith&title=Fibroblast+Growth+Factor+Signaling%3A+A+New+Therapeutic+Opportunity+in+Cancer&doi=10.1158%2F1078-0432.CCR-11-0699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer</span></div><div class="casAuthors">Brooks, A. Nigel; Kilgour, Elaine; Smith, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1855-1862</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling axis plays an important role in normal organ, vascular, and skeletal development.  Deregulation of FGFR signaling through genetic modification or overexpression of the receptors (or their ligands) has been obsd. in numerous tumor settings, whereas the FGF/FGFR axis also plays a key role in driving tumor angiogenesis.  A growing body of preclin. data shows that inhibition of FGFR signaling can result in antiproliferative and/or proapoptotic effects, both in vitro and in vivo, thus confirming the validity of the FGF/FGFR axis as a potential therapeutic target.  In the past, development of therapeutic approaches to target this axis has been hampered by our inability to develop FGFR-selective agents.  With the advent of a no. of new modalities for selectively inhibiting FGF/FGFR signaling, we are now in a unique position to test and validate clin. the many hypotheses that have been generated preclinically.  Clin Cancer Res; 18(7); 1855-62.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpysOACrAOfsbVg90H21EOLACvtfcHk0lj2kIdnqLo7dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFOmurk%253D&md5=a355aee7dc1b310177c6165b43896b75</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0699%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DA.%2BN.%26aulast%3DKilgour%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26atitle%3DFibroblast%2520Growth%2520Factor%2520Signaling%253A%2520A%2520New%2520Therapeutic%2520Opportunity%2520in%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26issue%3D7%26spage%3D1855%26epage%3D1862%26doi%3D10.1158%2F1078-0432.CCR-11-0699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Llovet, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villanueva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachenmayer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, R. S.</span></span> <span> </span><span class="NLM_article-title">Advances in Targeted Therapies for Hepatocellular Carcinoma in the Genomic Era</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">408</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2015.103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1038%2Fnrclinonc.2015.103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=26054909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOjt7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=408-424&issue=7&author=J.+M.+Llovetauthor=A.+Villanuevaauthor=A.+Lachenmayerauthor=R.+S.+Finn&title=Advances+in+Targeted+Therapies+for+Hepatocellular+Carcinoma+in+the+Genomic+Era&doi=10.1038%2Fnrclinonc.2015.103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in targeted therapies for hepatocellular carcinoma in the genomic era</span></div><div class="casAuthors">Llovet, Josep M.; Villanueva, Augusto; Lachenmayer, Anja; Finn, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">408-424</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mortality owing to liver cancer has increased in the past 20 years, and the latest ests. indicate that the global health burden of this disease will continue to grow.  Most patients with hepatocellular carcinoma (HCC) are still diagnosed at intermediate or advanced disease stages, where curative approaches are often not feasible.  Among the treatment options available, the mol. targeted agent sorafenib is able to significantly increase overall survival in these patients.  Thereafter, up to seven large, randomized phase III clin. trials investigating other mol. therapies in the first-line and second-line settings have failed to improve on the results obsd. with this agent.  Potential reasons for this include intertumor heterogeneity, issues with trial design and a lack of predictive biomarkers of response.  During the past 5 years, substantial advances in our knowledge of the human genome have provided a comprehensive picture of commonly mutated genes in patients with HCC.  This knowledge has not yet influenced clin. decision-making or current clin. practice guidelines.  In this Review the authors summarize the mol. concepts of progression, discuss the potential reasons for clin. trial failure and propose new concepts of drug development, which might lead to clin. implementation of emerging targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqC0YZE_nAFrVg90H21EOLACvtfcHk0ljJoWTMnf8_cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOjt7vM&md5=14f4caeb7cc1e58c51ef8a7aab9354cd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2015.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2015.103%26sid%3Dliteratum%253Aachs%26aulast%3DLlovet%26aufirst%3DJ.%2BM.%26aulast%3DVillanueva%26aufirst%3DA.%26aulast%3DLachenmayer%26aufirst%3DA.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DAdvances%2520in%2520Targeted%2520Therapies%2520for%2520Hepatocellular%2520Carcinoma%2520in%2520the%2520Genomic%2520Era%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D12%26issue%3D7%26spage%3D408%26epage%3D424%26doi%3D10.1038%2Fnrclinonc.2015.103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vainikka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joukov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennstrom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelicci, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alitalo, K.</span></span> <span> </span><span class="NLM_article-title">Signal Transduction by Fibroblast Growth Factor Receptor-4 (FGFR-4). Comparison with FGFR-1</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>269</i></span> (<span class="NLM_issue">28</span>),  <span class="NLM_fpage">18320</span>– <span class="NLM_lpage">18326</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1994&pages=18320-18326&issue=28&author=S.+Vainikkaauthor=V.+Joukovauthor=S.+Wennstromauthor=M.+Bergmanauthor=P.+G.+Pelicciauthor=K.+Alitalo&title=Signal+Transduction+by+Fibroblast+Growth+Factor+Receptor-4+%28FGFR-4%29.+Comparison+with+FGFR-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVainikka%26aufirst%3DS.%26aulast%3DJoukov%26aufirst%3DV.%26aulast%3DWennstrom%26aufirst%3DS.%26aulast%3DBergman%26aufirst%3DM.%26aulast%3DPelicci%26aufirst%3DP.%2BG.%26aulast%3DAlitalo%26aufirst%3DK.%26atitle%3DSignal%2520Transduction%2520by%2520Fibroblast%2520Growth%2520Factor%2520Receptor-4%2520%2528FGFR-4%2529.%2520Comparison%2520with%2520FGFR-1%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1994%26volume%3D269%26issue%3D28%26spage%3D18320%26epage%3D18326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liddle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastham-Anderson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonoda, J.</span></span> <span> </span><span class="NLM_article-title">FGF19 Regulates Cell Proliferation, Glucose and Bile Acid Metabolism Via FGFR4-Dependent and Independent Pathways</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">e17868</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0017868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1371%2Fjournal.pone.0017868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=21437243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt1Slsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e17868&issue=3&author=A.-L.+Wuauthor=S.+Coulterauthor=C.+Liddleauthor=A.+Wongauthor=J.+Eastham-Andersonauthor=D.+M.+Frenchauthor=A.+S.+Petersonauthor=J.+Sonoda&title=FGF19+Regulates+Cell+Proliferation%2C+Glucose+and+Bile+Acid+Metabolism+Via+FGFR4-Dependent+and+Independent+Pathways&doi=10.1371%2Fjournal.pone.0017868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways</span></div><div class="casAuthors">Wu, Ai-Luen; Coulter, Sally; Liddle, Christopher; Wong, Anne; Eastham-Anderson, Jeffrey; French, Dorothy M.; Peterson, Andrew S.; Sonoda, Junichiro</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e17868</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Fibroblast growth factor 19 (FGF19) is a hormone-like protein that regulates carbohydrate, lipid and bile acid metab.  At supra-physiol. doses, FGF19 also increases hepatocyte proliferation and induces hepatocellular carcinogenesis in mice.  Much of FGF19 activity is attributed to the activation of the liver enriched FGF receptor 4 (FGFR4), although FGF19 can activate other FGFRs in vitro in the presence of the coreceptor βKlotho (KLB).  In this report, we investigate the role of FGFR4 in mediating FGF19 activity by using Fgfr4 deficient mice as well as a variant of FGF19 protein (FGF19v) which is specifically impaired in activating FGFR4.  Our results demonstrate that FGFR4 activation mediates the induction of hepatocyte proliferation and the suppression of bile acid biosynthesis by FGF19, but is not essential for FGF19 to improve glucose and lipid metab. in high fat diet fed mice as well as in leptin-deficient ob/ob mice.  Thus, FGF19 acts through multiple receptor pathways to elicit pleiotropic effects in regulating nutrient metab. and cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2MXOOgDkQnrVg90H21EOLACvtfcHk0ljJoWTMnf8_cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt1Slsb8%253D&md5=e847efbc1da8d333bf08806904739349</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0017868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0017868%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DA.-L.%26aulast%3DCoulter%26aufirst%3DS.%26aulast%3DLiddle%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DA.%26aulast%3DEastham-Anderson%26aufirst%3DJ.%26aulast%3DFrench%26aufirst%3DD.%2BM.%26aulast%3DPeterson%26aufirst%3DA.%2BS.%26aulast%3DSonoda%26aufirst%3DJ.%26atitle%3DFGF19%2520Regulates%2520Cell%2520Proliferation%252C%2520Glucose%2520and%2520Bile%2520Acid%2520Metabolism%2520Via%2520FGFR4-Dependent%2520and%2520Independent%2520Pathways%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26issue%3D3%26spage%3De17868%26doi%3D10.1371%2Fjournal.pone.0017868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Repana, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, P.</span></span> <span> </span><span class="NLM_article-title">Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma</span>. <i>Diseases</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">294</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.3390/diseases3040294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.3390%2Fdiseases3040294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=28943626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFCgurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=294-305&issue=4&author=D.+Repanaauthor=P.+Ross&title=Targeting+FGF19%2FFGFR4+Pathway%3A+A+Novel+Therapeutic+Strategy+for+Hepatocellular+Carcinoma&doi=10.3390%2Fdiseases3040294"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting FGF19/FGFR4 pathway: a novel therapeutic strategy for hepatocellular carcinoma</span></div><div class="casAuthors">Repana, Dimitra; Ross, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">294-305</span>CODEN:
                <span class="NLM_cas:coden">DISECP</span>;
        ISSN:<span class="NLM_cas:issn">2079-9721</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is a lethal cancer with limited systemic therapeutic options.  Liver carcinogenesis is a complex procedure and various pathways have been found to be deregulated which are potential targets for novel treatments.  Aberrant signalling through FGF19 and its receptor FGFR4 seems to be the oncogenic driver for a subset of HCCs and is assocd. with poor prognosis.  Inhibition of the pathway in preclin. models has shown antitumor activity and has triggered further evaluation of this strategy to in vivo models.  This review aims to describe the role of the FGF19/FGFR4 pathway in hepatocellular carcinoma and its role as a potential predictive biomarker for novel targeted agents against FGF19/FGFR4 signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpREsw9FM-_67Vg90H21EOLACvtfcHk0ljJoWTMnf8_cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFCgurs%253D&md5=319e81e1d0135c096c86f024dc1694cf</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3390%2Fdiseases3040294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fdiseases3040294%26sid%3Dliteratum%253Aachs%26aulast%3DRepana%26aufirst%3DD.%26aulast%3DRoss%26aufirst%3DP.%26atitle%3DTargeting%2520FGF19%252FFGFR4%2520Pathway%253A%2520A%2520Novel%2520Therapeutic%2520Strategy%2520for%2520Hepatocellular%2520Carcinoma%26jtitle%3DDiseases%26date%3D2015%26volume%3D3%26issue%3D4%26spage%3D294%26epage%3D305%26doi%3D10.3390%2Fdiseases3040294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desnoyers, L. R.</span></span> <span> </span><span class="NLM_article-title">FGF19 and Cancer</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>728</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">194</span>, <span class="refDoi"> DOI: 10.1007/978-1-4614-0887-1_12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1007%2F978-1-4614-0887-1_12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=22396170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtlynsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=728&publication_year=2012&pages=183-194&author=B.+C.+Linauthor=L.+R.+Desnoyers&title=FGF19+and+Cancer&doi=10.1007%2F978-1-4614-0887-1_12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">FGF19 and cancer</span></div><div class="casAuthors">Lin, Benjamin C.; Desnoyers, Luc R.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">728</span>
        (<span class="NLM_cas:issue">Endocrine FGFs and Klothos</span>),
    <span class="NLM_cas:pages">183-194</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">0065-2598</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors (FGFs) and their cognate receptors, FGF receptors (FGFRs), play crit. roles in a variety of normal developmental and physiol. processes.  Numerous reports support a role for deregulation of FGF-FGFR signaling, whether it is at the ligand and/or receptor level, in tumor development and progression.  The FGF19-FGFR4 signaling axis has been implicated in the pathogenesis of several cancers, including hepatocellular carcinomas in mice and potentially in humans.  This chapter focuses on recent progress in the understanding of the mol. mechanisms of FGF19 action and its potential involvement in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO7H6HWklzy7Vg90H21EOLACvtfcHk0lgF1YmJ_9cihQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtlynsb3K&md5=083026a28a3e9da69ca46d32347c44be</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2F978-1-4614-0887-1_12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4614-0887-1_12%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DB.%2BC.%26aulast%3DDesnoyers%26aufirst%3DL.%2BR.%26atitle%3DFGF19%2520and%2520Cancer%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2012%26volume%3D728%26spage%3D183%26epage%3D194%26doi%3D10.1007%2F978-1-4614-0887-1_12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinzle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdem, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paur, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasl-Kraupp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grusch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marian, B.</span></span> <span> </span><span class="NLM_article-title">Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">2881</span>– <span class="NLM_lpage">2898</span>, <span class="refDoi"> DOI: 10.2174/13816128113199990594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.2174%2F13816128113199990594" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2881-2898&issue=17&author=C.+Heinzleauthor=Z.+Erdemauthor=J.+Paurauthor=B.+Grasl-Krauppauthor=K.+Holzmannauthor=M.+Gruschauthor=W.+Bergerauthor=B.+Marian&title=Is+Fibroblast+Growth+Factor+Receptor+4+a+Suitable+Target+of+Cancer+Therapy%3F&doi=10.2174%2F13816128113199990594"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F13816128113199990594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F13816128113199990594%26sid%3Dliteratum%253Aachs%26aulast%3DHeinzle%26aufirst%3DC.%26aulast%3DErdem%26aufirst%3DZ.%26aulast%3DPaur%26aufirst%3DJ.%26aulast%3DGrasl-Kraupp%26aufirst%3DB.%26aulast%3DHolzmann%26aufirst%3DK.%26aulast%3DGrusch%26aufirst%3DM.%26aulast%3DBerger%26aufirst%3DW.%26aulast%3DMarian%26aufirst%3DB.%26atitle%3DIs%2520Fibroblast%2520Growth%2520Factor%2520Receptor%25204%2520a%2520Suitable%2520Target%2520of%2520Cancer%2520Therapy%253F%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2014%26volume%3D20%26issue%3D17%26spage%3D2881%26epage%3D2898%26doi%3D10.2174%2F13816128113199990594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. C.</span></span> <span> </span><span class="NLM_article-title">Research Progress of FGFR4 Targeted Anti-Tumor Drug</span>. <i>Cancer. Res. Prev. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">65</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=26907461" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=61-65&author=D.+C.+Wuauthor=L.+Chenauthor=Y.+H.+Chenauthor=Z.+C.+Chen&title=Research+Progress+of+FGFR4+Targeted+Anti-Tumor+Drug"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DD.%2BC.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%2BH.%26aulast%3DChen%26aufirst%3DZ.%2BC.%26atitle%3DResearch%2520Progress%2520of%2520FGFR4%2520Targeted%2520Anti-Tumor%2520Drug%26jtitle%3DCancer.%2520Res.%2520Prev.%2520Treat.%26date%3D2016%26volume%3D44%26spage%3D61%26epage%3D65" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S.
E.</span></span> <span> </span><span class="NLM_article-title">Differential Expression of the Fibroblast Growth Factor Receptor (FGFR) Multigene Family in Normal Human Adult Tissues</span>. <i>J. Histochem. Cytochem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1019</span>, <span class="refDoi"> DOI: 10.1177/002215549704500710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1177%2F002215549704500710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=9212826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADyaK2sXkt1Cjtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1997&pages=1005-1019&issue=7&author=S.%0AE.+Hughes&title=Differential+Expression+of+the+Fibroblast+Growth+Factor+Receptor+%28FGFR%29+Multigene+Family+in+Normal+Human+Adult+Tissues&doi=10.1177%2F002215549704500710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues</span></div><div class="casAuthors">Hughes, Sian E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Histochemistry and Cytochemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1005-1019</span>CODEN:
                <span class="NLM_cas:coden">JHCYAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-1554</span>.
    
            (<span class="NLM_cas:orgname">Histochemical Society, Inc.</span>)
        </div><div class="casAbstract">This report describes a systematic anal. of the expression of the fibroblast growth factor receptor (FGFR) multigene family (FGFR1, FGFR2, FGFR3, and FGFR4) in archival serial sections of normal human adult tissues representing the major organ systems, using immunohistochem. techniques.  Polyclonal antisera specific for FGFR1, FGFR2, FGFR3, and FGFR4 and a three-stage immunoperoxidase technique were employed to det. the cellular distribution of these receptors at the protein level.  The expression profiles for the tissue-specific cellular localization of the FGFR multigene family demonstrated widespread and striking differential patterns of expression of individual receptors in the epithelia and mesenchyme of multiple tissues (stomach, salivary glands, pancreas, thymus, ureter, and cornea) and co-expression of FGFR1-4 in the same cell types of other tissues.  The widespread expression of FGFR1-4 in multiple organ systems suggests an important functional role in normal tissue homeostasis.  Differences in the spatial patterns of FGFR gene expression may generate functional diversity in response to FGF-1 and FGF-2, both of which bind with equally high affinity to more than one receptor subtype.  In vivo, this may lead to functional differences that are crucial for the regulation of normal physiol. processes and are responsible for the pathol. mechanisms that orchestrate various disease processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolfZivL4r94LVg90H21EOLACvtfcHk0lgF1YmJ_9cihQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkt1Cjtbc%253D&md5=ee0cd2d9676cd4e2fac30843c78d4f5a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1177%2F002215549704500710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F002215549704500710%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DS.%2BE.%26atitle%3DDifferential%2520Expression%2520of%2520the%2520Fibroblast%2520Growth%2520Factor%2520Receptor%2520%2528FGFR%2529%2520Multigene%2520Family%2520in%2520Normal%2520Human%2520Adult%2520Tissues%26jtitle%3DJ.%2520Histochem.%2520Cytochem.%26date%3D1997%26volume%3D45%26issue%3D7%26spage%3D1005%26epage%3D1019%26doi%3D10.1177%2F002215549704500710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goetz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beenken, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahimi, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eliseenkova, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubert, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linhardt, R. J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Molecular Insights into the Klotho-Dependent, Endocrine Mode of Action of Fibroblast Growth Factor 19 Subfamily Members</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3417</span>– <span class="NLM_lpage">3428</span>, <span class="refDoi"> DOI: 10.1128/MCB.02249-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1128%2FMCB.02249-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=17339340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltFCksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=3417-3428&issue=9&author=R.+Goetzauthor=A.+Beenkenauthor=O.+A.+Ibrahimiauthor=J.+Kalininaauthor=S.+K.+Olsenauthor=A.+V.+Eliseenkovaauthor=C.+Xuauthor=T.+A.+Neubertauthor=F.+Zhangauthor=R.+J.+Linhardt&title=Molecular+Insights+into+the+Klotho-Dependent%2C+Endocrine+Mode+of+Action+of+Fibroblast+Growth+Factor+19+Subfamily+Members&doi=10.1128%2FMCB.02249-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular insights into the Klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members</span></div><div class="casAuthors">Goetz, Regina; Beenken, Andrew; Ibrahimi, Omar A.; Kalinina, Juliya; Olsen, Shaun K.; Eliseenkova, Anna V.; Xu, ChongFeng; Neubert, Thomas A.; Zhang, Fuming; Linhardt, Robert J.; Yu, Xijie; White, Kenneth E.; Inagaki, Takeshi; Kliewer, Steven A.; Yamamoto, Masaya; Kurosu, Hiroshi; Ogawa, Yasushi; Kuro-o, Makoto; Lanske, Beate; Razzaque, Mohammed S.; Mohammadi, Moosa</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3417-3428</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Unique among fibroblast growth factors (FGFs), FGF19, -21, and -23 act in an endocrine fashion to regulate energy, bile acid, glucose, lipid, phosphate, and vitamin D homeostasis.  These FGFs require the presence of Klotho/βKlotho in their target tissues.  Here, the authors present the crystal structures of FGF19 alone and FGF23 in complex with sucrose octasulfate, a disaccharide chem. related to heparin.  The conformation of the heparin-binding region between β strands 10 and 12 in FGF19 and FGF23 diverges completely from the common conformation adopted by paracrine-acting FGFs.  A cleft between this region and the β1-β2 loop, the other heparin-binding region, precludes direct interaction between heparin/heparan sulfate and backbone atoms of FGF19/23.  This reduces the heparin-binding affinity of these ligands and confers endocrine function.  Klotho/βKlotho have evolved as a compensatory mechanism for the poor ability of heparin/heparan sulfate to promote binding of FGF19, -21, and -23 to their cognate receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8e4h5P_2HyLVg90H21EOLACvtfcHk0lhQw-Zh5R9ksQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltFCksLY%253D&md5=b536406165299f062d8bc5f3e5de1882</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FMCB.02249-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.02249-06%26sid%3Dliteratum%253Aachs%26aulast%3DGoetz%26aufirst%3DR.%26aulast%3DBeenken%26aufirst%3DA.%26aulast%3DIbrahimi%26aufirst%3DO.%2BA.%26aulast%3DKalinina%26aufirst%3DJ.%26aulast%3DOlsen%26aufirst%3DS.%2BK.%26aulast%3DEliseenkova%26aufirst%3DA.%2BV.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DNeubert%26aufirst%3DT.%2BA.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DLinhardt%26aufirst%3DR.%2BJ.%26atitle%3DMolecular%2520Insights%2520into%2520the%2520Klotho-Dependent%252C%2520Endocrine%2520Mode%2520of%2520Action%2520of%2520Fibroblast%2520Growth%2520Factor%252019%2520Subfamily%2520Members%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2007%26volume%3D27%26issue%3D9%26spage%3D3417%26epage%3D3428%26doi%3D10.1128%2FMCB.02249-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicholes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frantz, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillard-Telm, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephan, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, D. M.</span></span> <span> </span><span class="NLM_article-title">A Mouse Model of Hepatocellular Carcinoma: Ectopic Expression of Fibroblast Growth Factor 19 in Skeletal Muscle of Transgenic Mice</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>160</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2295</span>– <span class="NLM_lpage">2307</span>, <span class="refDoi"> DOI: 10.1016/S0002-9440(10)61177-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1016%2FS0002-9440%2810%2961177-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=12057932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BD38XltFOrsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2002&pages=2295-2307&issue=6&author=K.+Nicholesauthor=S.+Guilletauthor=E.+Tomlinsonauthor=K.+Hillanauthor=B.+Wrightauthor=G.+D.+Frantzauthor=T.+A.+Phamauthor=L.+Dillard-Telmauthor=S.+P.+Tsaiauthor=J.-P.+Stephanauthor=J.+Stinsonauthor=T.+Stewartauthor=D.+M.+French&title=A+Mouse+Model+of+Hepatocellular+Carcinoma%3A+Ectopic+Expression+of+Fibroblast+Growth+Factor+19+in+Skeletal+Muscle+of+Transgenic+Mice&doi=10.1016%2FS0002-9440%2810%2961177-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A mouse model of hepatocellular carcinoma: Ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice</span></div><div class="casAuthors">Nicholes, Katrina; Guillet, Susan; Tomlinson, Elizabeth; Hillan, Kenneth; Wright, Barbara; Frantz, Gretchen D.; Pham, Thinh A.; Dillard-Telm, Lisa; Tsai, Siao Ping; Stephan, Jean-Philippe; Stinson, Jeremy; Stewart, Timothy; French, Dorothy M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2295-2307</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Most mouse models of hepatocellular carcinoma have expressed growth factors and oncogenes under the control of a liver-specific promoter.  In contrast, the authors describe here the formation of liver tumors in transgenic mice overexpressing human fibroblast growth factor 19 (FGF19) in skeletal muscle.  FGF19 transgenic mice had elevated hepatic α-fetoprotein mRNA as early as 2 mo of age, and hepatocellular carcinomas were evident by 10 mo of age.  Increased proliferation of pericentral hepatocytes was demonstrated by 5-bromo-2'-deoxyuridine incorporation in the FGF19 transgenic mice before tumor formation and in nontransgenic mice injected with recombinant FGF19 protein.  Areas of small cell dysplasia were initially evident pericentrally, and dysplastic/neoplastic foci throughout the hepatic lobule were glutamine synthetase-pos., suggestive of a pericentral origin.  Consistent with chronic activation of the Wingless/Wnt pathway, 44% of the hepatocellular tumors from FGF19 transgenic mice had nuclear staining for β-catenin.  Sequencing of the tumor DNA encoding β-catenin revealed point mutations that resulted in amino acid substitutions.  These findings suggest a previously unknown role for FGF19 in hepatocellular carcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9ekQaICJqerVg90H21EOLACvtfcHk0lhQw-Zh5R9ksQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltFOrsbs%253D&md5=c3355b5f65fea242cfb7ee357e2dd4a7</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2961177-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252961177-7%26sid%3Dliteratum%253Aachs%26aulast%3DNicholes%26aufirst%3DK.%26aulast%3DGuillet%26aufirst%3DS.%26aulast%3DTomlinson%26aufirst%3DE.%26aulast%3DHillan%26aufirst%3DK.%26aulast%3DWright%26aufirst%3DB.%26aulast%3DFrantz%26aufirst%3DG.%2BD.%26aulast%3DPham%26aufirst%3DT.%2BA.%26aulast%3DDillard-Telm%26aufirst%3DL.%26aulast%3DTsai%26aufirst%3DS.%2BP.%26aulast%3DStephan%26aufirst%3DJ.-P.%26aulast%3DStinson%26aufirst%3DJ.%26aulast%3DStewart%26aufirst%3DT.%26aulast%3DFrench%26aufirst%3DD.%2BM.%26atitle%3DA%2520Mouse%2520Model%2520of%2520Hepatocellular%2520Carcinoma%253A%2520Ectopic%2520Expression%2520of%2520Fibroblast%2520Growth%2520Factor%252019%2520in%2520Skeletal%2520Muscle%2520of%2520Transgenic%2520Mice%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2002%26volume%3D160%26issue%3D6%26spage%3D2295%26epage%3D2307%26doi%3D10.1016%2FS0002-9440%2810%2961177-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonderfecht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiszmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecht, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupte, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">FGF19-Induced Hepatocyte Proliferation Is Mediated through FGFR4 Activation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>285</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">5165</span>– <span class="NLM_lpage">5170</span>, <span class="refDoi"> DOI: 10.1074/jbc.M109.068783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1074%2Fjbc.M109.068783" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=5165-5170&issue=8&author=X.+Wuauthor=H.+Geauthor=B.+Lemonauthor=S.+Vonderfechtauthor=J.+Weiszmannauthor=R.+Hechtauthor=J.+Gupteauthor=T.+Hagerauthor=Z.+Wangauthor=R.+Lindbergauthor=Y.+Li&title=FGF19-Induced+Hepatocyte+Proliferation+Is+Mediated+through+FGFR4+Activation&doi=10.1074%2Fjbc.M109.068783"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.068783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.068783%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DGe%26aufirst%3DH.%26aulast%3DLemon%26aufirst%3DB.%26aulast%3DVonderfecht%26aufirst%3DS.%26aulast%3DWeiszmann%26aufirst%3DJ.%26aulast%3DHecht%26aufirst%3DR.%26aulast%3DGupte%26aufirst%3DJ.%26aulast%3DHager%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLindberg%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DFGF19-Induced%2520Hepatocyte%2520Proliferation%2520Is%2520Mediated%2520through%2520FGFR4%2520Activation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26issue%3D8%26spage%3D5165%26epage%3D5170%26doi%3D10.1074%2Fjbc.M109.068783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, Y.</span></span> <span> </span><span class="NLM_article-title">FGF19 Promotes Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma Cells by Modulating the GSK3β/β-Catenin Signaling Cascade Via FGFR4 Activation</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">13575</span>– <span class="NLM_lpage">13586</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.6185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.18632%2Foncotarget.6185" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13575-13586&issue=12&author=H.+Zhaoauthor=F.+Lvauthor=G.+Liangauthor=X.+Huangauthor=G.+Wuauthor=W.+Zhangauthor=L.+Yuauthor=L.+Shiauthor=Y.+Teng&title=FGF19+Promotes+Epithelial-Mesenchymal+Transition+in+Hepatocellular+Carcinoma+Cells+by+Modulating+the+GSK3%CE%B2%2F%CE%B2-Catenin+Signaling+Cascade+Via+FGFR4+Activation&doi=10.18632%2Foncotarget.6185"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.6185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.6185%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLv%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DTeng%26aufirst%3DY.%26atitle%3DFGF19%2520Promotes%2520Epithelial-Mesenchymal%2520Transition%2520in%2520Hepatocellular%2520Carcinoma%2520Cells%2520by%2520Modulating%2520the%2520GSK3%25CE%25B2%252F%25CE%25B2-Catenin%2520Signaling%2520Cascade%2520Via%2520FGFR4%2520Activation%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D12%26spage%3D13575%26epage%3D13586%26doi%3D10.18632%2Foncotarget.6185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gauglhofer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paur, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrottmaier, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wingelhofer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naegelen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinzle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulte-Hermann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krupitza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grusch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasl-Kraupp, B.</span></span> <span> </span><span class="NLM_article-title">Fibroblast Growth Factor Receptor 4: A Putative Key Driver for the Aggressive Phenotype of Hepatocellular Carcinoma</span>. <i>Carcinogenesis</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2331</span>– <span class="NLM_lpage">2338</span>, <span class="refDoi"> DOI: 10.1093/carcin/bgu151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1093%2Fcarcin%2Fbgu151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=25031272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtF2ltLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=2331-2338&issue=10&author=C.+Gauglhoferauthor=J.+Paurauthor=W.+C.+Schrottmaierauthor=B.+Wingelhoferauthor=D.+Huberauthor=I.+Naegelenauthor=C.+Pirkerauthor=T.+Mohrauthor=C.+Heinzleauthor=K.+Holzmannauthor=B.+Marianauthor=R.+Schulte-Hermannauthor=W.+Bergerauthor=G.+Krupitzaauthor=M.+Gruschauthor=B.+Grasl-Kraupp&title=Fibroblast+Growth+Factor+Receptor+4%3A+A+Putative+Key+Driver+for+the+Aggressive+Phenotype+of+Hepatocellular+Carcinoma&doi=10.1093%2Fcarcin%2Fbgu151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma</span></div><div class="casAuthors">Gauglhofer, Christine; Paur, Jakob; Schrottmaier, Waltraud C.; Wingelhofer, Bettina; Huber, Daniela; Naegelen, Isabelle; Pirker, Christine; Mohr, Thomas; Heinzle, Christine; Holzmann, Klaus; Marian, Brigitte; Schulte-Hermann, Rolf; Berger, Walter; Krupitza, Georg; Grusch, Michael; Grasl-Kraupp, Bettina</div><div class="citationInfo"><span class="NLM_cas:title">Carcinogenesis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2331-2338</span>CODEN:
                <span class="NLM_cas:coden">CRNGDP</span>;
        ISSN:<span class="NLM_cas:issn">0143-3334</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Recently, we found upregulation of fibroblast growth factor receptor 4 (FGFR4) in a subset of hepatocellular carcinoma (HCC).  Here, we provide mechanistic insight into the role of FGFR4-mediated signalling for the aggressive behavior of HCC cells.  To overexpress FGFR4, hepatoma/hepatocarcinoma cells were transfected with a construct coding for FGFR4.  For downmodulation of endogenous FGFR4, we used small interfering RNA or adenoviral infection with dominant-neg. FGFR4 constructs being either kinase dead (kdFGFR4) or coding for the autoinhibitory sol. domain (solFGFR4).  FGFR4 overexpression in non-tumorigenic hepatocarcinoma cells significantly reduced cell-matrix adhesion, enabled cells to grow anchorage-independently in soft agar, to disintegrate the lymph-/blood-endothelial barrier for intra-/extravasation of tumor cells and to form tumors in SCID mice.  Transcriptome anal. revealed altered expression of genes involved in cell-matrix interactions.  Conversely, in highly tumorigenic cell lines, kdFGFR4 or solFGFR4 lowered the proportion of cells in S phase of the cell cycle, enhanced the G0/G1 and G2/M-phase proportions, reduced anchorage-independent growth in vitro and attenuated disintegration of the lymph-/blood-endothelium and tumor formation in vivo.  These findings were confirmed by altered expression profiles of genes being important for late stages of cell division.  Deregulated FGFR4 expression appears to be one of the key drivers of the malignant phenotype of HCC cells.  Accordingly, blockade of FGFR4-mediated signalling by sol. dominant-neg. constructs, like solFGFR4, may be a feasible and promising therapeutic approach to antagonize aggressive behavior of hepatoma/hepatocarcinoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM2s006KqFlrVg90H21EOLACvtfcHk0lgQCjPhwcuFZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtF2ltLfF&md5=4703b05e6584d855dbf2eace3ab07a47</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgu151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgu151%26sid%3Dliteratum%253Aachs%26aulast%3DGauglhofer%26aufirst%3DC.%26aulast%3DPaur%26aufirst%3DJ.%26aulast%3DSchrottmaier%26aufirst%3DW.%2BC.%26aulast%3DWingelhofer%26aufirst%3DB.%26aulast%3DHuber%26aufirst%3DD.%26aulast%3DNaegelen%26aufirst%3DI.%26aulast%3DPirker%26aufirst%3DC.%26aulast%3DMohr%26aufirst%3DT.%26aulast%3DHeinzle%26aufirst%3DC.%26aulast%3DHolzmann%26aufirst%3DK.%26aulast%3DMarian%26aufirst%3DB.%26aulast%3DSchulte-Hermann%26aufirst%3DR.%26aulast%3DBerger%26aufirst%3DW.%26aulast%3DKrupitza%26aufirst%3DG.%26aulast%3DGrusch%26aufirst%3DM.%26aulast%3DGrasl-Kraupp%26aufirst%3DB.%26atitle%3DFibroblast%2520Growth%2520Factor%2520Receptor%25204%253A%2520A%2520Putative%2520Key%2520Driver%2520for%2520the%2520Aggressive%2520Phenotype%2520of%2520Hepatocellular%2520Carcinoma%26jtitle%3DCarcinogenesis%26date%3D2014%26volume%3D35%26issue%3D10%26spage%3D2331%26epage%3D2338%26doi%3D10.1093%2Fcarcin%2Fbgu151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Sola, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uriarte, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latasa, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urtasun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bárcena-Varela, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elizalde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Ortigosa, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corrales, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Barrena, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berasain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, M. A.</span></span> <span> </span><span class="NLM_article-title">Fibroblast Growth Factor 15/19 in Hepatocarcinogenesis</span>. <i>Dig. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1159/000450905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1159%2F000450905" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=28249259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A280%3ADC%252BC1czhslymtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=158-165&issue=3&author=G.+Alvarez-Solaauthor=I.+Uriarteauthor=M.+U.+Latasaauthor=R.+Urtasunauthor=M.+B%C3%A1rcena-Varelaauthor=M.+Elizaldeauthor=M.+Jim%C3%A9nezauthor=C.+M.+Rodriguez-Ortigosaauthor=F.+J.+Corralesauthor=M.+G.+Fern%C3%A1ndez-Barrenaauthor=C.+Berasainauthor=M.+A.+Avila&title=Fibroblast+Growth+Factor+15%2F19+in+Hepatocarcinogenesis&doi=10.1159%2F000450905"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast Growth Factor 15/19 in Hepatocarcinogenesis</span></div><div class="casAuthors">Alvarez-Sola Gloria; Uriarte Iker; Latasa M Ujue; Urtasun Raquel; Barcena-Varela Marina; Elizalde Maria; Jimenez Maddalen; Rodriguez-Ortigosa Carlos M; Corrales Fernando J; Fernandez-Barrena Maite G; Berasain Carmen; Avila Matias A</div><div class="citationInfo"><span class="NLM_cas:title">Digestive diseases (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">158-165</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Advanced hepatocellular carcinoma (HCC) is a neoplastic disease with a very bad prognosis and increasing worldwide incidence.  HCCs are resistant to conventional chemotherapy and the multikinase inhibitor sorafenib is the only agent that has shown some clinical efficacy.  It is therefore important to identify key molecular mechanisms driving hepatocarcinogenesis for the development of more efficacious therapies.  However, HCCs are heterogeneous tumors and different molecular subclasses have been characterized.  This heterogeneity may underlie the poor performance of most of the targeted therapies so far tested in HCC patients.  The fibroblast growth factor 15/19 (FGF15/19), FGF receptor 4 (FGFR4) and beta-Klotho (KLB) correceptor signaling system, a key regulator of bile acids (BA) synthesis and intermediary metabolism, is emerging as an important player in hepatocarcinogenesis.  Key Messages: Aberrant signaling through the FGF15/19-FGFR4 pathway participates in the neoplastic behavior of HCC cells, promotes HCC development in mice and its overexpression has been characterized in a subset of HCC tumors from patients with poorer prognosis.  Pharmacological interference with FGF15/19-FGFR4 signaling inhibits experimental hepatocarcinogenesis, and specific FGFR4 inhibitors are currently being tested in selected HCC patients with tumoral FGF19-FGFR4/KLB expression.  CONCLUSIONS:  Interference with FGF19-FGFR4 signaling represents a novel strategy in HCC therapy.  Selection of candidate patients based on tumoral FGF19-FGFR4/KLB levels as biomarkers may result in increased efficacy of FGFR4-targeted drugs.  Nevertheless, attention should be paid to the potential on target toxic effects of FGFR4 inhibitors due to the key role of this signaling system in BA metabolism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSocD_7LO2XS669lAbTj9rGfW6udTcc2eYFJz_1fzeXrrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czhslymtQ%253D%253D&md5=ad9215978bb9194257a33f74ffdcc881</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1159%2F000450905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000450905%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez-Sola%26aufirst%3DG.%26aulast%3DUriarte%26aufirst%3DI.%26aulast%3DLatasa%26aufirst%3DM.%2BU.%26aulast%3DUrtasun%26aufirst%3DR.%26aulast%3DB%25C3%25A1rcena-Varela%26aufirst%3DM.%26aulast%3DElizalde%26aufirst%3DM.%26aulast%3DJim%25C3%25A9nez%26aufirst%3DM.%26aulast%3DRodriguez-Ortigosa%26aufirst%3DC.%2BM.%26aulast%3DCorrales%26aufirst%3DF.%2BJ.%26aulast%3DFern%25C3%25A1ndez-Barrena%26aufirst%3DM.%2BG.%26aulast%3DBerasain%26aufirst%3DC.%26aulast%3DAvila%26aufirst%3DM.%2BA.%26atitle%3DFibroblast%2520Growth%2520Factor%252015%252F19%2520in%2520Hepatocarcinogenesis%26jtitle%3DDig.%2520Dis.%26date%3D2017%26volume%3D35%26issue%3D3%26spage%3D158%26epage%3D165%26doi%3D10.1159%2F000450905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahimi, O. A.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for Fibroblast Growth Factor Receptor Activation</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1016/j.cytogfr.2005.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1016%2Fj.cytogfr.2005.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=15863029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVOns7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=107-137&issue=2&author=M.+Mohammadiauthor=S.+K.+Olsenauthor=O.+A.+Ibrahimi&title=Structural+Basis+for+Fibroblast+Growth+Factor+Receptor+Activation&doi=10.1016%2Fj.cytogfr.2005.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for fibroblast growth factor receptor activation</span></div><div class="casAuthors">Mohammadi, Moosa; Olsen, Shaun K.; Ibrahimi, Omar A.</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-137</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  FGF signaling plays a ubiquitous role in human biol. as a regulator of embryonic development, homeostasis and regenerative processes.  In addn., aberrant FGF signaling leads to diverse human pathologies including skeletal, olfactory, and metabolic disorders as well as cancer.  FGFs execute their pleiotropic biol. actions by binding, dimerizing and activating cell surface FGF receptors (FGFRs).  Proper regulation of FGF-FGFR binding specificity is essential for the regulation of FGF signaling and is achieved through primary sequence variations among the 18 FGFs and seven FGFRs.  The severity of human skeletal syndromes arising from mutations that violate FGF-FGFR specificity is a testament to the importance of maintaining precision in FGF-FGFR specificity.  The discovery that heparin/heparan sulfate (HS) proteoglycans are required for FGF signaling led to numerous models for FGFR dimerization and heralded one of the most controversial issues in FGF signaling.  Recent crystallog. analyses have led to two fundamentally different models for FGFR dimerization.  These models differ in both the stoichiometry and minimal length of heparin required for dimerization, the quaternary arrangement of FGF, FGFR and heparin in the dimer, and in the mechanism of 1:1 FGF-FGFR recognition and specificity.  In this review, we provide an overview of recent structural and biochem. studies used to differentiate between the two crystallog. models.  Interestingly, the structural and biophys. analyses of naturally occurring pathogenic FGFR mutations have provided the most compelling and unbiased evidences for the correct mechanisms for FGF-FGFR dimerization and binding specificity.  The structural analyses of different FGF-FGFR complexes have also shed light on the intricate mechanisms detg. FGF-FGFR binding specificity and promiscuity and also provide a plausible explanation for the mol. basis of a large no. craniosynostosis mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7MZ4mx8ZrHrVg90H21EOLACvtfcHk0lgQCjPhwcuFZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVOns7g%253D&md5=746ae413058ad52c77d77a553003746c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2005.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2005.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DOlsen%26aufirst%3DS.%2BK.%26aulast%3DIbrahimi%26aufirst%3DO.%2BA.%26atitle%3DStructural%2520Basis%2520for%2520Fibroblast%2520Growth%2520Factor%2520Receptor%2520Activation%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2005%26volume%3D16%26issue%3D2%26spage%3D107%26epage%3D137%26doi%3D10.1016%2Fj.cytogfr.2005.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeehan, W. L.</span></span> <span> </span><span class="NLM_article-title">Alternately Spliced NH2-Terminal Immunoglobulin-Like Loop I in the Ectodomain of the Fibroblast Growth Factor (FGF) Receptor 1 Lowers Affinity for Both Heparin and FGF-1</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">10231</span>– <span class="NLM_lpage">10235</span>, <span class="refDoi"> DOI: 10.1074/jbc.270.17.10231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1074%2Fjbc.270.17.10231" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=10231-10235&issue=17&author=F.+Wangauthor=M.+Kanauthor=G.+Yanauthor=J.+Xuauthor=W.+L.+McKeehan&title=Alternately+Spliced+NH2-Terminal+Immunoglobulin-Like+Loop+I+in+the+Ectodomain+of+the+Fibroblast+Growth+Factor+%28FGF%29+Receptor+1+Lowers+Affinity+for+Both+Heparin+and+FGF-1&doi=10.1074%2Fjbc.270.17.10231"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.17.10231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.17.10231%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKan%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DMcKeehan%26aufirst%3DW.%2BL.%26atitle%3DAlternately%2520Spliced%2520NH2-Terminal%2520Immunoglobulin-Like%2520Loop%2520I%2520in%2520the%2520Ectodomain%2520of%2520the%2520Fibroblast%2520Growth%2520Factor%2520%2528FGF%2529%2520Receptor%25201%2520Lowers%2520Affinity%2520for%2520Both%2520Heparin%2520and%2520FGF-1%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26issue%3D17%26spage%3D10231%26epage%3D10235%26doi%3D10.1074%2Fjbc.270.17.10231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breeze, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span> <span> </span><span class="NLM_article-title">Structural Insights into FGFR Kinase Isoform Selectivity: Diverse Binding Modes of AZD4547 and Ponatinib in Complex with FGFR1 and FGFR4</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1764</span>– <span class="NLM_lpage">1774</span>, <span class="refDoi"> DOI: 10.1016/j.str.2014.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1016%2Fj.str.2014.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=25465127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVWrsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=1764-1774&issue=12&author=J.+A.+Tuckerauthor=T.+Kleinauthor=J.+Breedauthor=A.+L.+Breezeauthor=R.+Overmanauthor=C.+Phillipsauthor=R.+A.+Norman&title=Structural+Insights+into+FGFR+Kinase+Isoform+Selectivity%3A+Diverse+Binding+Modes+of+AZD4547+and+Ponatinib+in+Complex+with+FGFR1+and+FGFR4&doi=10.1016%2Fj.str.2014.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Insights into FGFR Kinase Isoform Selectivity: Diverse Binding Modes of AZD4547 and Ponatinib in Complex with FGFR1 and FGFR4</span></div><div class="casAuthors">Tucker, Julie A.; Klein, Tobias; Breed, Jason; Breeze, Alexander L.; Overman, Ross; Phillips, Chris; Norman, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1764-1774</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The fibroblast growth factor receptor (FGFR) family of receptor tyrosine kinases has been implicated in a wide variety of cancers.  Despite a high level of sequence homol. in the ATP-binding site, the majority of reported inhibitors are selective for the FGFR1-3 isoforms and display much reduced potency toward FGFR4, an exception being the Bcr-Abl inhibitor ponatinib.  Here we present the crystal structure of the FGFR4 kinase domain and show that both FGFR1 and FGFR4 kinase domains in complex with ponatinib adopt a DFG-out activation loop conformation.  Comparison with the structure of FGFR1 in complex with the candidate drug AZD4547, combined with kinetic characterization of the binding of ponatinib and AZD4547 to FGFR1 and FGFR4, sheds light on the obsd. differences in selectivity profiles and provides a rationale for developing FGFR4-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAm8d8S6VMy7Vg90H21EOLACvtfcHk0lhRafG0cSkGDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVWrsb3K&md5=575188359fec7b4e586233a5585c259a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2014.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2014.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DTucker%26aufirst%3DJ.%2BA.%26aulast%3DKlein%26aufirst%3DT.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DBreeze%26aufirst%3DA.%2BL.%26aulast%3DOverman%26aufirst%3DR.%26aulast%3DPhillips%26aufirst%3DC.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26atitle%3DStructural%2520Insights%2520into%2520FGFR%2520Kinase%2520Isoform%2520Selectivity%253A%2520Diverse%2520Binding%2520Modes%2520of%2520AZD4547%2520and%2520Ponatinib%2520in%2520Complex%2520with%2520FGFR1%2520and%2520FGFR4%26jtitle%3DStructure%26date%3D2014%26volume%3D22%26issue%3D12%26spage%3D1764%26epage%3D1774%26doi%3D10.1016%2Fj.str.2014.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eliseenkova, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubert, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span> <span> </span><span class="NLM_article-title">A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine Kinases</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">730</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2007.06.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1016%2Fj.molcel.2007.06.028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=717-730&issue=5&author=H.+Chenauthor=J.+Maauthor=W.+Liauthor=A.+V.+Eliseenkovaauthor=C.+Xuauthor=T.+A.+Neubertauthor=W.+T.+Millerauthor=M.+Mohammadi&title=A+Molecular+Brake+in+the+Kinase+Hinge+Region+Regulates+the+Activity+of+Receptor+Tyrosine+Kinases&doi=10.1016%2Fj.molcel.2007.06.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2007.06.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2007.06.028%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DEliseenkova%26aufirst%3DA.%2BV.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DNeubert%26aufirst%3DT.%2BA.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DMohammadi%26aufirst%3DM.%26atitle%3DA%2520Molecular%2520Brake%2520in%2520the%2520Kinase%2520Hinge%2520Region%2520Regulates%2520the%2520Activity%2520of%2520Receptor%2520Tyrosine%2520Kinases%26jtitle%3DMol.%2520Cell%26date%3D2007%26volume%3D27%26issue%3D5%26spage%3D717%26epage%3D730%26doi%3D10.1016%2Fj.molcel.2007.06.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miduturu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stransky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifulco, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodous, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooijmans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shutes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzi, T.</span></span> <span> </span><span class="NLM_article-title">First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-1029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F2159-8290.CD-14-1029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=25776529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsVSrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=424-437&issue=4&author=M.+Hagelauthor=C.+Miduturuauthor=M.+Sheetsauthor=N.+Rubinauthor=W.+Wengauthor=N.+Stranskyauthor=N.+Bifulcoauthor=J.+L.+Kimauthor=B.+Hodousauthor=N.+Brooijmansauthor=A.+Shutesauthor=C.+Winterauthor=C.+Lengauerauthor=N.+E.+Kohlauthor=T.+Guzi&title=First+Selective+Small+Molecule+Inhibitor+of+FGFR4+for+the+Treatment+of+Hepatocellular+Carcinomas+with+an+Activated+FGFR4+Signaling+Pathway&doi=10.1158%2F2159-8290.CD-14-1029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway</span></div><div class="casAuthors">Hagel, Margit; Miduturu, Chandra; Sheets, Michael; Rubin, Nooreen; Weng, Weifan; Stransky, Nicolas; Bifulco, Neil; Kim, Joseph L.; Hodous, Brian; Brooijmans, Natasja; Shutes, Adam; Winter, Christopher; Lengauer, Christoph; Kohl, Nancy E.; Guzi, Timothy</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">424-437</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HCC cells with FGF19 gene amplification or overexpression and an intact FGFR4 signaling pathway are sensitive to potent and selective FGFR4 inhibition by the small mol. BLU9931 in vitro and in xenograft models.  Aberrant signaling through the fibroblast growth factor 19 (FGF19)/fibroblast growth factor receptor 4 (FGFR 4) signaling complex has been shown to cause hepatocellular carcinoma (HCC) in mice and has been implicated to play a similar role in humans.  We have developed BLU9931, a potent and irreversible small-mol. inhibitor of FGFR4, as a targeted therapy to treat patients with HCC whose tumors have an activated FGFR4 signaling pathway.  BLU9931 is exquisitely selective for FGFR4 vs. other FGFR family members and all other kinases.  BLU9931 shows remarkable antitumor activity in mice bearing an HCC tumor xenograft that overexpresses FGF19 due to amplification as well as a liver tumor xenograft that overexpresses FGF19 mRNA but lacks FGF19 amplification.  Approx. one third of patients with HCC whose tumors express FGF19 together with FGFR4 and its coreceptor klotho β (KLB) could potentially respond to treatment with an FGFR4 inhibitor.  These findings are the first demonstration of a therapeutic strategy that targets a subset of patients with HCC.  Significance: This article documents the discovery of BLU9931, a novel irreversible kinase inhibitor that specifically targets FGFR4 while sparing all other FGFR paralogs and demonstrates exquisite kinome selectivity.  BLU9931 is efficacious in tumors with an intact FGFR4 signaling pathway that includes FGF19, FGFR4, and KLB.  BLU9931 is the first FGFR4-selective mol. for the treatment of patients with HCC with aberrant FGFR4 signaling.  Cancer Discov; 5(4); 424-37. cpr2015 AACR.  See related commentary by Packer and Pollock, p. 355 This article is highlighted in the In This Issue feature, p.  333.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqcHNr-1ZnG7Vg90H21EOLACvtfcHk0lhRafG0cSkGDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsVSrtL8%253D&md5=4a69439aee01a3c090c14851a785362e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-1029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-1029%26sid%3Dliteratum%253Aachs%26aulast%3DHagel%26aufirst%3DM.%26aulast%3DMiduturu%26aufirst%3DC.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DRubin%26aufirst%3DN.%26aulast%3DWeng%26aufirst%3DW.%26aulast%3DStransky%26aufirst%3DN.%26aulast%3DBifulco%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DHodous%26aufirst%3DB.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DShutes%26aufirst%3DA.%26aulast%3DWinter%26aufirst%3DC.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DKohl%26aufirst%3DN.%2BE.%26aulast%3DGuzi%26aufirst%3DT.%26atitle%3DFirst%2520Selective%2520Small%2520Molecule%2520Inhibitor%2520of%2520FGFR4%2520for%2520the%2520Treatment%2520of%2520Hepatocellular%2520Carcinomas%2520with%2520an%2520Activated%2520FGFR4%2520Signaling%2520Pathway%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26issue%3D4%26spage%3D424%26epage%3D437%26doi%3D10.1158%2F2159-8290.CD-14-1029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gozgit, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span> <span> </span><span class="NLM_article-title">Ponatinib (AP24534), a Multi-Targeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">690</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F1535-7163.MCT-11-0450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=22238366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=690-699&issue=3&author=J.+M.+Gozgitauthor=M.+J.+Wongauthor=L.+Moranauthor=S.+Wardwellauthor=Q.+K.+Mohemmadauthor=N.+I.+Narasimhanauthor=W.+C.+Shakespeareauthor=F.+Wangauthor=T.+Clacksonauthor=V.+M.+Rivera&title=Ponatinib+%28AP24534%29%2C+a+Multi-Targeted+Pan-FGFR+Inhibitor+with+Activity+in+Multiple+FGFR-Amplified+or+Mutated+Cancer+Models&doi=10.1158%2F1535-7163.MCT-11-0450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models</span></div><div class="casAuthors">Gozgit, Joseph M.; Wong, Matthew J.; Moran, Lauren; Wardwell, Scott; Mohemmad, Qurish K.; Narasimhan, Narayana I.; Shakespeare, William C.; Wang, Frank; Clackson, Tim; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">690-699</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Members of the fibroblast growth factor receptor family of kinases (FGFR1-4) are dysregulated in multiple cancers.  Ponatinib (AP24534) is an oral multitargeted tyrosine kinase inhibitor being explored in a pivotal phase II trial in patients with chronic myelogenous leukemia due to its potent activity against BCR-ABL.  Ponatinib has also been shown to inhibit the in vitro kinase activity of all four FGFRs, prompting us to examine its potential as an FGFR inhibitor.  In Ba/F3 cells engineered to express activated FGFR1-4, ponatinib potently inhibited FGFR-mediated signaling and viability with IC50 values <40 nmol/L, with substantial selectivity over parental Ba/F3 cells.  In a panel of 14 cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon) and contg. FGFRs dysregulated by a variety of mechanisms, ponatinib inhibited FGFR-mediated signaling with IC50 values <40 nmol/L and inhibited cell growth with GI50 (concn. needed to reduce the growth of treated cells to half that of untreated cells) values of 7 to 181 nmol/L.  Daily oral dosing of ponatinib (10-30 mg/kg) to mice reduced tumor growth and inhibited signaling in all three tumor models examd.  Importantly, the potency of ponatinib in these models is similar to that previously obsd. in BCR-ABL-driven models and plasma levels of ponatinib that exceed the IC50 values for FGFR1-4 inhibition can be sustained in patients.  These results show that ponatinib is a potent pan-FGFR inhibitor and provide strong rationale for its evaluation in patients with FGFR-driven cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4-w5b7EPxLLVg90H21EOLACvtfcHk0lhFVujPZiu_4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKis70%253D&md5=771979af1fba727510e073d19335ef5a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0450%26sid%3Dliteratum%253Aachs%26aulast%3DGozgit%26aufirst%3DJ.%2BM.%26aulast%3DWong%26aufirst%3DM.%2BJ.%26aulast%3DMoran%26aufirst%3DL.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DPonatinib%2520%2528AP24534%2529%252C%2520a%2520Multi-Targeted%2520Pan-FGFR%2520Inhibitor%2520with%2520Activity%2520in%2520Multiple%2520FGFR-Amplified%2520or%2520Mutated%2520Cancer%2520Models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D3%26spage%3D690%26epage%3D699%26doi%3D10.1158%2F1535-7163.MCT-11-0450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hilberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krssak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kautschitsch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommergruber, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tontsch-Grunt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garin-Chesa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettig, W. J.</span></span> <span> </span><span class="NLM_article-title">BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4774</span>– <span class="NLM_lpage">4782</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-6307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F0008-5472.CAN-07-6307" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=4774-4782&issue=12&author=F.+Hilbergauthor=G.+J.+Rothauthor=M.+Krssakauthor=S.+Kautschitschauthor=W.+Sommergruberauthor=U.+Tontsch-Gruntauthor=P.+Garin-Chesaauthor=G.+Baderauthor=A.+Zoephelauthor=J.+Quantauthor=A.+Heckelauthor=W.+J.+Rettig&title=BIBF+1120%3A+Triple+Angiokinase+Inhibitor+with+Sustained+Receptor+Blockade+and+Good+Antitumor+Efficacy&doi=10.1158%2F0008-5472.CAN-07-6307"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-6307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-6307%26sid%3Dliteratum%253Aachs%26aulast%3DHilberg%26aufirst%3DF.%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26aulast%3DKrssak%26aufirst%3DM.%26aulast%3DKautschitsch%26aufirst%3DS.%26aulast%3DSommergruber%26aufirst%3DW.%26aulast%3DTontsch-Grunt%26aufirst%3DU.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DQuant%26aufirst%3DJ.%26aulast%3DHeckel%26aufirst%3DA.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26atitle%3DBIBF%25201120%253A%2520Triple%2520Angiokinase%2520Inhibitor%2520with%2520Sustained%2520Receptor%2520Blockade%2520and%2520Good%2520Antitumor%2520Efficacy%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26issue%3D12%26spage%3D4774%26epage%3D4782%26doi%3D10.1158%2F0008-5472.CAN-07-6307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachelot, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalenc, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Garcia, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurvitz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deudon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yovine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3693</span>– <span class="NLM_lpage">3702</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F1078-0432.CCR-13-0190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=23658459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtValt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=3693-3702&issue=13&author=F.+Andreauthor=T.+Bachelotauthor=M.+Camponeauthor=F.+Dalencauthor=J.+M.+Perez-Garciaauthor=S.+A.+Hurvitzauthor=N.+Turnerauthor=H.+Rugoauthor=J.+W.+Smithauthor=S.+Deudonauthor=M.+Shiauthor=Y.+Zhangauthor=A.+Kayauthor=D.+G.+Portaauthor=A.+Yovineauthor=J.+Baselga&title=Targeting+FGFR+with+Dovitinib+%28TKI258%29%3A+Preclinical+and+Clinical+Data+in+Breast+Cancer&doi=10.1158%2F1078-0432.CCR-13-0190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer</span></div><div class="casAuthors">Andre, Fabrice; Bachelot, Thomas; Campone, Mario; Dalenc, Florence; Perez-Garcia, Jose M.; Hurvitz, Sara A.; Turner, Nicholas; Rugo, Hope; Smith, John W.; Deudon, Stephanie; Shi, Michael; Zhang, Yong; Kay, Andrea; Graus Porta, Diana; Yovine, Alejandro; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3693-3702</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Fibroblast growth factor receptor 1 (FGFR1) and FGFR2 amplifications are obsd. in approx. 10% of breast cancers and are related to poor outcomes.  We evaluated whether dovitinib (TKI258), an inhibitor of FGFR1, FGFR2, and FGFR3, presented antitumor activity in FGFR-amplified breast cancers.  Exptl. Design: Preclin. activity of dovitinib was evaluated in both breast cancer cell lines and an FGFR1-amplified xenograft model (HBCx2).  Dovitinib was then evaluated in a phase II trial that included 4 groups of patients with human EGF receptor 2-neg. metastatic breast cancer on the basis of FGFR1 amplification and hormone receptor (HR) status.  FGFR1 amplification was assessed by silver in situ hybridization.  Preplanned retrospective analyses assessed predictive value of FGFR1, FGFR2, and FGF3 amplifications by quant. PCR (qPCR).  Results: Dovitinib monotherapy inhibits proliferation in FGFR1- and FGFR2-amplified, but not FGFR-normal, breast cancer cell lines.  Dovitinib also inhibits tumor growth in FGFR1-amplified breast cancer xenografts.  Eighty-one patients were enrolled in the trial.  Unconfirmed response or stable disease for more than 6 mo was obsd. in 5 (25%) and 1 (3%) patient(s) with FGFR1-amplified/HR-pos. and FGFR1-nonamplified/HR-pos. breast cancer.  When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-pos. patients, the mean redn. in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.  Conclusion: Dovitinib showed antitumor activity in FGFR-amplified breast cancer cell lines and may have activity in breast cancers with FGF pathway amplification.  Clin Cancer Res; 19(13); 3693-702. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqsUkPK9d9YrVg90H21EOLACvtfcHk0lhFVujPZiu_4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtValt7fK&md5=8c6e6a67540e15a67ea71c93eeda92a9</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0190%26sid%3Dliteratum%253Aachs%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DBachelot%26aufirst%3DT.%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DDalenc%26aufirst%3DF.%26aulast%3DPerez-Garcia%26aufirst%3DJ.%2BM.%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DRugo%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DJ.%2BW.%26aulast%3DDeudon%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKay%26aufirst%3DA.%26aulast%3DPorta%26aufirst%3DD.%2BG.%26aulast%3DYovine%26aufirst%3DA.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DTargeting%2520FGFR%2520with%2520Dovitinib%2520%2528TKI258%2529%253A%2520Preclinical%2520and%2520Clinical%2520Data%2520in%2520Breast%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26issue%3D13%26spage%3D3693%26epage%3D3702%26doi%3D10.1158%2F1078-0432.CCR-13-0190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBraud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahleda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dientsmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delmonte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cereda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litten, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Phase I/IIa Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Lucitanib in Advanced Solid Tumors</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2244</span>– <span class="NLM_lpage">2251</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdu390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1093%2Fannonc%2Fmdu390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=25193991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252Fos1Ohtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=2244-2251&issue=11&author=J.-C.+Soriaauthor=F.+DeBraudauthor=R.+Bahledaauthor=B.+Adamoauthor=F.+Andreauthor=R.+Dientsmannauthor=A.+Delmonteauthor=R.+Ceredaauthor=J.+Isaacsonauthor=J.+Litten&title=Phase+I%2FIIa+Study+Evaluating+the+Safety%2C+Efficacy%2C+Pharmacokinetics%2C+and+Pharmacodynamics+of+Lucitanib+in+Advanced+Solid+Tumors&doi=10.1093%2Fannonc%2Fmdu390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors</span></div><div class="casAuthors">Soria J-C; Bahleda R; Andre F; DeBraud F; Delmonte A; Adamo B; Tabernero J; Dienstmann R; Dientsmann R; Cereda R; Isaacson J; Litten J; Allen A; Camboni M G; Dubois F; Saba C; Robert R; D'Incalci M; Zucchetti M</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2244-51</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lucitanib is a potent, oral inhibitor fibroblast growth factor receptor types 1 and 2 (FGFR), vascular endothelial growth factor receptor types 1, 2, and 3 (VEGFR), platelet-derived growth factor receptor types α and β (PGFRα/β), which are essential kinases for tumor growth, survival, migration, and angiogenesis.  Several tumor types, including breast carcinoma, demonstrate amplification of fibroblast growth factor (FGF)-related genes.  There are no approved drugs for molecularly defined FGF-aberrant (FGFR1- or FGF3/4/19-amplified) tumors.  METHODS:  This open-label phase I/IIa study involved a dose-escalation phase to determine maximum tolerated dose (MTD), recommended dose (RD), and pharmacokinetics of lucitanib in patients with advanced solid tumors, followed by a dose-expansion phase to obtain preliminary evidence of efficacy in patients who could potentially benefit from treatment (i.e. with tumors harboring FGF-aberrant pathway or considered angiogenesis-sensitive).  RESULTS:  Doses from 5 to 30 mg were evaluated with dose-limiting toxic effects dominated by vascular endothelial growth factor (VEGF) inhibition-related toxic effects at the 30 mg dose level (one case of grade 4 depressed level of consciousness and two cases of grade 3 thrombotic microangiopathy).  The most common adverse events (all grades, all cohorts) were hypertension (91%), asthenia (42%), and proteinuria (57%).  Exposure increased with dose and t1/2 was 31-40 h, suitable for once daily administration.  Seventy-six patients were included.  All but one had stage IV; 42% had >3 lines of previous chemotherapy.  Sixty-four patients were assessable for response; 58 had measurable disease.  Clinical activity was observed at all doses tested with durable Response Evaluation Criteria In Solid Tumors (RECIST) partial responses in a variety of tumor types.  In the angiogenesis-sensitive group, objective RECIST response rate (complete response + partial response) was 26% (7 of 27) and progression-free survival (PFS) was 25 weeks.  In assessable FGF-aberrant breast cancer patients, 50% (6 of 12) achieved RECIST partial response with a median PFS of 40.4 weeks for all treated patients.  CONCLUSION:  Lucitanib has promising efficacy and a manageable side-effect profile.  The spectrum of activity observed demonstrates clinical benefit in both FGF-aberrant and angiogenesis-sensitive populations.  A comprehensive phase II program is planned.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSuRYQ_A4HkTGlSCSgBhwJFfW6udTcc2eaAbNDYrPCY77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252Fos1Ohtg%253D%253D&md5=d63e6b7930eb5562b56fb4cd02900844</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu390%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.-C.%26aulast%3DDeBraud%26aufirst%3DF.%26aulast%3DBahleda%26aufirst%3DR.%26aulast%3DAdamo%26aufirst%3DB.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DDientsmann%26aufirst%3DR.%26aulast%3DDelmonte%26aufirst%3DA.%26aulast%3DCereda%26aufirst%3DR.%26aulast%3DIsaacson%26aufirst%3DJ.%26aulast%3DLitten%26aufirst%3DJ.%26atitle%3DPhase%2520I%252FIIa%2520Study%2520Evaluating%2520the%2520Safety%252C%2520Efficacy%252C%2520Pharmacokinetics%252C%2520and%2520Pharmacodynamics%2520of%2520Lucitanib%2520in%2520Advanced%2520Solid%2520Tumors%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26issue%3D11%26spage%3D2244%26epage%3D2251%26doi%3D10.1093%2Fannonc%2Fmdu390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Hare, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2009.09.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1016%2Fj.ccr.2009.09.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=19878872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFKltb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=401-412&issue=5&author=T.+O%E2%80%99Hareauthor=W.+C.+Shakespeareauthor=X.+Zhuauthor=C.+A.+Eideauthor=V.+M.+Riveraauthor=F.+Wangauthor=L.+T.+Adrianauthor=T.+Zhouauthor=W.-S.+Huangauthor=Q.+Xu&title=AP24534%2C+a+Pan-BCR-ABL+Inhibitor+for+Chronic+Myeloid+Leukemia%2C+Potently+Inhibits+the+T315I+Mutant+and+Overcomes+Mutation-Based+Resistance&doi=10.1016%2Fj.ccr.2009.09.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</span></div><div class="casAuthors">O'Hare, Thomas; Shakespeare, William C.; Zhu, Xiaotian; Eide, Christopher A.; Rivera, Victor M.; Wang, Frank; Adrian, Lauren T.; Zhou, Tianjun; Huang, Wei-Sheng; Xu, Qihong; Metcalf, Chester A., III; Tyner, Jeffrey W.; Loriaux, Marc M.; Corbin, Amie S.; Wardwell, Scott; Ning, Yaoyu; Keats, Jeffrey A.; Wang, Yihan; Sundaramoorthi, Raji; Thomas, Mathew; Zhou, Dong; Snodgrass, Joseph; Commodore, Lois; Sawyer, Tomi K.; Dalgarno, David C.; Deininger, Michael W. N.; Druker, Brian J.; Clackson, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">401-412</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to relapse and a switch to second-line therapy with nilotinib or dasatinib.  Despite three approved therapeutic options, the cross-resistant BCR-ABLT315I mutation and compd. mutants selected on sequential inhibitor therapy remain major clin. challenges.  We report design and preclin. evaluation of AP24534, a potent, orally available multitargeted kinase inhibitor active against T315I and other BCR-ABL mutants.  AP24534 inhibited all tested BCR-ABL mutants in cellular and biochem. assays, suppressed BCR-ABLT315I-driven tumor growth in mice, and completely abrogated resistance in cell-based mutagenesis screens.  Our work supports clin. evaluation of AP24534 as a pan-BCR-ABL inhibitor for treatment of CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox3g7ZYNXwLbVg90H21EOLACvtfcHk0liFh5vS3wjyOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFKltb3N&md5=62a383734fc345b97647ba71aa7aee04</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2009.09.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2009.09.028%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DXu%26aufirst%3DQ.%26atitle%3DAP24534%252C%2520a%2520Pan-BCR-ABL%2520Inhibitor%2520for%2520Chronic%2520Myeloid%2520Leukemia%252C%2520Potently%2520Inhibits%2520the%2520T315I%2520Mutant%2520and%2520Overcomes%2520Mutation-Based%2520Resistance%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26issue%3D5%26spage%3D401%26epage%3D412%26doi%3D10.1016%2Fj.ccr.2009.09.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lesca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustin, M.</span></span> <span> </span><span class="NLM_article-title">Structural Analysis of the Human Fibroblast Growth Factor Receptor 4 Kinase</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>426</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">3744</span>– <span class="NLM_lpage">3756</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2014.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1016%2Fj.jmb.2014.09.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2014&pages=3744-3756&issue=22&author=E.+Lescaauthor=A.+Lammensauthor=R.+Huberauthor=M.+Augustin&title=Structural+Analysis+of+the+Human+Fibroblast+Growth+Factor+Receptor+4+Kinase&doi=10.1016%2Fj.jmb.2014.09.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2014.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2014.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DLesca%26aufirst%3DE.%26aulast%3DLammens%26aufirst%3DA.%26aulast%3DHuber%26aufirst%3DR.%26aulast%3DAugustin%26aufirst%3DM.%26atitle%3DStructural%2520Analysis%2520of%2520the%2520Human%2520Fibroblast%2520Growth%2520Factor%2520Receptor%25204%2520Kinase%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D426%26issue%3D22%26spage%3D3744%26epage%3D3756%26doi%3D10.1016%2Fj.jmb.2014.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zia-Ebrahimi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloem, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huss, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.-b.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, D. J.</span></span> <span> </span><span class="NLM_article-title">A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2200</span>– <span class="NLM_lpage">2210</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F1535-7163.MCT-11-0306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=21900693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2200-2210&issue=11&author=G.+Zhaoauthor=W.-Y.+Liauthor=D.+Chenauthor=J.+R.+Henryauthor=H.-Y.+Liauthor=Z.+Chenauthor=M.+Zia-Ebrahimiauthor=L.+Bloemauthor=Y.+Zhaiauthor=K.+Hussauthor=S.-b.+Pengauthor=D.+J.+McCann&title=A+Novel%2C+Selective+Inhibitor+of+Fibroblast+Growth+Factor+Receptors+That+Shows+a+Potent+Broad+Spectrum+of+Antitumor+Activity+in+Several+Tumor+Xenograft+Models&doi=10.1158%2F1535-7163.MCT-11-0306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models</span></div><div class="casAuthors">Zhao, Genshi; Li, Wei-ying; Chen, Daohong; Henry, James R.; Li, Hong-Yu; Chen, Zhaogen; Zia-Ebrahimi, Mohammad; Bloem, Laura; Zhai, Yan; Huss, Karen; Peng, Sheng-bin; McCann, Denis J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2200-2210</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor receptors (FGFR) are tyrosine kinases that are present in many types of endothelial and tumor cells and play an important role in tumor cell growth, survival, and migration as well as in maintaining tumor angiogenesis.  Overexpression of FGFRs or aberrant regulation of their activities has been implicated in many forms of human malignancies.  Therefore, targeting FGFRs represents an attractive strategy for development of cancer treatment options by simultaneously inhibiting tumor cell growth, survival, and migration as well as tumor angiogenesis.  Here, we describe a potent, selective, small-mol. FGFR inhibitor, (R)-(E)-2-(4-(2-(5-(1-(3,5-Dichloropyridin-4-yl)ethoxy)-1H-indazol-3yl)vinyl)-1H-pyrazol-1-yl)ethanol, designated as LY2874455.  This mol. is active against all 4 FGFRs, with a similar potency in biochem. assays.  It exhibits a potent activity against FGF/FGFR-mediated signaling in several cancer cell lines and shows an excellent broad spectrum of antitumor activity in several tumor xenograft models representing the major FGF/FGFR relevant tumor histologies including lung, gastric, and bladder cancers and multiple myeloma, and with a well-defined pharmacokinetic/pharmacodynamic relationship.  LY2874455 also exhibits a 6- to 9-fold in vitro and in vivo selectivity on inhibition of FGF- over VEGF-mediated target signaling in mice.  Furthermore, LY2874455 did not show VEGF receptor 2-mediated toxicities such as hypertension at efficacious doses.  Currently, this mol. is being evaluated for its potential use in the clinic.  Mol Cancer Ther; 10(11); 2200-10.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLrzAyZQK_grVg90H21EOLACvtfcHk0lgvHVwcO5724A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7N&md5=eaf08fd213a836f48da2055e01bd9c29</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0306%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DW.-Y.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DLi%26aufirst%3DH.-Y.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZia-Ebrahimi%26aufirst%3DM.%26aulast%3DBloem%26aufirst%3DL.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DHuss%26aufirst%3DK.%26aulast%3DPeng%26aufirst%3DS.-b.%26aulast%3DMcCann%26aufirst%3DD.%2BJ.%26atitle%3DA%2520Novel%252C%2520Selective%2520Inhibitor%2520of%2520Fibroblast%2520Growth%2520Factor%2520Receptors%2520That%2520Shows%2520a%2520Potent%2520Broad%2520Spectrum%2520of%2520Antitumor%2520Activity%2520in%2520Several%2520Tumor%2520Xenograft%2520Models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26issue%3D11%26spage%3D2200%26epage%3D2210%26doi%3D10.1158%2F1535-7163.MCT-11-0306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">e0162491</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0162491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1371%2Fjournal.pone.0162491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=27618313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFKjt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0162491&issue=9&author=D.+Wuauthor=M.+Guoauthor=M.+A.+Philipsauthor=L.+Quauthor=L.+Jiangauthor=J.+Liauthor=X.+Chenauthor=Z.+Chenauthor=L.+Chenauthor=Y.+Chen&title=Crystal+Structure+of+the+FGFR4%2FLY2874455+Complex+Reveals+Insights+into+the+Pan-FGFR+Selectivity+of+LY2874455&doi=10.1371%2Fjournal.pone.0162491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the FGFR4/LY2874455 complex reveals insights into the pan-FGFR selectivity of LY2874455</span></div><div class="casAuthors">Wu, Daichao; Guo, Ming; Philips, Michael A.; Qu, Lingzhi; Jiang, Longying; Li, Jun; Chen, Xiaojuan; Chen, Zhuchu; Chen, Lin; Chen, Yongheng</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e0162491/1-e0162491/11</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Aberrant FGFR4 signaling has been documented abundantly in various human cancers.  The majority of FGFR inhibitors display significantly reduced potency toward FGFR4 compared to FGFR1-3.  However, LY2874455 has similar inhibition potency for FGFR1-4 with IC50 less than 6.4 nM.  To date, there is no published crystal structure of LY2874455 in complex with any kinase.  To better understand the pan-FGFR selectivity of LY2874455, we have detd. the crystal structure of the FGFR4 kinase domain bound to LY2874455 at a resoln. of 2.35 Å.  LY2874455, a type I inhibitor for FGFR4, binds to the ATP-binding pocket of FGFR4 in a DFG-in active conformation with three hydrogen bonds and a no. of van derWaals contacts.  After alignment of the kinase domain sequence of 4 FGFRs, and superposition of the ATP binding pocket of 4 FGFRs, our structural analyses reveal that the interactions of LY2874455 to FGFR4 are largely conserved in 4 FGFRs, explaining at least partly, the broad inhibitory activity of LY2874455 toward 4 FGFRs.  Consequently, our studies reveal new insights into the pan-FGFR selectivity of LY2874455 and provide a structural basis for developing novel FGFR inhibitors that target FGFR1-4 broadly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquH9zGVO6xArVg90H21EOLACvtfcHk0lgvHVwcO5724A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFKjt74%253D&md5=444e0d350dac9196672923565b10f2ba</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0162491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0162491%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DPhilips%26aufirst%3DM.%2BA.%26aulast%3DQu%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520FGFR4%252FLY2874455%2520Complex%2520Reveals%2520Insights%2520into%2520the%2520Pan-FGFR%2520Selectivity%2520of%2520LY2874455%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26issue%3D9%26spage%3De0162491%26doi%3D10.1371%2Fjournal.pone.0162491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perera, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jovcheva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mevellec, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vialard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lange, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhulst, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulussen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van De Ven, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freyne, E.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1010</span>– <span class="NLM_lpage">1020</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F1535-7163.MCT-16-0589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=28341788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=1010-1020&issue=6&author=T.+P.+Pereraauthor=E.+Jovchevaauthor=L.+Mevellecauthor=J.+Vialardauthor=D.+De+Langeauthor=T.+Verhulstauthor=C.+Paulussenauthor=K.+Van+De+Venauthor=P.+Kingauthor=E.+Freyne&title=Discovery+and+Pharmacological+Characterization+of+JNJ-42756493+%28Erdafitinib%29%2C+a+Functionally+Selective+Small-Molecule+FGFR+Family+Inhibitor&doi=10.1158%2F1535-7163.MCT-16-0589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor</span></div><div class="casAuthors">Perera, Timothy P. S.; Jovcheva, Eleonora; Mevellec, Laurence; Vialard, Jorge; De Lange, Desiree; Verhulst, Tinne; Paulussen, Caroline; Van De Ven, Kelly; King, Peter; Freyne, Eddy; Rees, David C.; Squires, Matthew; Saxty, Gordon; Page, Martin; Murray, Christopher W.; Gilissen, Ron; Ward, George; Thompson, Neil T.; Newell, David R.; Cheng, Na; Xie, Liang; Yang, Jennifer; Platero, Suso J.; Karkera, Jayaprakash D.; Moy, Christopher; Angibaud, Patrick; Laquerre, Sylvie; Lorenzi, Matthew V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1010-1020</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Fibroblast growth factor (FGF) signaling plays crit. roles in key biol. processes ranging from embryogenesis to wound healing and has strong links to several hallmarks of cancer.  Genetic alterations in FGF receptor (FGFR) family members are assocd. with increased tumor growth, metastasis, angiogenesis, and decreased survival.  JNJ-42756493, erdafitinib, is an orally active small mol. with potent tyrosine kinase inhibitory activity against all four FGFR family members and selectivity vs. other highly related kinases.  JNJ-42756493 shows rapid uptake into the lysosomal compartment of cells in culture, which is assocd. with prolonged inhibition of FGFR signaling, possibly due to sustained release of the inhibitor.  In xenografts from human tumor cell lines or patient-derived tumor tissue with activating FGFR alterations, JNJ-42756493 administration results in potent and dose-dependent antitumor activity accompanied by pharmacodynamic modulation of phospho-FGFR and phospho-ERK in tumors.  The results of the current study provide a strong rationale for the clin. investigation of JNJ-42756493 in patients with tumors harboring FGFR pathway alterations.  Mol Cancer Ther; 16(6); 1010-20. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhJZ2AgFcI6LVg90H21EOLACvtfcHk0lgvHVwcO5724A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht7g%253D&md5=2cae21f09ad519925ab2a3c760284b02</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0589%26sid%3Dliteratum%253Aachs%26aulast%3DPerera%26aufirst%3DT.%2BP.%26aulast%3DJovcheva%26aufirst%3DE.%26aulast%3DMevellec%26aufirst%3DL.%26aulast%3DVialard%26aufirst%3DJ.%26aulast%3DDe%2BLange%26aufirst%3DD.%26aulast%3DVerhulst%26aufirst%3DT.%26aulast%3DPaulussen%26aufirst%3DC.%26aulast%3DVan%2BDe%2BVen%26aufirst%3DK.%26aulast%3DKing%26aufirst%3DP.%26aulast%3DFreyne%26aufirst%3DE.%26atitle%3DDiscovery%2520and%2520Pharmacological%2520Characterization%2520of%2520JNJ-42756493%2520%2528Erdafitinib%2529%252C%2520a%2520Functionally%2520Selective%2520Small-Molecule%2520FGFR%2520Family%2520Inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26issue%3D6%26spage%3D1010%26epage%3D1020%26doi%3D10.1158%2F1535-7163.MCT-16-0589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunney, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiyagarajan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashford, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. V.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Landscape of Activating Cancer Mutations in FGFR Kinases and Their Differential Responses to Inhibitors in Clinical Use</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">24252</span>– <span class="NLM_lpage">24268</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.8132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.18632%2Foncotarget.8132" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=24252-24268&issue=17&author=H.+Pataniauthor=T.+D.+Bunneyauthor=N.+Thiyagarajanauthor=R.+A.+Normanauthor=D.+Oggauthor=J.+Breedauthor=P.+Ashfordauthor=A.+Pottertonauthor=M.+Edwardsauthor=S.+V.+Williams&title=Landscape+of+Activating+Cancer+Mutations+in+FGFR+Kinases+and+Their+Differential+Responses+to+Inhibitors+in+Clinical+Use&doi=10.18632%2Foncotarget.8132"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.8132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.8132%26sid%3Dliteratum%253Aachs%26aulast%3DPatani%26aufirst%3DH.%26aulast%3DBunney%26aufirst%3DT.%2BD.%26aulast%3DThiyagarajan%26aufirst%3DN.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DOgg%26aufirst%3DD.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DAshford%26aufirst%3DP.%26aulast%3DPotterton%26aufirst%3DA.%26aulast%3DEdwards%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DS.%2BV.%26atitle%3DLandscape%2520of%2520Activating%2520Cancer%2520Mutations%2520in%2520FGFR%2520Kinases%2520and%2520Their%2520Differential%2520Responses%2520to%2520Inhibitors%2520in%2520Clinical%2520Use%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D17%26spage%3D24252%26epage%3D24268%26doi%3D10.18632%2Foncotarget.8132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brameld, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venetsanakos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaStant, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6516</span>– <span class="NLM_lpage">6527</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00360</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00360" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVykt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6516-6527&issue=15&author=K.+Brameldauthor=T.+Owensauthor=E.+Vernerauthor=E.+Venetsanakosauthor=J.+Bradshawauthor=V.+Phanauthor=D.+Tamauthor=K.+Leungauthor=J.+Shuauthor=J.+LaStant&title=Discovery+of+the+Irreversible+Covalent+FGFR+Inhibitor+8-%283-%284-Acryloylpiperazin-1-yl%29propyl%29-6-%282%2C6-dichloro-3%2C5-dimethoxyphenyl%29-2-%28methylamino%29pyrido%5B2%2C3-d%5Dpyrimidin-7%288H%29-one+%28PRN1371%29+for+the+Treatment+of+Solid+Tumors&doi=10.1021%2Facs.jmedchem.7b00360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors</span></div><div class="casAuthors">Brameld, Ken A.; Owens, Timothy D.; Verner, Erik; Venetsanakos, Eleni; Bradshaw, J. Michael; Phan, Vernon T.; Tam, Danny; Leung, Kwan; Shu, Jin; LaStant, Jacob; Loughhead, David G.; Ton, Tony; Karr, Dane E.; Gerritsen, Mary E.; Goldstein, David M.; Funk, Jens Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6516-6527</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aberrant signaling of the FGF/FGFR pathway occurs frequently in cancers and is an oncogenic driver in many solid tumors.  Clin. validation of FGFR as a therapeutic target has been demonstrated in bladder, liver, lung, breast, and gastric cancers.  Our goal was to develop an irreversible covalent inhibitor of FGFR1-4 for use in oncol. indications.  An irreversible covalent binding mechanism imparts many desirable pharmacol. benefits including high potency, selectivity, and prolonged target inhibition.  Herein we report the structure-based design, medicinal chem. optimization, and unique ADME assays of our irreversible covalent drug discovery program which culminated in the discovery of compd. 34 (PRN1371), a highly selective and potent FGFR1-4 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpklTuvm1niy7Vg90H21EOLACvtfcHk0lhnTkAxhvwy5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVykt7fK&md5=987069b645d5e0e36ccda5e5c81520b9</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00360%26sid%3Dliteratum%253Aachs%26aulast%3DBrameld%26aufirst%3DK.%26aulast%3DOwens%26aufirst%3DT.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DVenetsanakos%26aufirst%3DE.%26aulast%3DBradshaw%26aufirst%3DJ.%26aulast%3DPhan%26aufirst%3DV.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLeung%26aufirst%3DK.%26aulast%3DShu%26aufirst%3DJ.%26aulast%3DLaStant%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520the%2520Irreversible%2520Covalent%2520FGFR%2520Inhibitor%25208-%25283-%25284-Acryloylpiperazin-1-yl%2529propyl%2529-6-%25282%252C6-dichloro-3%252C5-dimethoxyphenyl%2529-2-%2528methylamino%2529pyrido%255B2%252C3-d%255Dpyrimidin-7%25288H%2529-one%2520%2528PRN1371%2529%2520for%2520the%2520Treatment%2520of%2520Solid%2520Tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D15%26spage%3D6516%26epage%3D6527%26doi%3D10.1021%2Facs.jmedchem.7b00360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venetsanakos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brameld, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaStant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karr, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerritsen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span> <span> </span><span class="NLM_article-title">The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2668</span>– <span class="NLM_lpage">2676</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-0309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F1535-7163.MCT-17-0309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=28978721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWhsL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=2668-2676&issue=12&author=E.+Venetsanakosauthor=K.+A.+Brameldauthor=V.+T.+Phanauthor=E.+Vernerauthor=T.+D.+Owensauthor=Y.+Xingauthor=D.+Tamauthor=J.+LaStantauthor=K.+Leungauthor=D.+E.+Karrauthor=R.+J.+Hillauthor=M.+E.+Gerritsenauthor=D.+M.+Goldsteinauthor=J.+O.+Funkauthor=J.+M.+Bradshaw&title=The+Irreversible+Covalent+Fibroblast+Growth+Factor+Receptor+Inhibitor+PRN1371+Exhibits+Sustained+Inhibition+of+FGFR+after+Drug+Clearance&doi=10.1158%2F1535-7163.MCT-17-0309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance</span></div><div class="casAuthors">Venetsanakos, Eleni; Brameld, Ken A.; Phan, Vernon T.; Verner, Erik; Owens, Timothy D.; Xing, Yan; Tam, Danny; La Stant, Jacob; Leung, Kwan; Karr, Dane E.; Hill, Ronald J.; Gerritsen, Mary E.; Goldstein, David M.; Funk, Jens Oliver; Bradshaw, J. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2668-2676</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">An increasing no. of cancers are known to harbor mutations, translocations, or amplifications in the fibroblast growth factor receptor (FGFR) family of kinases.  The FGFR inhibitors evaluated in clin. trials to date have shown promise at treating these cancers.  Here, we describe PRN1371, an irreversible covalent inhibitor of FGFR1-4 targeting a cysteine within the kinase active site.  PRN1371 demonstrated strong FGFR potency and excellent kinome-wide selectivity in a no. of biochem. and cellular assays, including in various cancer cell lines exhibiting FGFR alterations.  Furthermore, PRN1371 maintained FGFR inhibition in vivo, not only when circulating drug levels were high but also after the drug had been cleared from circulation, indicating the possibility of sustained FGFR inhibition in the clinic without the need for continuous drug exposure.  Durable tumor regression was also obtained in multiple tumor xenografts and patient-derived tumor xenograft models and was sustained even using an intermittent dosing strategy that provided drug holidays.  PRN1371 is currently under clin. investigation for treatment of patients with solid tumors.  Mol Cancer Ther; 16(12); 2668-76. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzKzxYYE-2ZbVg90H21EOLACvtfcHk0lh7MpAQok89iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWhsL7J&md5=72f3af90d5e9a2f4060e5d0e4c8b99f9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0309%26sid%3Dliteratum%253Aachs%26aulast%3DVenetsanakos%26aufirst%3DE.%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DPhan%26aufirst%3DV.%2BT.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DXing%26aufirst%3DY.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLaStant%26aufirst%3DJ.%26aulast%3DLeung%26aufirst%3DK.%26aulast%3DKarr%26aufirst%3DD.%2BE.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGerritsen%26aufirst%3DM.%2BE.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520Irreversible%2520Covalent%2520Fibroblast%2520Growth%2520Factor%2520Receptor%2520Inhibitor%2520PRN1371%2520Exhibits%2520Sustained%2520Inhibition%2520of%2520FGFR%2520after%2520Drug%2520Clearance%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26issue%3D12%26spage%3D2668%26epage%3D2676%26doi%3D10.1158%2F1535-7163.MCT-17-0309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knoepfel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaul, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galuba, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trappe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voshol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genick, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunet-Lefeuvre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitsch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graus-Porta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span> <span> </span><span class="NLM_article-title">Approaches to Selective Fibroblast Growth Factor Receptor 4 Inhibition through Targeting the ATP-Pocket Middle-Hinge Region</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1604</span>– <span class="NLM_lpage">1613</span>, <span class="refDoi"> DOI: 10.1039/C7MD00213K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1039%2FC7MD00213K" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1604-1613&issue=8&author=R.+A.+Fairhurstauthor=T.+Knoepfelauthor=C.+Leblancauthor=N.+Buschmannauthor=C.+Gaulauthor=J.+Blankauthor=I.+Galubaauthor=J.+Trappeauthor=C.+Zouauthor=J.+Vosholauthor=C.+Genickauthor=P.+Brunet-Lefeuvreauthor=F.+Bitschauthor=D.+Graus-Portaauthor=P.+Furet&title=Approaches+to+Selective+Fibroblast+Growth+Factor+Receptor+4+Inhibition+through+Targeting+the+ATP-Pocket+Middle-Hinge+Region&doi=10.1039%2FC7MD00213K"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1039%2FC7MD00213K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00213K%26sid%3Dliteratum%253Aachs%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DKnoepfel%26aufirst%3DT.%26aulast%3DLeblanc%26aufirst%3DC.%26aulast%3DBuschmann%26aufirst%3DN.%26aulast%3DGaul%26aufirst%3DC.%26aulast%3DBlank%26aufirst%3DJ.%26aulast%3DGaluba%26aufirst%3DI.%26aulast%3DTrappe%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DC.%26aulast%3DVoshol%26aufirst%3DJ.%26aulast%3DGenick%26aufirst%3DC.%26aulast%3DBrunet-Lefeuvre%26aufirst%3DP.%26aulast%3DBitsch%26aufirst%3DF.%26aulast%3DGraus-Porta%26aufirst%3DD.%26aulast%3DFuret%26aufirst%3DP.%26atitle%3DApproaches%2520to%2520Selective%2520Fibroblast%2520Growth%2520Factor%2520Receptor%25204%2520Inhibition%2520through%2520Targeting%2520the%2520ATP-Pocket%2520Middle-Hinge%2520Region%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26issue%3D8%26spage%3D1604%26epage%3D1613%26doi%3D10.1039%2FC7MD00213K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xian, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">A Structure-Guided Approach to Creating Covalent FGFR Inhibitors</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1016%2Fj.chembiol.2010.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=20338520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=285-295&issue=3&author=W.+Zhouauthor=W.+Hurauthor=U.+McDermottauthor=A.+Duttauthor=W.+Xianauthor=S.+B.+Ficarroauthor=J.+Zhangauthor=S.+V.+Sharmaauthor=J.+Bruggeauthor=M.+Meyersonauthor=J.+Settlemanauthor=N.+S.+Gray&title=A+Structure-Guided+Approach+to+Creating+Covalent+FGFR+Inhibitors&doi=10.1016%2Fj.chembiol.2010.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A Structure-Guided Approach to Creating Covalent FGFR Inhibitors</span></div><div class="casAuthors">Zhou, Wenjun; Hur, Wooyoung; McDermott, Ultan; Dutt, Amit; Xian, Wa; Ficarro, Scott B.; Zhang, Jianming; Sharma, Sreenath V.; Brugge, Joan; Meyerson, Matthew; Settleman, Jeffrey; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-295</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The fibroblast growth factor receptor tyrosine kinases (FGFR1, 2, 3, and 4) represent promising therapeutic targets in a no. of cancers.  We have developed the first potent and selective irreversible inhibitor of FGFR1, 2, 3, and 4, which we named FIIN-1 that forms a covalent bond with cysteine 486 located in the P loop of the FGFR1 ATP binding site.  We demonstrated that the inhibitor potently inhibits Tel-FGFR1-transformed Ba/F3 cells (EC50 = 14 nM) as well as numerous FGFR-dependent cancer cell lines.  A biotin-derivatized version of the inhibitor, FIIN-1-biotin, was shown to covalently label FGFR1 at Cys486.  FIIN-1 is a useful probe of FGFR-dependent cellular phenomena and may provide a starting point of the development of therapeutically relevant irreversible inhibitors of wild-type and drug-resistant forms of FGFR kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqxMZh8QQP47Vg90H21EOLACvtfcHk0lh7MpAQok89iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D&md5=0b7b084a073b1c6f30f38565a0e4db81</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DDutt%26aufirst%3DA.%26aulast%3DXian%26aufirst%3DW.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBrugge%26aufirst%3DJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520Structure-Guided%2520Approach%2520to%2520Creating%2520Covalent%2520FGFR%2520Inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26issue%3D3%26spage%3D285%26epage%3D295%26doi%3D10.1016%2Fj.chembiol.2010.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyana-Sundaram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khazanov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ateeq, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonigro, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vats, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.-F.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Identification of Targetable FGFR Gene Fusions in Diverse Cancers</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">636</span>– <span class="NLM_lpage">647</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F2159-8290.CD-13-0050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=23558953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVOrt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=636-647&issue=6&author=Y.-M.+Wuauthor=F.+Suauthor=S.+Kalyana-Sundaramauthor=N.+Khazanovauthor=B.+Ateeqauthor=X.+Caoauthor=R.+J.+Lonigroauthor=P.+Vatsauthor=R.+Wangauthor=S.-F.+Lin&title=Identification+of+Targetable+FGFR+Gene+Fusions+in+Diverse+Cancers&doi=10.1158%2F2159-8290.CD-13-0050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Targetable FGFR Gene Fusions in Diverse Cancers</span></div><div class="casAuthors">Wu, Yi-Mi; Su, Fengyun; Kalyana-Sundaram, Shanker; Khazanov, Nickolay; Ateeq, Bushra; Cao, Xuhong; Lonigro, Robert J.; Vats, Pankaj; Wang, Rui; Lin, Su-Fang; Cheng, Ann-Joy; Kunju, Lakshmi P.; Siddiqui, Javed; Tomlins, Scott A.; Wyngaard, Peter; Sadis, Seth; Roychowdhury, Sameek; Hussain, Maha H.; Feng, Felix Y.; Zalupski, Mark M.; Talpaz, Moshe; Pienta, Kenneth J.; Rhodes, Daniel R.; Robinson, Dan R.; Chinnaiyan, Arul M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">636-647</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Through a prospective clin. sequencing program for advanced cancers, four index cases were identified which harbor gene rearrangements of FGFR2, including patients with cholangiocarcinoma, breast cancer, and prostate cancer.  After extending our assessment of FGFR rearrangements across multiple tumor cohorts, we identified addnl. FGFR fusions with intact kinase domains in lung squamous cell cancer, bladder cancer, thyroid cancer, oral cancer, glioblastoma, and head and neck squamous cell cancer.  All FGFR fusion partners tested exhibit oligomerization capability, suggesting a shared mode of kinase activation.  Overexpression of FGFR fusion proteins induced cell proliferation.  Two bladder cancer cell lines that harbor FGFR3 fusion proteins exhibited enhanced susceptibility to pharmacol. inhibition in vitro and in vivo.  Because of the combinatorial possibilities of FGFR family fusion to a variety of oligomerization partners, clin. sequencing efforts, which incorporate transcriptome anal. for gene fusions, are poised to identify rare, targetable FGFR fusions across diverse cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodvZGzChrbzrVg90H21EOLACvtfcHk0liXeteGX1SOjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVOrt7s%253D&md5=efee9f36e261e9df463e598f4018f07d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0050%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-M.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DKalyana-Sundaram%26aufirst%3DS.%26aulast%3DKhazanov%26aufirst%3DN.%26aulast%3DAteeq%26aufirst%3DB.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DLonigro%26aufirst%3DR.%2BJ.%26aulast%3DVats%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DS.-F.%26atitle%3DIdentification%2520of%2520Targetable%2520FGFR%2520Gene%2520Fusions%2520in%2520Diverse%2520Cancers%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26issue%3D6%26spage%3D636%26epage%3D647%26doi%3D10.1158%2F2159-8290.CD-13-0050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahleda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dienstmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Italiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazzah, A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced Solid Tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">30</span>),  <span class="NLM_fpage">3401</span>– <span class="NLM_lpage">3408</span>, <span class="refDoi"> DOI: 10.1200/JCO.2014.60.7341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1200%2FJCO.2014.60.7341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=26324363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFGrtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=3401-3408&issue=30&author=J.+Taberneroauthor=R.+Bahledaauthor=R.+Dienstmannauthor=J.+R.+Infanteauthor=A.+Mitaauthor=A.+Italianoauthor=E.+Calvoauthor=V.+Morenoauthor=B.+Adamoauthor=A.+Gazzah&title=Phase+I+Dose-Escalation+Study+of+JNJ-42756493%2C+an+Oral+Pan-Fibroblast+Growth+Factor+Receptor+Inhibitor%2C+in+Patients+with+Advanced+Solid+Tumors&doi=10.1200%2FJCO.2014.60.7341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I dose-escalation study of JNJ-42756493, an oral Pan-Fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors</span></div><div class="casAuthors">Tabernero, Josep; Bahleda, Rastislav; Dienstmann, Rodrigo; Infante, Jeffrey R.; Mita, Alain; Italiano, Antoine; Calvo, Emiliano; Moreno, Victor; Adamo, Barbara; Gazzah, Anas; Zhong, Bob; Platero, Suso J.; Smit, Johan W.; Stuyckens, Kim; Chatterjee-Kishore, Moitreyee; Radon, Jordi; Peddareddigari, Vijay; Luo, Feng R.; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">3401-3408</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: JNJ-42756493 is an orally administered pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.  This first-in-human study evaluates the safety, pharmacokinetics, and pharmaco-dynamics and defines the recommended phase II dose (RP2D) of JNJ-42756493.  Patients and Methods: Eligible patients with advanced solid tumors received escalating doses of JNJ-42756493 from 0.5 to 12 mg administered continuously daily or JNJ-42756493 10 or 12 mg administered intermittently (7 days on/7 days off).  Results: Sixty-five patients were enrolled.  The most common treatment-emergent adverse events included hyperphosphatemia (65%), asthenia (55%), dry mouth (45%), nail toxicity (35%), constipation (34%), decreased appetite (32%), and dysgeusia (31%).  Twenty-seven patients (42%) experi- enced grade ≥ 3 treatment-emergent adverse events, and one dose-limiting toxicity of grade 3 ALT elevation was obsd. at 12 mg daily.  Maximum-tolerated dose was not defined.  Nine milligrams daily was considered as the initial RP2D; however, tolerability was improved with intermittent schedules, and 10 mg administered on a 7-days-on/7-days-off schedule was considered the final RP2D.  Pharmacokinetics were linear, dose proportional, and predictable, with a half-life of 50 to 60 h.  Dose-dependent elevations in serum phosphate, a manifestation of pharmacodynamic effect, occurred in all patients starting at 4 mg daily.  Among 23 response- evaluable patients with tumor FGFR pathway alterations, four confirmed responses and one unconfirmed partial response were obsd. in patients with glioblastoma and urothelial and endometrial cancer (all with FGFR2 or FGFR3 translocations); 16 patients had stable disease.  Conclusion: JNJ-42756493 administered at 10 mg on a 7-days-on/7-days-off schedule achieved exposures at which clin. responses were obsd., demonstrated pharmacodynamic biomarker activity, and had a manageable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo08TfKyvsabVg90H21EOLACvtfcHk0liXeteGX1SOjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFGrtb4%253D&md5=6d4a6b3c2f06f3d5d1a490cf9ffe44c5</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.60.7341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.60.7341%26sid%3Dliteratum%253Aachs%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DBahleda%26aufirst%3DR.%26aulast%3DDienstmann%26aufirst%3DR.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DMita%26aufirst%3DA.%26aulast%3DItaliano%26aufirst%3DA.%26aulast%3DCalvo%26aufirst%3DE.%26aulast%3DMoreno%26aufirst%3DV.%26aulast%3DAdamo%26aufirst%3DB.%26aulast%3DGazzah%26aufirst%3DA.%26atitle%3DPhase%2520I%2520Dose-Escalation%2520Study%2520of%2520JNJ-42756493%252C%2520an%2520Oral%2520Pan-Fibroblast%2520Growth%2520Factor%2520Receptor%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26issue%3D30%26spage%3D3401%26epage%3D3408%26doi%3D10.1200%2FJCO.2014.60.7341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nogova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez Garcia, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delord, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassier, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Kinase Inhibitor, in Patients with Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.67.2048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1200%2FJCO.2016.67.2048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=27870574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlensr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=157-165&issue=2&author=L.+Nogovaauthor=L.+V.+Sequistauthor=J.+M.+Perez+Garciaauthor=F.+Andreauthor=J.-P.+Delordauthor=M.+Hidalgoauthor=J.+H.+Schellensauthor=P.+A.+Cassierauthor=D.+R.+Camidgeauthor=M.+Schuler&title=Evaluation+of+BGJ398%2C+a+Fibroblast+Growth+Factor+Receptor+1%E2%80%933+Kinase+Inhibitor%2C+in+Patients+with+Advanced+Solid+Tumors+Harboring+Genetic+Alterations+in+Fibroblast+Growth+Factor+Receptors%3A+Results+of+a+Global+Phase+I%2C+Dose-Escalation+and+Dose-Expansion+Study&doi=10.1200%2FJCO.2016.67.2048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study</span></div><div class="casAuthors">Nogova, Lucia; Sequist, Lecia V.; Garcia, Jose Manuel Perez; Andre, Fabrice; Delord, Jean-Pierre; Hidalgo, Manuel; Schellens, Jan H. M.; Cassier, Philippe A.; Camidge, D. Ross; Schuler, Martin; Vaishampayan, Ulka; Burris, Howard; Tian, G. Gary; Campone, Mario; Wainberg, Zev A.; Lim, Wan-Teck; Lo Russo, Patricia; Shapiro, Geoffrey I.; Parker, Katie; Chen, Xueying; Choudhury, Somesh; Ringeisen, Francois; Graus-Porta, Diana; Porter, Dale; Isaacs, Randi; Buettner, Reinhard; Wolf, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-175</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: This two-part, first-in-human study was initiated in patient swith advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors (FGFRs) to det. the max. tolerated dose (MTD), the recommended phase II dose (RP2D), and the schedule, safety, pharmacokinetics, pharmacodynamics, and antitumor activity of oral BGJ398, a selective FGFR1-3 tyrosine kinase inhibitor.  Patients and Methods: Adult patients were treated with escalating dosages of BGJ398 5 to 150 mg once daily or 50 mg twice daily continuously in 28-day cycles.  During expansion at the MTD, patients with FGFR1-amplified squamous cell non-small-cell lung cancer (sqNSCLC; arm 1) or other solid tumors with FGFR genetic alterations (mutations/amplifications/fusions) received BGJ398 daily on a continuous schedule (arm 2), or on a 3-wk-on/1-wk-off schedule (arm 3).  Results: Data in 132 patients from the escalation and expansion arms are reported (May 15, 2015, cutoff).  The MTD, 125 mg daily, was detd. on the basis of dose-limiting toxicities in four patients (100 mg, grade 3 aminotransferase elevations [n = 1]; 125 mg, hyperphosphatemia [n = 1]; 150 mg, grade 1 corneal toxicity [n = 1] and grade 3 aminotransferase elevations [n = 1]).  Common adverse events in patients treated at the MTD (n = 57) included hyperphosphatemia (82.5%), constipation (50.9%), decreased appetite (45.6%), and stomatitis (45.6%).  A similar safety profile was obsd. using the 3-wk-on/1-wk-off schedule (RP2D).  However, adverse event-related dose adjustments/interruptions were less frequent with the 3-wk-on/1-wk-off (50.0%) vs. the continuous (73.7%) schedule.  Antitumor activity (seven partial responses [six confirmed]) was demonstrated with BGJ398 doses ≥ 100 mg in patients with FGFR1-amplified sqNSCLC and FGFR3-mutant bladder/urothelial cancer.  Conclusion: BGJ398 at the MTD/RP2D had a tolerable and manageable safety profile and showed antitumor activity in several tumor types, including FGFR1-amplified sqNSCLC and FGFR3-mutant bladder/urothelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0KJ9yf2nMQrVg90H21EOLACvtfcHk0liXeteGX1SOjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlensr0%253D&md5=b0204f7a46eeaa059fe732ad35508ca9</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.67.2048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.67.2048%26sid%3Dliteratum%253Aachs%26aulast%3DNogova%26aufirst%3DL.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DPerez%2BGarcia%26aufirst%3DJ.%2BM.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DDelord%26aufirst%3DJ.-P.%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3DCassier%26aufirst%3DP.%2BA.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DSchuler%26aufirst%3DM.%26atitle%3DEvaluation%2520of%2520BGJ398%252C%2520a%2520Fibroblast%2520Growth%2520Factor%2520Receptor%25201%25E2%2580%25933%2520Kinase%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%2520Harboring%2520Genetic%2520Alterations%2520in%2520Fibroblast%2520Growth%2520Factor%2520Receptors%253A%2520Results%2520of%2520a%2520Global%2520Phase%2520I%252C%2520Dose-Escalation%2520and%2520Dose-Expansion%2520Study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26issue%3D2%26spage%3D157%26epage%3D165%26doi%3D10.1200%2FJCO.2016.67.2048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Degirolamo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbà, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moschetta, A.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Potential of the Endocrine Fibroblast Growth Factors FGF19, FGF21 and FGF23</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1038/nrd.2015.9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1038%2Fnrd.2015.9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=26567701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVCqsbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=51-69&issue=1&author=C.+Degirolamoauthor=C.+Sabb%C3%A0author=A.+Moschetta&title=Therapeutic+Potential+of+the+Endocrine+Fibroblast+Growth+Factors+FGF19%2C+FGF21+and+FGF23&doi=10.1038%2Fnrd.2015.9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23</span></div><div class="casAuthors">Degirolamo, Chiara; Sabba, Carlo; Moschetta, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-69</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The endocrine fibroblast growth factors (FGFs), FGF19, FGF21 and FGF23, are crit. for maintaining whole-body homeostasis, with roles in bile acid, glucose and lipid metab., modulation of vitamin D and phosphate homeostasis and metabolic adaptation during fasting.  Given these functions, the endocrine FGFs have therapeutic potential in a wide array of chronic human diseases, including obesity, type 2 diabetes, cancer, and kidney and cardiovascular disease.  However, the safety and feasibility of chronic endocrine FGF administration has been challenged, and FGF analogs and mimetics are now being investigated.  Here, we discuss current knowledge of the complex biol. of the endocrine FGFs and assess how this may be harnessed therapeutically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfwCe0KoqharVg90H21EOLACvtfcHk0lhF3RkAHWelgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVCqsbjK&md5=da061de431f62ea2bc62d046905f81bb</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2015.9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2015.9%26sid%3Dliteratum%253Aachs%26aulast%3DDegirolamo%26aufirst%3DC.%26aulast%3DSabb%25C3%25A0%26aufirst%3DC.%26aulast%3DMoschetta%26aufirst%3DA.%26atitle%3DTherapeutic%2520Potential%2520of%2520the%2520Endocrine%2520Fibroblast%2520Growth%2520Factors%2520FGF19%252C%2520FGF21%2520and%2520FGF23%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26issue%3D1%26spage%3D51%26epage%3D69%26doi%3D10.1038%2Fnrd.2015.9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bifulco, N.</span>; <span class="NLM_string-name">Dipietro, L. V.</span>; <span class="NLM_string-name">Hodous, B. L.</span>; <span class="NLM_string-name">Miduturu, C. V.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the Fibroblast Growth Factor Receptor</span>. <span class="NLM_patent">WO 2015061572</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=N.+Bifulco&author=L.+V.+Dipietro&author=B.+L.+Hodous&author=C.+V.+Miduturu&title=Inhibitors+of+the+Fibroblast+Growth+Factor+Receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBifulco%26aufirst%3DN.%26atitle%3DInhibitors%2520of%2520the%2520Fibroblast%2520Growth%2520Factor%2520Receptor%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R.</span>; <span class="NLM_string-name">Sarker, D.</span>; <span class="NLM_string-name">Macarulla, T.</span>; <span class="NLM_string-name">Yau, T.</span>; <span class="NLM_string-name">Choo, S. P.</span>; <span class="NLM_string-name">Meyer, T.</span>; <span class="NLM_string-name">Hollebecque, A.</span>; <span class="NLM_string-name">Whisenant, J.</span>; <span class="NLM_string-name">Sung, M.</span>; <span class="NLM_string-name">Yoon, J.</span></span>; <span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">365O Phase 1 Safety and Clinical Activity of BLU-554 in Advanced Hepatocellular Carcinoma (HCC)</span>.  <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume">28</span> (<span class="NLM_issue">Suppl. 5</span>),<span class="refDoi"> DOI: 10.1093/annonc/mdx367</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1093%2Fannonc%2Fmdx367" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&issue=Suppl.+5&author=R.+Kim&author=D.+Sarker&author=T.+Macarulla&author=T.+Yau&author=S.+P.+Choo&author=T.+Meyer&author=A.+Hollebecque&author=J.+Whisenant&author=M.+Sung&author=J.+Yoon&title=365O+Phase+1+Safety+and+Clinical+Activity+of+BLU-554+in+Advanced+Hepatocellular+Carcinoma+%28HCC%29&doi=10.1093%2Fannonc%2Fmdx367"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx367%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DR.%26atitle%3D365O%2520Phase%25201%2520Safety%2520and%2520Clinical%2520Activity%2520of%2520BLU-554%2520in%2520Advanced%2520Hepatocellular%2520Carcinoma%2520%2528HCC%2529%26jtitle%3DAnn.%2520Oncol.%26date%3D2017%26volume%3D28%26issue%3DSuppl.%25205%26doi%3D10.1093%2Fannonc%2Fmdx367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, D.</span>; <span class="NLM_string-name">Hao, M.</span>; <span class="NLM_string-name">Wang, J.</span>; <span class="NLM_string-name">Prajapati, S.</span>; <span class="NLM_string-name">Satoh, T.</span>; <span class="NLM_string-name">Selvaraj, A.</span></span> <span> </span><span class="NLM_article-title">Pyrimidine FGFR4 Inhibitors</span>. <span class="NLM_patent">WO 2015057938</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=D.+Reynolds&author=M.+Hao&author=J.+Wang&author=S.+Prajapati&author=T.+Satoh&author=A.+Selvaraj&title=Pyrimidine+FGFR4+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DReynolds%26aufirst%3DD.%26atitle%3DPyrimidine%2520FGFR4%2520Inhibitors%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffey, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prajapati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">6999</span>– <span class="NLM_lpage">7013</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-17-1865</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F0008-5472.CAN-17-1865" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=29247039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOgur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=6999-7013&issue=24&author=J.+J.+Joshiauthor=H.+Coffeyauthor=E.+Corcoranauthor=J.+Tsaiauthor=C.-L.+Huangauthor=K.+Ichikawaauthor=S.+Prajapatiauthor=M.-H.+Haoauthor=S.+Baileyauthor=J.+Wu&title=H3B-6527+Is+a+Potent+and+Selective+Inhibitor+of+FGFR4+in+FGF19-Driven+Hepatocellular+Carcinoma&doi=10.1158%2F0008-5472.CAN-17-1865"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma</span></div><div class="casAuthors">Joshi, Jaya Julie; Coffey, Heather; Corcoran, Erik; Tsai, Jennifer; Huang, Chia-Ling; Ichikawa, Kana; Prajapati, Sudeep; Hao, Ming-Hong; Bailey, Suzanna; Wu, Jeremy; Rimkunas, Victoria; Karr, Craig; Subramanian, Vanitha; Kumar, Pavan; MacKenzie, Crystal; Hurley, Raelene; Satoh, Takashi; Yu, Kun; Park, Eunice; Rioux, Nathalie; Kim, Amy; Lai, Weidong G.; Yu, Lihua; Zhu, Ping; Buonamici, Silvia; Larsen, Nicholas; Fekkes, Peter; Wang, John; Warmuth, Markus; Reynolds, Dominic J.; Smith, Peter G.; Selvaraj, Anand</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6999-7013</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activation of the fibroblast growth factor receptor FGFR4 by FGF19 drives hepatocellular carcinoma (HCC), a disease with few, if any, effective treatment options.  While a no. of pan-FGFR inhibitors are being clin. evaluated, their application to FGF19-driven HCC may be limited by dose-limiting toxicities mediated by FGFR1-3 receptors.  To evade the potential limitations of pan-FGFR inhibitors, we generated H3B-6527, a highly selective covalent FGFR4 inhibitor, through structure-guided drug design.  Studies in a panel of 40 HCC cell lines and 30 HCC PDX models showed that FGF19 expression is a predictive biomarker for H3B-6527 response.  Moreover, coadministration of the CDK4/6 inhibitor palbociclib in combination with H3B-6527 could effectively trigger tumor regression in a xenograft model of HCC.  Overall, our results offer preclin. proof of concept for H3B-6527 as a candidate therapeutic agent for HCC cases that exhibit increased expression of FGF19.  Cancer Res; 77(24); 6999-7013. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohONN1gEpft7Vg90H21EOLACvtfcHk0lhF3RkAHWelgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOgur%252FI&md5=9d7ea6245e3b047aa85fc6961a88e5eb</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-1865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-1865%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DJ.%2BJ.%26aulast%3DCoffey%26aufirst%3DH.%26aulast%3DCorcoran%26aufirst%3DE.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DC.-L.%26aulast%3DIchikawa%26aufirst%3DK.%26aulast%3DPrajapati%26aufirst%3DS.%26aulast%3DHao%26aufirst%3DM.-H.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DH3B-6527%2520Is%2520a%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520FGFR4%2520in%2520FGF19-Driven%2520Hepatocellular%2520Carcinoma%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D24%26spage%3D6999%26epage%3D7013%26doi%3D10.1158%2F0008-5472.CAN-17-1865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guise, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00091</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00091" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsVWhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=543-548&issue=5&author=C.+Moauthor=Z.+Zhangauthor=C.+P.+Guiseauthor=X.+Liauthor=J.+Luoauthor=Z.+Tuauthor=Y.+Xuauthor=A.+V.+Pattersonauthor=J.+B.+Smaillauthor=X.+Renauthor=X.+Luauthor=K.+Ding&title=2-Aminopyrimidine+Derivatives+as+New+Selective+Fibroblast+Growth+Factor+Receptor+4+%28FGFR4%29+Inhibitors&doi=10.1021%2Facsmedchemlett.7b00091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors</span></div><div class="casAuthors">Mo, Cheng; Zhang, Zhang; Guise, Christopher P.; Li, Xueqiang; Luo, Jinfeng; Tu, Zhengchao; Xu, Yong; Patterson, Adam V.; Smaill, Jeff B.; Ren, Xiaomei; Lu, Xiaoyun; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">543-548</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 2-aminopyrimidine derivs. were designed and synthesized as highly selective FGFR4 inhibitors.  One of the most promising compds. I tightly bound FGFR4 with a Kd value of 3.3 nM and potently inhibited its enzymic activity with an IC50 value of 2.6 nM, but completely spared FGFR1/2/3.  The compd. selectively suppressed proliferation of breast cancer cells harboring dysregulated FGFR4 signaling with an IC50 value of 0.38 μM.  Furthermore, I exhibited extraordinary target specificity in a Kinome-wide screen against 468 kinases, with S(35) and S(10) selectivity scores of 0.01 and 0.007 at 1.0 μM, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqZiLAE7lPj7Vg90H21EOLACvtfcHk0liChNRNG3hdfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsVWhu7s%253D&md5=63aec200353c08090a50a9c5988442bd</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00091%26sid%3Dliteratum%253Aachs%26aulast%3DMo%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DGuise%26aufirst%3DC.%2BP.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DPatterson%26aufirst%3DA.%2BV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3D2-Aminopyrimidine%2520Derivatives%2520as%2520New%2520Selective%2520Fibroblast%2520Growth%2520Factor%2520Receptor%25204%2520%2528FGFR4%2529%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D5%26spage%3D543%26epage%3D548%26doi%3D10.1021%2Facsmedchemlett.7b00091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, W.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of Selective FGFR4 Inhibitors Via Scaffold Hopping</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2420</span>– <span class="NLM_lpage">2423</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1016%2Fj.bmcl.2017.04.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2420-2423&issue=11&author=Y.+Wangauthor=Z.+Chenauthor=M.+Daiauthor=P.+Sunauthor=C.+Wangauthor=Y.+Gaoauthor=H.+Zhaoauthor=W.+Zengauthor=L.+Shenauthor=W.+Mao&title=Discovery+and+Optimization+of+Selective+FGFR4+Inhibitors+Via+Scaffold+Hopping&doi=10.1016%2Fj.bmcl.2017.04.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DDai%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DZeng%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DMao%26aufirst%3DW.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Selective%2520FGFR4%2520Inhibitors%2520Via%2520Scaffold%2520Hopping%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D11%26spage%3D2420%26epage%3D2423%26doi%3D10.1016%2Fj.bmcl.2017.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knoepfel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripoche, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graus-Porta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wartmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galuba, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. A.</span></span> <span> </span><span class="NLM_article-title">2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00485</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00485" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Srsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=215-220&issue=3&author=T.+Knoepfelauthor=P.+Furetauthor=R.+Mahauthor=N.+Buschmannauthor=C.+Leblancauthor=S.+Ripocheauthor=D.+Graus-Portaauthor=M.+Wartmannauthor=I.+Galubaauthor=R.+A.+Fairhurst&title=2-Formylpyridyl+Ureas+as+Highly+Selective+Reversible-Covalent+Inhibitors+of+Fibroblast+Growth+Factor+Receptor+4&doi=10.1021%2Facsmedchemlett.7b00485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4</span></div><div class="casAuthors">Knoepfel, Thomas; Furet, Pascal; Mah, Robert; Buschmann, Nicole; Leblanc, Catherine; Ripoche, Sebastien; Graus-Porta, Diana; Wartmann, Markus; Galuba, Inga; Fairhurst, Robin A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-220</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As part of a project to identify FGFR4 selective inhibitors, scaffold morphing of a 2-formylquinoline amide hit identified series of 2-formylpyridine ureas (2-FPUs) with improved potency and physicochem. properties.  In particular, tetrahydronaphthyridine urea analogs with cellular activities below 30 nM have been identified.  Consistent with the hypothesized reversible-covalent mechanism of inhibition, the 2-FPUs exhibited slow binding kinetics, and the aldehyde, as the putative electrophile, could be demonstrated to be a key structural element for activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA1PRltYPuWrVg90H21EOLACvtfcHk0liChNRNG3hdfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Srsb4%253D&md5=fd43811b8a9e5f7a02f27096569423f8</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00485%26sid%3Dliteratum%253Aachs%26aulast%3DKnoepfel%26aufirst%3DT.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DMah%26aufirst%3DR.%26aulast%3DBuschmann%26aufirst%3DN.%26aulast%3DLeblanc%26aufirst%3DC.%26aulast%3DRipoche%26aufirst%3DS.%26aulast%3DGraus-Porta%26aufirst%3DD.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DGaluba%26aufirst%3DI.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26atitle%3D2-Formylpyridyl%2520Ureas%2520as%2520Highly%2520Selective%2520Reversible-Covalent%2520Inhibitors%2520of%2520Fibroblast%2520Growth%2520Factor%2520Receptor%25204%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D3%26spage%3D215%26epage%3D220%26doi%3D10.1021%2Facsmedchemlett.7b00485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buschmann, N.</span>; <span class="NLM_string-name">Fairhurst, R. A.</span>; <span class="NLM_string-name">Furet, P.</span>; <span class="NLM_string-name">Knöpfel, T.</span>; <span class="NLM_string-name">Leblanc, C.</span>; <span class="NLM_string-name">Mah, R.</span>; <span class="NLM_string-name">Nimsgern, P.</span>; <span class="NLM_string-name">Ripoche, S.</span>; <span class="NLM_string-name">Liao, L.</span>; <span class="NLM_string-name">Xiong, J.</span>; <span class="NLM_string-name">Zhao, X.</span>; <span class="NLM_string-name">Han, B.</span>; <span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">Ring-Fused Bicyclic Pyridyl Derivatives as FGFR4 Inhibitors</span>. U.S. Patent <span class="NLM_patent">9,266,883</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=N.+Buschmann&author=R.+A.+Fairhurst&author=P.+Furet&author=T.+Kn%C3%B6pfel&author=C.+Leblanc&author=R.+Mah&author=P.+Nimsgern&author=S.+Ripoche&author=L.+Liao&author=J.+Xiong&author=X.+Zhao&author=B.+Han&author=C.+Wang&title=Ring-Fused+Bicyclic+Pyridyl+Derivatives+as+FGFR4+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBuschmann%26aufirst%3DN.%26atitle%3DRing-Fused%2520Bicyclic%2520Pyridyl%2520Derivatives%2520as%2520FGFR4%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porta, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wartmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinyamu-Akunda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span> <span> </span><span class="NLM_article-title">NVP-FGF401, a First-in-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of HCC</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">13 Suppl.</span>),  <span class="NLM_fpage">2098</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-2098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F1538-7445.AM2017-2098" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=2098&issue=13+Suppl.&author=D.+G.+Portaauthor=A.+Weissauthor=R.+A.+Fairhurstauthor=M.+Wartmannauthor=C.+Stammauthor=F.+Reimannauthor=A.+Buhlesauthor=J.+Kinyamu-Akundaauthor=D.+Sterkerauthor=M.+Murakamiauthor=Y.+Wangauthor=J.+Engelmanauthor=F.+Hofmannauthor=W.+R.+Sellers&title=NVP-FGF401%2C+a+First-in-Class+Highly+Selective+and+Potent+FGFR4+Inhibitor+for+the+Treatment+of+HCC&doi=10.1158%2F1538-7445.AM2017-2098"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-2098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-2098%26sid%3Dliteratum%253Aachs%26aulast%3DPorta%26aufirst%3DD.%2BG.%26aulast%3DWeiss%26aufirst%3DA.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DStamm%26aufirst%3DC.%26aulast%3DReimann%26aufirst%3DF.%26aulast%3DBuhles%26aufirst%3DA.%26aulast%3DKinyamu-Akunda%26aufirst%3DJ.%26aulast%3DSterker%26aufirst%3DD.%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DEngelman%26aufirst%3DJ.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26atitle%3DNVP-FGF401%252C%2520a%2520First-in-Class%2520Highly%2520Selective%2520and%2520Potent%2520FGFR4%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520HCC%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D13%2520Suppl%26spage%3D2098%26doi%3D10.1158%2F1538-7445.AM2017-2098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinyamu-Akunda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wartmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span> <span> </span><span class="NLM_article-title">NVP-FGF401: Cellular and in Vivo Profile of a Novel Highly Potent and Selective FGFR4 Inhibitor for the Treatment of FGF19/FGFR4/KLB+ Tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">13 Suppl.</span>),  <span class="NLM_fpage">2103</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-2103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F1538-7445.AM2017-2103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=2103&issue=13+Suppl.&author=A.+Weissauthor=D.+G.+Portaauthor=F.+Reimannauthor=A.+Buhlesauthor=C.+Stammauthor=R.+A.+Fairhurstauthor=J.+Kinyamu-Akundaauthor=D.+Sterkerauthor=M.+Murakamiauthor=M.+Wartmannauthor=Y.+Wangauthor=J.+A.+Engelmanauthor=F.+Hofmannauthor=W.+R.+Sellers&title=NVP-FGF401%3A+Cellular+and+in+Vivo+Profile+of+a+Novel+Highly+Potent+and+Selective+FGFR4+Inhibitor+for+the+Treatment+of+FGF19%2FFGFR4%2FKLB%2B+Tumors&doi=10.1158%2F1538-7445.AM2017-2103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-2103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-2103%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DA.%26aulast%3DPorta%26aufirst%3DD.%2BG.%26aulast%3DReimann%26aufirst%3DF.%26aulast%3DBuhles%26aufirst%3DA.%26aulast%3DStamm%26aufirst%3DC.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DKinyamu-Akunda%26aufirst%3DJ.%26aulast%3DSterker%26aufirst%3DD.%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26atitle%3DNVP-FGF401%253A%2520Cellular%2520and%2520in%2520Vivo%2520Profile%2520of%2520a%2520Novel%2520Highly%2520Potent%2520and%2520Selective%2520FGFR4%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520FGF19%252FFGFR4%252FKLB%252B%2520Tumors%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D13%2520Suppl%26spage%3D2103%26doi%3D10.1158%2F1538-7445.AM2017-2103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schadt, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahl, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuersch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couttet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emotte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C.-H.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Bile Acid Sequestration by Cholestyramine Mitigates FGFR4 Inhibition-Induced Alt Elevation</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>163</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">278</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfy031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1093%2Ftoxsci%2Fkfy031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=29432567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGksr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2018&pages=265-278&issue=1&author=H.+S.+Schadtauthor=A.+Wolfauthor=J.+A.+Mahlauthor=K.+Wuerschauthor=P.+Couttetauthor=M.+Schwaldauthor=A.+Fischerauthor=M.+Lienardauthor=C.+Emotteauthor=C.-H.+Teng&title=Bile+Acid+Sequestration+by+Cholestyramine+Mitigates+FGFR4+Inhibition-Induced+Alt+Elevation&doi=10.1093%2Ftoxsci%2Fkfy031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Bile acid sequestration by cholestyramine mitigates FGFR4 inhibition-induced ALT elevation</span></div><div class="casAuthors">Schadt, Heiko S.; Wolf, Armin; Mahl, Joerg Andreas; Wuersch, Kuno; Couttet, Philippe; Schwald, Marianne; Fischer, Audrey; Lienard, Mathilde; Emotte, Corinne; Teng, Chi-Hse; Skuba, Elizabeth; Richardson, Terrilyn A.; Manenti, Luigi; Weiss, Andreas; Porta, Diana Graus; Fairhurst, Robin A.; Kullak-Ublick, Gerd A.; Chibout, Salah-Dine; Pognan, Francois; Kluwe, William; Kinyamu-Akunda, Jacqueline</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">265-278</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The FGF19-fibroblast growth factor receptor (FGFR4)-βKlotho (KLB) pathway plays an important role in the regulation of bile acid (BA) homeostasis.  Aberrant activation of this pathway has been described in the development and progression of a subset of liver cancers including hepatocellular carcinoma, establishing FGFR4 as an attractive therapeutic target for such solid tumors.  FGF401 is a highly selective FGFR4 kinase inhibitor being developed for hepatocellular carcinoma, currently in phase I/II clin. studies.  In preclin. studies in mice and dogs, oral administration of FGF401 led to induction of Cyp7a1, elevation of its peripheral marker 7alpha-hydroxy-4-cholesten-3-one, increased BA pool size, decreased serum cholesterol and diarrhea in dogs.  FGF401 was also assocd. with increases of serum aminotransferases, primarily alanine aminotransferase (ALT), in the absence of any observable adverse histopathol. in the liver, or in any other organs.  The authors hypothesized that the increase in ALT could be secondary to increased BAs and conducted an investigative study in dogs with FGF401 and coadministration of the BA sequestrant cholestyramine (CHO).  CHO prevented and reversed FGF401-related increases in ALT in dogs in parallel to its ability to reduce BAs in the circulation.  Correlation anal. showed that FGF401-mediated increases in ALT strongly correlated with increases in taurolithocholic acid and taurodeoxycholic acid, the major secondary BAs in dog plasma, indicating a mechanistic link between ALT elevation and changes in BA pool hydrophobicity.  Thus, CHO may offer the potential to mitigate elevations in serum amtransferases in human subjects that are caused by targeted FGFR4 inhibition and elevated intracellular BA levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4tzKAwiqUR7Vg90H21EOLACvtfcHk0lg0BgFFQ5Ohxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGksr%252FF&md5=e11d415d68d5b1b326a9547d35ef727a</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfy031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfy031%26sid%3Dliteratum%253Aachs%26aulast%3DSchadt%26aufirst%3DH.%2BS.%26aulast%3DWolf%26aufirst%3DA.%26aulast%3DMahl%26aufirst%3DJ.%2BA.%26aulast%3DWuersch%26aufirst%3DK.%26aulast%3DCouttet%26aufirst%3DP.%26aulast%3DSchwald%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DA.%26aulast%3DLienard%26aufirst%3DM.%26aulast%3DEmotte%26aufirst%3DC.%26aulast%3DTeng%26aufirst%3DC.-H.%26atitle%3DBile%2520Acid%2520Sequestration%2520by%2520Cholestyramine%2520Mitigates%2520FGFR4%2520Inhibition-Induced%2520Alt%2520Elevation%26jtitle%3DToxicol.%2520Sci.%26date%3D2018%26volume%3D163%26issue%3D1%26spage%3D265%26epage%3D278%26doi%3D10.1093%2Ftoxsci%2Fkfy031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span>; <span class="NLM_string-name">Sun, G.</span>; <span class="NLM_string-name">Tan, S.</span>; <span class="NLM_string-name">Liu, L.</span>; <span class="NLM_string-name">Bao, R.</span></span> <span> </span><span class="NLM_article-title">FGFR4 Inhibitor and Preparation Method and Use Thereof</span>. <span class="NLM_patent">WO 2018028664</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=P.+Gao&author=G.+Sun&author=S.+Tan&author=L.+Liu&author=R.+Bao&title=FGFR4+Inhibitor+and+Preparation+Method+and+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DP.%26atitle%3DFGFR4%2520Inhibitor%2520and%2520Preparation%2520Method%2520and%2520Use%2520Thereof%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanizaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aref, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Development of Covalent Inhibitors That Can Overcome Resistance to First-Generation FGFR Kinase Inhibitors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span> (<span class="NLM_issue">45</span>),  <span class="NLM_fpage">4869</span>– <span class="NLM_lpage">4877</span>, <span class="refDoi"> DOI: 10.1073/pnas.1403438111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1073%2Fpnas.1403438111" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=4869-4877&issue=45&author=L.+Tanauthor=J.+Wangauthor=J.+Tanizakiauthor=Z.+Huangauthor=A.+R.+Arefauthor=M.+Rusanauthor=S.+J.+Zhuauthor=Y.+Zhangauthor=D.+Ercanauthor=R.+G.+Liaoauthor=M.+Capellettiauthor=W.+Zhouauthor=W.+Hurauthor=N.+Kimauthor=T.+Simauthor=S.+Gaudetauthor=D.+A.+Barbieauthor=J.+R.+Yehauthor=C.+H.+Yunauthor=P.+S.+Hammermanauthor=M.+Mohammadiauthor=P.+A.+Janneauthor=N.+S.+Gray&title=Development+of+Covalent+Inhibitors+That+Can+Overcome+Resistance+to+First-Generation+FGFR+Kinase+Inhibitors&doi=10.1073%2Fpnas.1403438111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1403438111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1403438111%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTanizaki%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAref%26aufirst%3DA.%2BR.%26aulast%3DRusan%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DLiao%26aufirst%3DR.%2BG.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DGaudet%26aufirst%3DS.%26aulast%3DBarbie%26aufirst%3DD.%2BA.%26aulast%3DYeh%26aufirst%3DJ.%2BR.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDevelopment%2520of%2520Covalent%2520Inhibitors%2520That%2520Can%2520Overcome%2520Resistance%2520to%2520First-Generation%2520FGFR%2520Kinase%2520Inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26issue%3D45%26spage%3D4869%26epage%3D4877%26doi%3D10.1073%2Fpnas.1403438111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blais, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubert, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span> <span> </span><span class="NLM_article-title">DFG-out Mode of Inhibition by an Irreversible Type-1 Inhibitor Capable of Overcoming Gate-Keeper Mutations in FGF Receptors</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1021/cb500674s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500674s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=299-309&issue=1&author=Z.+Huangauthor=L.+Tanauthor=H.+Wangauthor=Y.+Liuauthor=S.+Blaisauthor=J.+Dengauthor=T.+A.+Neubertauthor=N.+S.+Grayauthor=X.+Liauthor=M.+Mohammadi&title=DFG-out+Mode+of+Inhibition+by+an+Irreversible+Type-1+Inhibitor+Capable+of+Overcoming+Gate-Keeper+Mutations+in+FGF+Receptors&doi=10.1021%2Fcb500674s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fcb500674s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500674s%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DBlais%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DJ.%26aulast%3DNeubert%26aufirst%3DT.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DMohammadi%26aufirst%3DM.%26atitle%3DDFG-out%2520Mode%2520of%2520Inhibition%2520by%2520an%2520Irreversible%2520Type-1%2520Inhibitor%2520Capable%2520of%2520Overcoming%2520Gate-Keeper%2520Mutations%2520in%2520FGF%2520Receptors%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26issue%3D1%26spage%3D299%26epage%3D309%26doi%3D10.1021%2Fcb500674s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 24 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Wuqing Deng, Xiaojuan Chen, Kaili Jiang, Xiaojuan Song, Minhao Huang, Zheng-Chao Tu, Zhang Zhang, Xiaojing Lin, Raquel Ortega, Adam V. Patterson, Jeff B. Smaill, Ke Ding, Suming Chen, Yongheng Chen, <span class="NLM_string-name hlFld-ContribAuthor">Xiaoyun Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (4)
                                     , 647-652. <a href="https://doi.org/10.1021/acsmedchemlett.1c00052" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.1c00052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.1c00052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.1c00052%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DInvestigation%252Bof%252BCovalent%252BWarheads%252Bin%252Bthe%252BDesign%252Bof%252B2-Aminopyrimidine-based%252BFGFR4%252BInhibitors%26aulast%3DDeng%26aufirst%3DWuqing%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D23012021%26date%3D19032021%26date%3D22032021%26volume%3D12%26issue%3D4%26spage%3D647%26epage%3D652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Robin A. Fairhurst, Thomas Knoepfel, Nicole Buschmann, Catherine Leblanc, Robert Mah, Milen Todorov, Pierre Nimsgern, Sebastien Ripoche, Michel Niklaus, Nicolas Warin, Van Huy Luu, Mario Madoerin, Jasmin Wirth, Diana Graus-Porta, Andreas Weiss, Michael Kiffe, Markus Wartmann, Jacqueline Kinyamu-Akunda, Dario Sterker, Christelle Stamm, Flavia Adler, Alexandra Buhles, Heiko Schadt, Philippe Couttet, Jutta Blank, Inga Galuba, Jörg Trappe, Johannes Voshol, Nils Ostermann, Chao Zou, Jörg Berghausen, Alberto Del Rio Espinola, Wolfgang Jahnke, <span class="NLM_string-name hlFld-ContribAuthor">Pascal Furet</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12542-12573. <a href="https://doi.org/10.1021/acs.jmedchem.0c01019" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01019%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BRoblitinib%252B%252528FGF401%252529%252Bas%252Ba%252BReversible-Covalent%252BInhibitor%252Bof%252Bthe%252BKinase%252BActivity%252Bof%252BFibroblast%252BGrowth%252BFactor%252BReceptor%252B4%26aulast%3DFairhurst%26aufirst%3DRobin%2BA.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15062020%26date%3D01102020%26date%3D15092020%26volume%3D63%26issue%3D21%26spage%3D12542%26epage%3D12573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Renata Rezende Miranda, Ying Fu, Xiaojuan Chen, John Perino, Ping Cao, John Carpten, Yongheng Chen, <span class="NLM_string-name hlFld-ContribAuthor">Chao Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11484-11497. <a href="https://doi.org/10.1021/acs.jmedchem.0c00044" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00044%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252Ba%252BPotent%252Band%252BSpecific%252BFGFR4%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BHepatocellular%252BCarcinoma%26aulast%3DRezende%2BMiranda%26aufirst%3DRenata%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D09012020%26date%3D08102020%26volume%3D63%26issue%3D20%26spage%3D11484%26epage%3D11497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Haibo Liu, Deqiang Niu, Robert Tjin Tham Sjin, Alex Dubrovskiy, Zhendong Zhu, Joseph J. McDonald, Kelly Fahnoe, Zhigang Wang, Mark Munson, Andrew Scholte, Matthieu Barrague, Maria Fitzgerald, Jinyu Liu, Michael Kothe, Fangxian Sun, Joshua Murtie, Jie Ge, Jennifer Rocnik, Darren Harvey, Beatriz Ospina, Keli Perron, Gang Zheng, Elvis Shehu, <span class="NLM_string-name hlFld-ContribAuthor">Laura Akullian D’Agostino</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Selective, Covalent FGFR4 Inhibitors with Antitumor Activity in Models of Hepatocellular Carcinoma. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (10)
                                     , 1899-1904. <a href="https://doi.org/10.1021/acsmedchemlett.9b00601" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00601</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00601%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BSelective%25252C%252BCovalent%252BFGFR4%252BInhibitors%252Bwith%252BAntitumor%252BActivity%252Bin%252BModels%252Bof%252BHepatocellular%252BCarcinoma%26aulast%3DLiu%26aufirst%3DHaibo%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D14122019%26date%3D06032020%26date%3D30032020%26date%3D06032020%26volume%3D11%26issue%3D10%26spage%3D1899%26epage%3D1904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaojing Lin, Yuliana Yosaatmadja, Maria Kalyukina, Martin J. Middleditch, Zhen Zhang, Xiaoyun Lu, Ke Ding, Adam V. Patterson, Jeff B. Smaill, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. Squire</span>. </span><span class="cited-content_cbyCitation_article-title">Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (8)
                                     , 1180-1186. <a href="https://doi.org/10.1021/acsmedchemlett.9b00196" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00196</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00196%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DRotational%252BFreedom%25252C%252BSteric%252BHindrance%25252C%252Band%252BProtein%252BDynamics%252BExplain%252BBLU554%252BSelectivity%252Bfor%252Bthe%252BHinge%252BCysteine%252Bof%252BFGFR4%26aulast%3DLin%26aufirst%3DXiaojing%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D30042019%26date%3D03072019%26date%3D09072019%26date%3D03072019%26volume%3D10%26issue%3D8%26spage%3D1180%26epage%3D1186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sitong  Yue</span>, <span class="hlFld-ContribAuthor ">Yukun  Li</span>, <span class="hlFld-ContribAuthor ">Xiaojuan  Chen</span>, <span class="hlFld-ContribAuthor ">Juan  Wang</span>, <span class="hlFld-ContribAuthor ">Meixiang  Li</span>, <span class="hlFld-ContribAuthor ">Yongheng  Chen</span>, <span class="hlFld-ContribAuthor ">Daichao  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">FGFR-TKI resistance in cancer: current status and perspectives. </span><span class="cited-content_cbyCitation_journal-name">Journal of Hematology & Oncology</span><span> <strong>2021,</strong> <em>14 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13045-021-01040-2" title="DOI URL">https://doi.org/10.1186/s13045-021-01040-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13045-021-01040-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13045-021-01040-2%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Hematology%2520%2526%2520Oncology%26atitle%3DFGFR-TKI%252Bresistance%252Bin%252Bcancer%25253A%252Bcurrent%252Bstatus%252Band%252Bperspectives%26aulast%3DYue%26aufirst%3DSitong%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ji-Yon  Shin</span>, <span class="hlFld-ContribAuthor ">Sung-Min  Ahn</span>. </span><span class="cited-content_cbyCitation_article-title">Src is essential for the endosomal delivery of the FGFR4 signaling complex in hepatocellular carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Translational Medicine</span><span> <strong>2021,</strong> <em>19 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12967-021-02807-4" title="DOI URL">https://doi.org/10.1186/s12967-021-02807-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12967-021-02807-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12967-021-02807-4%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Translational%2520Medicine%26atitle%3DSrc%252Bis%252Bessential%252Bfor%252Bthe%252Bendosomal%252Bdelivery%252Bof%252Bthe%252BFGFR4%252Bsignaling%252Bcomplex%252Bin%252Bhepatocellular%252Bcarcinoma%26aulast%3DShin%26aufirst%3DJi-Yon%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiang-Yuan  Luo</span>, <span class="hlFld-ContribAuthor ">Kong-Ming  Wu</span>, <span class="hlFld-ContribAuthor ">Xing-Xing  He</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. </span><span class="cited-content_cbyCitation_journal-name">Journal of Experimental & Clinical Cancer Research</span><span> <strong>2021,</strong> <em>40 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13046-021-01968-w" title="DOI URL">https://doi.org/10.1186/s13046-021-01968-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13046-021-01968-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13046-021-01968-w%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Experimental%2520%2526%2520Clinical%2520Cancer%2520Research%26atitle%3DAdvances%252Bin%252Bdrug%252Bdevelopment%252Bfor%252Bhepatocellular%252Bcarcinoma%25253A%252Bclinical%252Btrials%252Band%252Bpotential%252Btherapeutic%252Btargets%26aulast%3DLuo%26aufirst%3DXiang-Yuan%26date%3D2021%26date%3D2021%26volume%3D40%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoxia  Liang</span>, <span class="hlFld-ContribAuthor ">Pan  Wu</span>, <span class="hlFld-ContribAuthor ">Qian  Yang</span>, <span class="hlFld-ContribAuthor ">Yunyu  Xie</span>, <span class="hlFld-ContribAuthor ">Changliang  He</span>, <span class="hlFld-ContribAuthor ">Lizi  Yin</span>, <span class="hlFld-ContribAuthor ">Zhongqiong  Yin</span>, <span class="hlFld-ContribAuthor ">Guizhou  Yue</span>, <span class="hlFld-ContribAuthor ">Yuanfeng  Zou</span>, <span class="hlFld-ContribAuthor ">Lixia  Li</span>, <span class="hlFld-ContribAuthor ">Xu  Song</span>, <span class="hlFld-ContribAuthor ">Cheng  Lv</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Bo  Jing</span>. </span><span class="cited-content_cbyCitation_article-title">An update of new small-molecule anticancer drugs approved from 2015 to 2020. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>220 </em>, 113473. <a href="https://doi.org/10.1016/j.ejmech.2021.113473" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113473</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113473%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAn%252Bupdate%252Bof%252Bnew%252Bsmall-molecule%252Banticancer%252Bdrugs%252Bapproved%252Bfrom%252B2015%252Bto%252B2020%26aulast%3DLiang%26aufirst%3DXiaoxia%26date%3D2021%26volume%3D220%26spage%3D113473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haijun  Wang</span>, <span class="hlFld-ContribAuthor ">Jie  Yang</span>, <span class="hlFld-ContribAuthor ">Ke  Zhang</span>, <span class="hlFld-ContribAuthor ">Jia  Liu</span>, <span class="hlFld-ContribAuthor ">Yushan  Li</span>, <span class="hlFld-ContribAuthor ">Wei  Su</span>, <span class="hlFld-ContribAuthor ">Na  Song</span>. </span><span class="cited-content_cbyCitation_article-title">Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fphar.2021.650388" title="DOI URL">https://doi.org/10.3389/fphar.2021.650388</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2021.650388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2021.650388%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DAdvances%252Bof%252BFibroblast%252BGrowth%252BFactor%25252FReceptor%252BSignaling%252BPathway%252Bin%252BHepatocellular%252BCarcinoma%252Band%252Bits%252BPharmacotherapeutic%252BTargets%26aulast%3DWang%26aufirst%3DHaijun%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yijun  Wang</span>, <span class="hlFld-ContribAuthor ">Danfei  Liu</span>, <span class="hlFld-ContribAuthor ">Tongyue  Zhang</span>, <span class="hlFld-ContribAuthor ">Limin  Xia</span>. </span><span class="cited-content_cbyCitation_article-title">FGF/FGFR Signaling in Hepatocellular Carcinoma: From Carcinogenesis to Recent Therapeutic Intervention. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (6)
                                     , 1360. <a href="https://doi.org/10.3390/cancers13061360" title="DOI URL">https://doi.org/10.3390/cancers13061360</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13061360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13061360%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DFGF%25252FFGFR%252BSignaling%252Bin%252BHepatocellular%252BCarcinoma%25253A%252BFrom%252BCarcinogenesis%252Bto%252BRecent%252BTherapeutic%252BIntervention%26aulast%3DWang%26aufirst%3DYijun%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D6%26spage%3D1360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaolu  Chen</span>, <span class="hlFld-ContribAuthor ">Yanan  Liu</span>, <span class="hlFld-ContribAuthor ">Liting  Zhang</span>, <span class="hlFld-ContribAuthor ">Daoxing  Chen</span>, <span class="hlFld-ContribAuthor ">Zhaojun  Dong</span>, <span class="hlFld-ContribAuthor ">Chengguang  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhiguo  Liu</span>, <span class="hlFld-ContribAuthor ">Qinqin  Xia</span>, <span class="hlFld-ContribAuthor ">Jianzhang  Wu</span>, <span class="hlFld-ContribAuthor ">Yongheng  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaohui  Zheng</span>, <span class="hlFld-ContribAuthor ">Yuepiao  Cai</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113219. <a href="https://doi.org/10.1016/j.ejmech.2021.113219" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113219</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113219%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bindazole%252Bderivatives%252Bas%252Bselective%252Band%252Bpotent%252BFGFR4%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252BFGF19-driven%252Bhepatocellular%252Bcancer%26aulast%3DChen%26aufirst%3DXiaolu%26date%3D2021%26volume%3D214%26spage%3D113219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Taku  Shigesawa</span>, <span class="hlFld-ContribAuthor ">Osamu  Maehara</span>, <span class="hlFld-ContribAuthor ">Goki  Suda</span>, <span class="hlFld-ContribAuthor ">Mitsuteru  Natsuizaka</span>, <span class="hlFld-ContribAuthor ">Megumi  Kimura</span>, <span class="hlFld-ContribAuthor ">Tomoe  Shimazaki</span>, <span class="hlFld-ContribAuthor ">Koji  Yamamoto</span>, <span class="hlFld-ContribAuthor ">Ren  Yamada</span>, <span class="hlFld-ContribAuthor ">Takashi  Kitagataya</span>, <span class="hlFld-ContribAuthor ">Akihisa  Nakamura</span>, <span class="hlFld-ContribAuthor ">Kazuharu  Suzuki</span>, <span class="hlFld-ContribAuthor ">Masatsugu  Ohara</span>, <span class="hlFld-ContribAuthor ">Naoki  Kawagishi</span>, <span class="hlFld-ContribAuthor ">Machiko  Umemura</span>, <span class="hlFld-ContribAuthor ">Masato  Nakai</span>, <span class="hlFld-ContribAuthor ">Takuya  Sho</span>, <span class="hlFld-ContribAuthor ">Kenichi  Morikawa</span>, <span class="hlFld-ContribAuthor ">Koji  Ogawa</span>, <span class="hlFld-ContribAuthor ">Shunsuke  Ohnishi</span>, <span class="hlFld-ContribAuthor ">Masaya  Sugiyama</span>, <span class="hlFld-ContribAuthor ">Masashi  Mizokami</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Takeda</span>, <span class="hlFld-ContribAuthor ">Naoya  Sakamoto</span>. </span><span class="cited-content_cbyCitation_article-title">Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1–3 signaling, but not FGFR4 signaling. </span><span class="cited-content_cbyCitation_journal-name">Carcinogenesis</span><span> <strong>2021,</strong> <em>42 </em>
                                    (1)
                                     , 58-69. <a href="https://doi.org/10.1093/carcin/bgaa049" title="DOI URL">https://doi.org/10.1093/carcin/bgaa049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/carcin/bgaa049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fcarcin%2Fbgaa049%26sid%3Dliteratum%253Aachs%26jtitle%3DCarcinogenesis%26atitle%3DLenvatinib%252Bsuppresses%252Bcancer%252Bstem-like%252Bcells%252Bin%252BHCC%252Bby%252Binhibiting%252BFGFR1%2525E2%252580%2525933%252Bsignaling%25252C%252Bbut%252Bnot%252BFGFR4%252Bsignaling%26aulast%3DShigesawa%26aufirst%3DTaku%26date%3D2021%26date%3D2020%26volume%3D42%26issue%3D1%26spage%3D58%26epage%3D69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tatjana  Seitz</span>, <span class="hlFld-ContribAuthor ">Kim  Freese</span>, <span class="hlFld-ContribAuthor ">Peter  Dietrich</span>, <span class="hlFld-ContribAuthor ">Wolfgang Erwin  Thasler</span>, <span class="hlFld-ContribAuthor ">Anja  Bosserhoff</span>, <span class="hlFld-ContribAuthor ">Claus  Hellerbrand</span>. </span><span class="cited-content_cbyCitation_article-title">Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-61510-4" title="DOI URL">https://doi.org/10.1038/s41598-020-61510-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-61510-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-61510-4%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DFibroblast%252BGrowth%252BFactor%252B9%252Bis%252Bexpressed%252Bby%252Bactivated%252Bhepatic%252Bstellate%252Bcells%252Band%252Bpromotes%252Bprogression%252Bof%252Bhepatocellular%252Bcarcinoma%26aulast%3DSeitz%26aufirst%3DTatjana%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hiroshi  Sootome</span>, <span class="hlFld-ContribAuthor ">Hidenori  Fujita</span>, <span class="hlFld-ContribAuthor ">Kenjiro  Ito</span>, <span class="hlFld-ContribAuthor ">Hiroaki  Ochiiwa</span>, <span class="hlFld-ContribAuthor ">Yayoi  Fujioka</span>, <span class="hlFld-ContribAuthor ">Kimihiro  Ito</span>, <span class="hlFld-ContribAuthor ">Akihiro  Miura</span>, <span class="hlFld-ContribAuthor ">Takeshi  Sagara</span>, <span class="hlFld-ContribAuthor ">Satoru  Ito</span>, <span class="hlFld-ContribAuthor ">Hirokazu  Ohsawa</span>, <span class="hlFld-ContribAuthor ">Sachie  Otsuki</span>, <span class="hlFld-ContribAuthor ">Kaoru  Funabashi</span>, <span class="hlFld-ContribAuthor ">Masakazu  Yashiro</span>, <span class="hlFld-ContribAuthor ">Kenichi  Matsuo</span>, <span class="hlFld-ContribAuthor ">Kazuhiko  Yonekura</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Hirai</span>. </span><span class="cited-content_cbyCitation_article-title">Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2020,</strong> <em>80 </em>
                                    (22)
                                     , 4986-4997. <a href="https://doi.org/10.1158/0008-5472.CAN-19-2568" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-19-2568</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-19-2568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-19-2568%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DFutibatinib%252BIs%252Ba%252BNovel%252BIrreversible%252BFGFR%252B1%2525E2%252580%2525934%252BInhibitor%252BThat%252BShows%252BSelective%252BAntitumor%252BActivity%252Bagainst%252BFGFR-Deregulated%252BTumors%26aulast%3DSootome%26aufirst%3DHiroshi%26date%3D2020%26date%3D2020%26volume%3D80%26issue%3D22%26spage%3D4986%26epage%3D4997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuo  Yuan</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Hong-Min  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">New drug approvals for 2019: Synthesis and clinical applications. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>205 </em>, 112667. <a href="https://doi.org/10.1016/j.ejmech.2020.112667" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112667</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112667%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNew%252Bdrug%252Bapprovals%252Bfor%252B2019%25253A%252BSynthesis%252Band%252Bclinical%252Bapplications%26aulast%3DYuan%26aufirst%3DShuo%26date%3D2020%26volume%3D205%26spage%3D112667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lin  Ji</span>, <span class="hlFld-ContribAuthor ">Zhongjie  Lin</span>, <span class="hlFld-ContribAuthor ">Zhe  Wan</span>, <span class="hlFld-ContribAuthor ">Shunjie  Xia</span>, <span class="hlFld-ContribAuthor ">Shi  Jiang</span>, <span class="hlFld-ContribAuthor ">Dong  Cen</span>, <span class="hlFld-ContribAuthor ">Liuxin  Cai</span>, <span class="hlFld-ContribAuthor ">Junjie  Xu</span>, <span class="hlFld-ContribAuthor ">Xiujun  Cai</span>. </span><span class="cited-content_cbyCitation_article-title">miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR. </span><span class="cited-content_cbyCitation_journal-name">Cell Death & Disease</span><span> <strong>2020,</strong> <em>11 </em>
                                    (4)
                                     <a href="https://doi.org/10.1038/s41419-020-2413-4" title="DOI URL">https://doi.org/10.1038/s41419-020-2413-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41419-020-2413-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41419-020-2413-4%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Death%2520%2526%2520Disease%26atitle%3DmiR-486-3p%252Bmediates%252Bhepatocellular%252Bcarcinoma%252Bsorafenib%252Bresistance%252Bby%252Btargeting%252BFGFR4%252Band%252BEGFR%26aulast%3DJi%26aufirst%3DLin%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenlong  Li</span>, <span class="hlFld-ContribAuthor ">Rolf  Sparidans</span>, <span class="hlFld-ContribAuthor ">Mujtaba  El-lari</span>, <span class="hlFld-ContribAuthor ">Yaogeng  Wang</span>, <span class="hlFld-ContribAuthor ">Maria C.  Lebre</span>, <span class="hlFld-ContribAuthor ">Jos H.  Beijnen</span>, <span class="hlFld-ContribAuthor ">Alfred H.  Schinkel</span>. </span><span class="cited-content_cbyCitation_article-title">P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554). </span><span class="cited-content_cbyCitation_journal-name">International Journal of Pharmaceutics</span><span> <strong>2020,</strong> <em>573 </em>, 118842. <a href="https://doi.org/10.1016/j.ijpharm.2019.118842" title="DOI URL">https://doi.org/10.1016/j.ijpharm.2019.118842</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijpharm.2019.118842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijpharm.2019.118842%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Pharmaceutics%26atitle%3DP-glycoprotein%252B%252528ABCB1%25252FMDR1%252529%252Blimits%252Bbrain%252Baccumulation%252Band%252BCytochrome%252BP450-3A%252B%252528CYP3A%252529%252Brestricts%252Boral%252Bavailability%252Bof%252Bthe%252Bnovel%252BFGFR4%252Binhibitor%252Bfisogatinib%252B%252528BLU-554%252529%26aulast%3DLi%26aufirst%3DWenlong%26date%3D2020%26volume%3D573%26spage%3D118842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian  Liu</span>, <span class="hlFld-ContribAuthor ">Yu  Wen</span>, <span class="hlFld-ContribAuthor ">Lina  Gao</span>, <span class="hlFld-ContribAuthor ">Liang  Gao</span>, <span class="hlFld-ContribAuthor ">Fengjun  He</span>, <span class="hlFld-ContribAuthor ">Jingxian  Zhou</span>, <span class="hlFld-ContribAuthor ">Junwei  Wang</span>, <span class="hlFld-ContribAuthor ">Rupeng  Dai</span>, <span class="hlFld-ContribAuthor ">Xiaojing  Chen</span>, <span class="hlFld-ContribAuthor ">Di  Kang</span>, <span class="hlFld-ContribAuthor ">Lihong  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 1
              H
              -1,2,4-triazole, benzothiazole and indazole-based derivatives as potent FGFR1 inhibitors
              via
              fragment-based virtual screening. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2020,</strong> <em>35 </em>
                                    (1)
                                     , 72-84. <a href="https://doi.org/10.1080/14756366.2019.1673745" title="DOI URL">https://doi.org/10.1080/14756366.2019.1673745</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2019.1673745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2019.1673745%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B1%252BH%252B-1%25252C2%25252C4-triazole%25252C%252Bbenzothiazole%252Band%252Bindazole-based%252Bderivatives%252Bas%252Bpotent%252BFGFR1%252Binhibitors%252Bvia%252Bfragment-based%252Bvirtual%252Bscreening%26aulast%3DLiu%26aufirst%3DJian%26date%3D2020%26date%3D2019%26volume%3D35%26issue%3D1%26spage%3D72%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sangchul  Kim</span>, <span class="hlFld-ContribAuthor ">Amina  Bolatkan</span>, <span class="hlFld-ContribAuthor ">Syuzo  Kaneko</span>, <span class="hlFld-ContribAuthor ">Noriko  Ikawa</span>, <span class="hlFld-ContribAuthor ">Ken  Asada</span>, <span class="hlFld-ContribAuthor ">Masaaki  Komatsu</span>, <span class="hlFld-ContribAuthor ">Shinya  Hayami</span>, <span class="hlFld-ContribAuthor ">Hidenori  Ojima</span>, <span class="hlFld-ContribAuthor ">Nobutsugu  Abe</span>, <span class="hlFld-ContribAuthor ">Hiroki  Yamaue</span>, <span class="hlFld-ContribAuthor ">Ryuji  Hamamoto</span>. </span><span class="cited-content_cbyCitation_article-title">Deregulation of the Histone Lysine-Specific Demethylase 1 Is Involved in Human Hepatocellular Carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2019,</strong> <em>9 </em>
                                    (12)
                                     , 810. <a href="https://doi.org/10.3390/biom9120810" title="DOI URL">https://doi.org/10.3390/biom9120810</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom9120810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom9120810%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DDeregulation%252Bof%252Bthe%252BHistone%252BLysine-Specific%252BDemethylase%252B1%252BIs%252BInvolved%252Bin%252BHuman%252BHepatocellular%252BCarcinoma%26aulast%3DKim%26aufirst%3DSangchul%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D12%26spage%3D810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuting  Liu</span>, <span class="hlFld-ContribAuthor ">Chang-Ling  Wang</span>, <span class="hlFld-ContribAuthor ">Hui-Min  Xia</span>, <span class="hlFld-ContribAuthor ">Zhijuan  Wang</span>, <span class="hlFld-ContribAuthor ">Yi-Feng  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Direct Csp
              3
              –H methylenation of 2-arylacetamides using DMF/Me
              2
              NH-BH
              3
              as the methylene source. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (25)
                                     , 6153-6157. <a href="https://doi.org/10.1039/C9OB00875F" title="DOI URL">https://doi.org/10.1039/C9OB00875F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9OB00875F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9OB00875F%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DDirect%252BCsp%252B3%252B%2525E2%252580%252593H%252Bmethylenation%252Bof%252B2-arylacetamides%252Busing%252BDMF%25252FMe%252B2%252BNH-BH%252B3%252Bas%252Bthe%252Bmethylene%252Bsource%26aulast%3DLiu%26aufirst%3DYuting%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D25%26spage%3D6153%26epage%3D6157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuyan  Dai</span>, <span class="hlFld-ContribAuthor ">Zhan  Zhou</span>, <span class="hlFld-ContribAuthor ">Zhuchu  Chen</span>, <span class="hlFld-ContribAuthor ">Guangyu  Xu</span>, <span class="hlFld-ContribAuthor ">Yongheng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2019,</strong> <em>8 </em>
                                    (6)
                                     , 614. <a href="https://doi.org/10.3390/cells8060614" title="DOI URL">https://doi.org/10.3390/cells8060614</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells8060614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells8060614%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DFibroblast%252BGrowth%252BFactor%252BReceptors%252B%252528FGFRs%252529%25253A%252BStructures%252Band%252BSmall%252BMolecule%252BInhibitors%26aulast%3DDai%26aufirst%3DShuyan%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D6%26spage%3D614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhan  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiaojuan  Chen</span>, <span class="hlFld-ContribAuthor ">Ying  Fu</span>, <span class="hlFld-ContribAuthor ">Ye  Zhang</span>, <span class="hlFld-ContribAuthor ">Shuyan  Dai</span>, <span class="hlFld-ContribAuthor ">Jun  Li</span>, <span class="hlFld-ContribAuthor ">Lin  Chen</span>, <span class="hlFld-ContribAuthor ">Guangyu  Xu</span>, <span class="hlFld-ContribAuthor ">Zhuchu  Chen</span>, <span class="hlFld-ContribAuthor ">Yongheng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2019,</strong> <em>55 </em>
                                    (42)
                                     , 5890-5893. <a href="https://doi.org/10.1039/C9CC02052G" title="DOI URL">https://doi.org/10.1039/C9CC02052G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CC02052G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CC02052G%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DCharacterization%252Bof%252BFGF401%252Bas%252Ba%252Breversible%252Bcovalent%252Binhibitor%252Bof%252Bfibroblast%252Bgrowth%252Bfactor%252Breceptor%252B4%26aulast%3DZhou%26aufirst%3DZhan%26date%3D2019%26date%3D2019%26volume%3D55%26issue%3D42%26spage%3D5890%26epage%3D5893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei-xun  Chen</span>, <span class="hlFld-ContribAuthor ">Gan-xun  Li</span>, <span class="hlFld-ContribAuthor ">Zheng-nan  Hu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhu</span>, <span class="hlFld-ContribAuthor ">Bi-xiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Ze-yang  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis. </span><span class="cited-content_cbyCitation_journal-name">Medicine</span><span> <strong>2019,</strong> <em>98 </em>
                                    (45)
                                     , e17832. <a href="https://doi.org/10.1097/MD.0000000000017832" title="DOI URL">https://doi.org/10.1097/MD.0000000000017832</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/MD.0000000000017832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FMD.0000000000017832%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicine%26atitle%3DSignificant%252Bresponse%252Bto%252Banti-PD-1%252Bbased%252Bimmunotherapy%252Bplus%252Blenvatinib%252Bfor%252Brecurrent%252Bintrahepatic%252Bcholangiocarcinoma%252Bwith%252Bbone%252Bmetastasis%26aulast%3DChen%26aufirst%3DWei-xun%26date%3D2019%26date%3D2019%26volume%3D98%26issue%3D45%26spage%3De17832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. FGF19-FGFR4 mediated signaling pathway. FGF19 regulates cell functions by binding with its receptor FGFR4 and co-receptor β-Klotho, leading to the activation of four signaling branches PI3K/AKT (depicted in yellow), PLCγ/DAG/PKC (green), RAS/RAF/MAPK (gray), and GSK3β/β-catenin (orange), which are involved in proliferation, antiapoptosis, angiogenesis, drug resistance, invasion, and epithelial-to-mesenchymal transition (EMT) in HCC cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic structure overview of FGFR4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structural overview of a cocrystal structure of FGFR4 with BLU9931 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4xcu">4xcu</a>). Expanded view is comparison of Cys552 in FGFR4 and Tyr 563 in FGFR1 (PD code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4v04">4v04</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Chemical structure and pharmacophore of ponatinib. (B) Binding mode of ponatinib with FGFR4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4uxq">4uxq</a>). Hydrogen bonds are indicated by yellow dashed lines to key amino acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Structure and pharmacophore of LY2874455. (B) Binding mode of LY2874455 with FGFR4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JKG">5JKG</a>). Hydrogen bonds are indicated by yellow dashed lines to key amino acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Structure and pharmacophore of JNJ-42756493. (B) Binding mode of JNJ-42756493 with FGFR1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EW8">5EW8</a>). Hydrogen bonds are indicated by yellow dashed lines to key amino acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structure and pharmacophore of PRN1371.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Optimization strategy of compound <b>6</b>. (B) Binding mode of <b>6</b> with FGFR4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5nwz">5nwz</a>). Hydrogen bonds are indicated by yellow dashed lines to key amino acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Optimization process of BLU9931 and BLU554.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Binding mode of BLU9931with FGFR4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4xcu">4xcu</a>). Hydrogen bonds are indicated by yellow dashed lines to key amino acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) Optimization strategy of H3B-6527. (B) Binding mode of H3B-6527 with FGFR1-Y563C (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5vnd">5vnd</a>). Hydrogen bonds are indicated by yellow dashed lines to key amino acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Optimization strategy of 2-aminopyrimidine <b>14</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Optimization process of 2-aminopyrimidine <b>17</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. (A) Chemical structure of dipyridylamine <b>18</b>. (B) Binding mode of <b>18</b> with FGFR4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5nud">5nud</a>). Hydrogen bonds are indicated by yellow dashed lines to key amino acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Optimization process of FGF401 and its analogue <b>23</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/medium/jm-2018-015314_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Optimization of the reversible selective FGFR4 inhibitors <b>24</b> and <b>26</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01531/20190321/images/large/jm-2018-015314_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01531&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i32">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86573" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86573" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 53 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Best, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schotten, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerken, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechêne, A.</span></span> <span> </span><span class="NLM_article-title">Tivantinib for the Treatment of Hepatocellular Carcinoma</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">733</span>, <span class="refDoi"> DOI: 10.1080/14656566.2017.1316376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1080%2F14656566.2017.1316376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=28414564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlOgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=727-733&issue=7&author=J.+Bestauthor=C.+Schottenauthor=G.+Lohmannauthor=G.+Gerkenauthor=A.+Dech%C3%AAne&title=Tivantinib+for+the+Treatment+of+Hepatocellular+Carcinoma&doi=10.1080%2F14656566.2017.1316376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Tivantinib for the treatment of hepatocellular carcinoma</span></div><div class="casAuthors">Best, Jan; Schotten, Clemens; Lohmann, Gregor; Gerken, Guido; Dechene, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">727-733</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide with a poor prognosis due to late diagnosis in the majority of cases.  Physicians are frequently confronted with patients who are not eligible for curative or locoregional treatments any more.  In this scenario, the multi-tyrosine kinase inhibitor sorafenib remains the only systemic first-line treatment option providing modest survival benefit compared to placebo with significant but for most patients acceptable adverse effects.  Areas covered: Tivantinib was the first antiproliferative agent to be been applied in a phase III trial based on receptor overexpression analyses after disease progression on sorafenib.  While phase I and II trials with tivantinib in second line showed encouraging results, a recent press release announced that the METIV-HCC phase III study of tivantinib in HCC did not meet its primary endpoint of improving overall survival.  Expert commentary: Evidence for antiangiogenetic therapy inducing tumor hypoxia leading to overexpression of proliferative genes, including cMET, underlines the potential of tivantinib as second-line treatment.  However, as the mechanism of action of tivantinib through cMET inhibition has recently been questioned by several groups, identification of alternative proliferative markers or targets is mandatory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotJjBNgdYxY7Vg90H21EOLACvtfcHk0lhl7AS2oBzDNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlOgsL0%253D&md5=038cad92d2a175d2ec0c8860c54c1784</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1080%2F14656566.2017.1316376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2017.1316376%26sid%3Dliteratum%253Aachs%26aulast%3DBest%26aufirst%3DJ.%26aulast%3DSchotten%26aufirst%3DC.%26aulast%3DLohmann%26aufirst%3DG.%26aulast%3DGerken%26aufirst%3DG.%26aulast%3DDech%25C3%25AAne%26aufirst%3DA.%26atitle%3DTivantinib%2520for%2520the%2520Treatment%2520of%2520Hepatocellular%2520Carcinoma%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2017%26volume%3D18%26issue%3D7%26spage%3D727%26epage%3D733%26doi%3D10.1080%2F14656566.2017.1316376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilgour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. D.</span></span> <span> </span><span class="NLM_article-title">Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1855</span>– <span class="NLM_lpage">1862</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-0699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F1078-0432.CCR-11-0699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=22388515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFOmurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1855-1862&issue=7&author=A.+N.+Brooksauthor=E.+Kilgourauthor=P.+D.+Smith&title=Fibroblast+Growth+Factor+Signaling%3A+A+New+Therapeutic+Opportunity+in+Cancer&doi=10.1158%2F1078-0432.CCR-11-0699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer</span></div><div class="casAuthors">Brooks, A. Nigel; Kilgour, Elaine; Smith, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1855-1862</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling axis plays an important role in normal organ, vascular, and skeletal development.  Deregulation of FGFR signaling through genetic modification or overexpression of the receptors (or their ligands) has been obsd. in numerous tumor settings, whereas the FGF/FGFR axis also plays a key role in driving tumor angiogenesis.  A growing body of preclin. data shows that inhibition of FGFR signaling can result in antiproliferative and/or proapoptotic effects, both in vitro and in vivo, thus confirming the validity of the FGF/FGFR axis as a potential therapeutic target.  In the past, development of therapeutic approaches to target this axis has been hampered by our inability to develop FGFR-selective agents.  With the advent of a no. of new modalities for selectively inhibiting FGF/FGFR signaling, we are now in a unique position to test and validate clin. the many hypotheses that have been generated preclinically.  Clin Cancer Res; 18(7); 1855-62.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpysOACrAOfsbVg90H21EOLACvtfcHk0lhl7AS2oBzDNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFOmurk%253D&md5=a355aee7dc1b310177c6165b43896b75</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0699%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DA.%2BN.%26aulast%3DKilgour%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26atitle%3DFibroblast%2520Growth%2520Factor%2520Signaling%253A%2520A%2520New%2520Therapeutic%2520Opportunity%2520in%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26issue%3D7%26spage%3D1855%26epage%3D1862%26doi%3D10.1158%2F1078-0432.CCR-11-0699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Llovet, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villanueva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachenmayer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, R. S.</span></span> <span> </span><span class="NLM_article-title">Advances in Targeted Therapies for Hepatocellular Carcinoma in the Genomic Era</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">408</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2015.103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1038%2Fnrclinonc.2015.103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=26054909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOjt7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=408-424&issue=7&author=J.+M.+Llovetauthor=A.+Villanuevaauthor=A.+Lachenmayerauthor=R.+S.+Finn&title=Advances+in+Targeted+Therapies+for+Hepatocellular+Carcinoma+in+the+Genomic+Era&doi=10.1038%2Fnrclinonc.2015.103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in targeted therapies for hepatocellular carcinoma in the genomic era</span></div><div class="casAuthors">Llovet, Josep M.; Villanueva, Augusto; Lachenmayer, Anja; Finn, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">408-424</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mortality owing to liver cancer has increased in the past 20 years, and the latest ests. indicate that the global health burden of this disease will continue to grow.  Most patients with hepatocellular carcinoma (HCC) are still diagnosed at intermediate or advanced disease stages, where curative approaches are often not feasible.  Among the treatment options available, the mol. targeted agent sorafenib is able to significantly increase overall survival in these patients.  Thereafter, up to seven large, randomized phase III clin. trials investigating other mol. therapies in the first-line and second-line settings have failed to improve on the results obsd. with this agent.  Potential reasons for this include intertumor heterogeneity, issues with trial design and a lack of predictive biomarkers of response.  During the past 5 years, substantial advances in our knowledge of the human genome have provided a comprehensive picture of commonly mutated genes in patients with HCC.  This knowledge has not yet influenced clin. decision-making or current clin. practice guidelines.  In this Review the authors summarize the mol. concepts of progression, discuss the potential reasons for clin. trial failure and propose new concepts of drug development, which might lead to clin. implementation of emerging targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqC0YZE_nAFrVg90H21EOLACvtfcHk0lhl7AS2oBzDNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOjt7vM&md5=14f4caeb7cc1e58c51ef8a7aab9354cd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2015.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2015.103%26sid%3Dliteratum%253Aachs%26aulast%3DLlovet%26aufirst%3DJ.%2BM.%26aulast%3DVillanueva%26aufirst%3DA.%26aulast%3DLachenmayer%26aufirst%3DA.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DAdvances%2520in%2520Targeted%2520Therapies%2520for%2520Hepatocellular%2520Carcinoma%2520in%2520the%2520Genomic%2520Era%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D12%26issue%3D7%26spage%3D408%26epage%3D424%26doi%3D10.1038%2Fnrclinonc.2015.103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vainikka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joukov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennstrom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelicci, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alitalo, K.</span></span> <span> </span><span class="NLM_article-title">Signal Transduction by Fibroblast Growth Factor Receptor-4 (FGFR-4). Comparison with FGFR-1</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>269</i></span> (<span class="NLM_issue">28</span>),  <span class="NLM_fpage">18320</span>– <span class="NLM_lpage">18326</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1994&pages=18320-18326&issue=28&author=S.+Vainikkaauthor=V.+Joukovauthor=S.+Wennstromauthor=M.+Bergmanauthor=P.+G.+Pelicciauthor=K.+Alitalo&title=Signal+Transduction+by+Fibroblast+Growth+Factor+Receptor-4+%28FGFR-4%29.+Comparison+with+FGFR-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVainikka%26aufirst%3DS.%26aulast%3DJoukov%26aufirst%3DV.%26aulast%3DWennstrom%26aufirst%3DS.%26aulast%3DBergman%26aufirst%3DM.%26aulast%3DPelicci%26aufirst%3DP.%2BG.%26aulast%3DAlitalo%26aufirst%3DK.%26atitle%3DSignal%2520Transduction%2520by%2520Fibroblast%2520Growth%2520Factor%2520Receptor-4%2520%2528FGFR-4%2529.%2520Comparison%2520with%2520FGFR-1%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1994%26volume%3D269%26issue%3D28%26spage%3D18320%26epage%3D18326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liddle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastham-Anderson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonoda, J.</span></span> <span> </span><span class="NLM_article-title">FGF19 Regulates Cell Proliferation, Glucose and Bile Acid Metabolism Via FGFR4-Dependent and Independent Pathways</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">e17868</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0017868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1371%2Fjournal.pone.0017868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=21437243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt1Slsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e17868&issue=3&author=A.-L.+Wuauthor=S.+Coulterauthor=C.+Liddleauthor=A.+Wongauthor=J.+Eastham-Andersonauthor=D.+M.+Frenchauthor=A.+S.+Petersonauthor=J.+Sonoda&title=FGF19+Regulates+Cell+Proliferation%2C+Glucose+and+Bile+Acid+Metabolism+Via+FGFR4-Dependent+and+Independent+Pathways&doi=10.1371%2Fjournal.pone.0017868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways</span></div><div class="casAuthors">Wu, Ai-Luen; Coulter, Sally; Liddle, Christopher; Wong, Anne; Eastham-Anderson, Jeffrey; French, Dorothy M.; Peterson, Andrew S.; Sonoda, Junichiro</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e17868</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Fibroblast growth factor 19 (FGF19) is a hormone-like protein that regulates carbohydrate, lipid and bile acid metab.  At supra-physiol. doses, FGF19 also increases hepatocyte proliferation and induces hepatocellular carcinogenesis in mice.  Much of FGF19 activity is attributed to the activation of the liver enriched FGF receptor 4 (FGFR4), although FGF19 can activate other FGFRs in vitro in the presence of the coreceptor βKlotho (KLB).  In this report, we investigate the role of FGFR4 in mediating FGF19 activity by using Fgfr4 deficient mice as well as a variant of FGF19 protein (FGF19v) which is specifically impaired in activating FGFR4.  Our results demonstrate that FGFR4 activation mediates the induction of hepatocyte proliferation and the suppression of bile acid biosynthesis by FGF19, but is not essential for FGF19 to improve glucose and lipid metab. in high fat diet fed mice as well as in leptin-deficient ob/ob mice.  Thus, FGF19 acts through multiple receptor pathways to elicit pleiotropic effects in regulating nutrient metab. and cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2MXOOgDkQnrVg90H21EOLACvtfcHk0lhrVX8o7oSAag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt1Slsb8%253D&md5=e847efbc1da8d333bf08806904739349</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0017868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0017868%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DA.-L.%26aulast%3DCoulter%26aufirst%3DS.%26aulast%3DLiddle%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DA.%26aulast%3DEastham-Anderson%26aufirst%3DJ.%26aulast%3DFrench%26aufirst%3DD.%2BM.%26aulast%3DPeterson%26aufirst%3DA.%2BS.%26aulast%3DSonoda%26aufirst%3DJ.%26atitle%3DFGF19%2520Regulates%2520Cell%2520Proliferation%252C%2520Glucose%2520and%2520Bile%2520Acid%2520Metabolism%2520Via%2520FGFR4-Dependent%2520and%2520Independent%2520Pathways%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26issue%3D3%26spage%3De17868%26doi%3D10.1371%2Fjournal.pone.0017868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Repana, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, P.</span></span> <span> </span><span class="NLM_article-title">Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma</span>. <i>Diseases</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">294</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.3390/diseases3040294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.3390%2Fdiseases3040294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=28943626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFCgurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=294-305&issue=4&author=D.+Repanaauthor=P.+Ross&title=Targeting+FGF19%2FFGFR4+Pathway%3A+A+Novel+Therapeutic+Strategy+for+Hepatocellular+Carcinoma&doi=10.3390%2Fdiseases3040294"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting FGF19/FGFR4 pathway: a novel therapeutic strategy for hepatocellular carcinoma</span></div><div class="casAuthors">Repana, Dimitra; Ross, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">294-305</span>CODEN:
                <span class="NLM_cas:coden">DISECP</span>;
        ISSN:<span class="NLM_cas:issn">2079-9721</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is a lethal cancer with limited systemic therapeutic options.  Liver carcinogenesis is a complex procedure and various pathways have been found to be deregulated which are potential targets for novel treatments.  Aberrant signalling through FGF19 and its receptor FGFR4 seems to be the oncogenic driver for a subset of HCCs and is assocd. with poor prognosis.  Inhibition of the pathway in preclin. models has shown antitumor activity and has triggered further evaluation of this strategy to in vivo models.  This review aims to describe the role of the FGF19/FGFR4 pathway in hepatocellular carcinoma and its role as a potential predictive biomarker for novel targeted agents against FGF19/FGFR4 signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpREsw9FM-_67Vg90H21EOLACvtfcHk0lhrVX8o7oSAag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFCgurs%253D&md5=319e81e1d0135c096c86f024dc1694cf</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3390%2Fdiseases3040294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fdiseases3040294%26sid%3Dliteratum%253Aachs%26aulast%3DRepana%26aufirst%3DD.%26aulast%3DRoss%26aufirst%3DP.%26atitle%3DTargeting%2520FGF19%252FFGFR4%2520Pathway%253A%2520A%2520Novel%2520Therapeutic%2520Strategy%2520for%2520Hepatocellular%2520Carcinoma%26jtitle%3DDiseases%26date%3D2015%26volume%3D3%26issue%3D4%26spage%3D294%26epage%3D305%26doi%3D10.3390%2Fdiseases3040294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desnoyers, L. R.</span></span> <span> </span><span class="NLM_article-title">FGF19 and Cancer</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>728</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">194</span>, <span class="refDoi"> DOI: 10.1007/978-1-4614-0887-1_12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1007%2F978-1-4614-0887-1_12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=22396170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtlynsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=728&publication_year=2012&pages=183-194&author=B.+C.+Linauthor=L.+R.+Desnoyers&title=FGF19+and+Cancer&doi=10.1007%2F978-1-4614-0887-1_12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">FGF19 and cancer</span></div><div class="casAuthors">Lin, Benjamin C.; Desnoyers, Luc R.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">728</span>
        (<span class="NLM_cas:issue">Endocrine FGFs and Klothos</span>),
    <span class="NLM_cas:pages">183-194</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">0065-2598</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors (FGFs) and their cognate receptors, FGF receptors (FGFRs), play crit. roles in a variety of normal developmental and physiol. processes.  Numerous reports support a role for deregulation of FGF-FGFR signaling, whether it is at the ligand and/or receptor level, in tumor development and progression.  The FGF19-FGFR4 signaling axis has been implicated in the pathogenesis of several cancers, including hepatocellular carcinomas in mice and potentially in humans.  This chapter focuses on recent progress in the understanding of the mol. mechanisms of FGF19 action and its potential involvement in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO7H6HWklzy7Vg90H21EOLACvtfcHk0liX6X06Xqbweg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtlynsb3K&md5=083026a28a3e9da69ca46d32347c44be</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2F978-1-4614-0887-1_12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4614-0887-1_12%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DB.%2BC.%26aulast%3DDesnoyers%26aufirst%3DL.%2BR.%26atitle%3DFGF19%2520and%2520Cancer%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2012%26volume%3D728%26spage%3D183%26epage%3D194%26doi%3D10.1007%2F978-1-4614-0887-1_12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinzle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdem, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paur, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasl-Kraupp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grusch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marian, B.</span></span> <span> </span><span class="NLM_article-title">Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">2881</span>– <span class="NLM_lpage">2898</span>, <span class="refDoi"> DOI: 10.2174/13816128113199990594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.2174%2F13816128113199990594" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2881-2898&issue=17&author=C.+Heinzleauthor=Z.+Erdemauthor=J.+Paurauthor=B.+Grasl-Krauppauthor=K.+Holzmannauthor=M.+Gruschauthor=W.+Bergerauthor=B.+Marian&title=Is+Fibroblast+Growth+Factor+Receptor+4+a+Suitable+Target+of+Cancer+Therapy%3F&doi=10.2174%2F13816128113199990594"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F13816128113199990594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F13816128113199990594%26sid%3Dliteratum%253Aachs%26aulast%3DHeinzle%26aufirst%3DC.%26aulast%3DErdem%26aufirst%3DZ.%26aulast%3DPaur%26aufirst%3DJ.%26aulast%3DGrasl-Kraupp%26aufirst%3DB.%26aulast%3DHolzmann%26aufirst%3DK.%26aulast%3DGrusch%26aufirst%3DM.%26aulast%3DBerger%26aufirst%3DW.%26aulast%3DMarian%26aufirst%3DB.%26atitle%3DIs%2520Fibroblast%2520Growth%2520Factor%2520Receptor%25204%2520a%2520Suitable%2520Target%2520of%2520Cancer%2520Therapy%253F%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2014%26volume%3D20%26issue%3D17%26spage%3D2881%26epage%3D2898%26doi%3D10.2174%2F13816128113199990594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. C.</span></span> <span> </span><span class="NLM_article-title">Research Progress of FGFR4 Targeted Anti-Tumor Drug</span>. <i>Cancer. Res. Prev. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">65</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=26907461" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=61-65&author=D.+C.+Wuauthor=L.+Chenauthor=Y.+H.+Chenauthor=Z.+C.+Chen&title=Research+Progress+of+FGFR4+Targeted+Anti-Tumor+Drug"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DD.%2BC.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%2BH.%26aulast%3DChen%26aufirst%3DZ.%2BC.%26atitle%3DResearch%2520Progress%2520of%2520FGFR4%2520Targeted%2520Anti-Tumor%2520Drug%26jtitle%3DCancer.%2520Res.%2520Prev.%2520Treat.%26date%3D2016%26volume%3D44%26spage%3D61%26epage%3D65" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S.
E.</span></span> <span> </span><span class="NLM_article-title">Differential Expression of the Fibroblast Growth Factor Receptor (FGFR) Multigene Family in Normal Human Adult Tissues</span>. <i>J. Histochem. Cytochem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1019</span>, <span class="refDoi"> DOI: 10.1177/002215549704500710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1177%2F002215549704500710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=9212826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADyaK2sXkt1Cjtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1997&pages=1005-1019&issue=7&author=S.%0AE.+Hughes&title=Differential+Expression+of+the+Fibroblast+Growth+Factor+Receptor+%28FGFR%29+Multigene+Family+in+Normal+Human+Adult+Tissues&doi=10.1177%2F002215549704500710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues</span></div><div class="casAuthors">Hughes, Sian E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Histochemistry and Cytochemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1005-1019</span>CODEN:
                <span class="NLM_cas:coden">JHCYAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-1554</span>.
    
            (<span class="NLM_cas:orgname">Histochemical Society, Inc.</span>)
        </div><div class="casAbstract">This report describes a systematic anal. of the expression of the fibroblast growth factor receptor (FGFR) multigene family (FGFR1, FGFR2, FGFR3, and FGFR4) in archival serial sections of normal human adult tissues representing the major organ systems, using immunohistochem. techniques.  Polyclonal antisera specific for FGFR1, FGFR2, FGFR3, and FGFR4 and a three-stage immunoperoxidase technique were employed to det. the cellular distribution of these receptors at the protein level.  The expression profiles for the tissue-specific cellular localization of the FGFR multigene family demonstrated widespread and striking differential patterns of expression of individual receptors in the epithelia and mesenchyme of multiple tissues (stomach, salivary glands, pancreas, thymus, ureter, and cornea) and co-expression of FGFR1-4 in the same cell types of other tissues.  The widespread expression of FGFR1-4 in multiple organ systems suggests an important functional role in normal tissue homeostasis.  Differences in the spatial patterns of FGFR gene expression may generate functional diversity in response to FGF-1 and FGF-2, both of which bind with equally high affinity to more than one receptor subtype.  In vivo, this may lead to functional differences that are crucial for the regulation of normal physiol. processes and are responsible for the pathol. mechanisms that orchestrate various disease processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolfZivL4r94LVg90H21EOLACvtfcHk0liX6X06Xqbweg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkt1Cjtbc%253D&md5=ee0cd2d9676cd4e2fac30843c78d4f5a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1177%2F002215549704500710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F002215549704500710%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DS.%2BE.%26atitle%3DDifferential%2520Expression%2520of%2520the%2520Fibroblast%2520Growth%2520Factor%2520Receptor%2520%2528FGFR%2529%2520Multigene%2520Family%2520in%2520Normal%2520Human%2520Adult%2520Tissues%26jtitle%3DJ.%2520Histochem.%2520Cytochem.%26date%3D1997%26volume%3D45%26issue%3D7%26spage%3D1005%26epage%3D1019%26doi%3D10.1177%2F002215549704500710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goetz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beenken, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahimi, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eliseenkova, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubert, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linhardt, R. J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Molecular Insights into the Klotho-Dependent, Endocrine Mode of Action of Fibroblast Growth Factor 19 Subfamily Members</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3417</span>– <span class="NLM_lpage">3428</span>, <span class="refDoi"> DOI: 10.1128/MCB.02249-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1128%2FMCB.02249-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=17339340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltFCksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=3417-3428&issue=9&author=R.+Goetzauthor=A.+Beenkenauthor=O.+A.+Ibrahimiauthor=J.+Kalininaauthor=S.+K.+Olsenauthor=A.+V.+Eliseenkovaauthor=C.+Xuauthor=T.+A.+Neubertauthor=F.+Zhangauthor=R.+J.+Linhardt&title=Molecular+Insights+into+the+Klotho-Dependent%2C+Endocrine+Mode+of+Action+of+Fibroblast+Growth+Factor+19+Subfamily+Members&doi=10.1128%2FMCB.02249-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular insights into the Klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members</span></div><div class="casAuthors">Goetz, Regina; Beenken, Andrew; Ibrahimi, Omar A.; Kalinina, Juliya; Olsen, Shaun K.; Eliseenkova, Anna V.; Xu, ChongFeng; Neubert, Thomas A.; Zhang, Fuming; Linhardt, Robert J.; Yu, Xijie; White, Kenneth E.; Inagaki, Takeshi; Kliewer, Steven A.; Yamamoto, Masaya; Kurosu, Hiroshi; Ogawa, Yasushi; Kuro-o, Makoto; Lanske, Beate; Razzaque, Mohammed S.; Mohammadi, Moosa</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3417-3428</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Unique among fibroblast growth factors (FGFs), FGF19, -21, and -23 act in an endocrine fashion to regulate energy, bile acid, glucose, lipid, phosphate, and vitamin D homeostasis.  These FGFs require the presence of Klotho/βKlotho in their target tissues.  Here, the authors present the crystal structures of FGF19 alone and FGF23 in complex with sucrose octasulfate, a disaccharide chem. related to heparin.  The conformation of the heparin-binding region between β strands 10 and 12 in FGF19 and FGF23 diverges completely from the common conformation adopted by paracrine-acting FGFs.  A cleft between this region and the β1-β2 loop, the other heparin-binding region, precludes direct interaction between heparin/heparan sulfate and backbone atoms of FGF19/23.  This reduces the heparin-binding affinity of these ligands and confers endocrine function.  Klotho/βKlotho have evolved as a compensatory mechanism for the poor ability of heparin/heparan sulfate to promote binding of FGF19, -21, and -23 to their cognate receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8e4h5P_2HyLVg90H21EOLACvtfcHk0li6j_7v7cwWMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltFCksLY%253D&md5=b536406165299f062d8bc5f3e5de1882</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FMCB.02249-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.02249-06%26sid%3Dliteratum%253Aachs%26aulast%3DGoetz%26aufirst%3DR.%26aulast%3DBeenken%26aufirst%3DA.%26aulast%3DIbrahimi%26aufirst%3DO.%2BA.%26aulast%3DKalinina%26aufirst%3DJ.%26aulast%3DOlsen%26aufirst%3DS.%2BK.%26aulast%3DEliseenkova%26aufirst%3DA.%2BV.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DNeubert%26aufirst%3DT.%2BA.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DLinhardt%26aufirst%3DR.%2BJ.%26atitle%3DMolecular%2520Insights%2520into%2520the%2520Klotho-Dependent%252C%2520Endocrine%2520Mode%2520of%2520Action%2520of%2520Fibroblast%2520Growth%2520Factor%252019%2520Subfamily%2520Members%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2007%26volume%3D27%26issue%3D9%26spage%3D3417%26epage%3D3428%26doi%3D10.1128%2FMCB.02249-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicholes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frantz, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillard-Telm, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephan, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, D. M.</span></span> <span> </span><span class="NLM_article-title">A Mouse Model of Hepatocellular Carcinoma: Ectopic Expression of Fibroblast Growth Factor 19 in Skeletal Muscle of Transgenic Mice</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>160</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2295</span>– <span class="NLM_lpage">2307</span>, <span class="refDoi"> DOI: 10.1016/S0002-9440(10)61177-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1016%2FS0002-9440%2810%2961177-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=12057932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BD38XltFOrsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2002&pages=2295-2307&issue=6&author=K.+Nicholesauthor=S.+Guilletauthor=E.+Tomlinsonauthor=K.+Hillanauthor=B.+Wrightauthor=G.+D.+Frantzauthor=T.+A.+Phamauthor=L.+Dillard-Telmauthor=S.+P.+Tsaiauthor=J.-P.+Stephanauthor=J.+Stinsonauthor=T.+Stewartauthor=D.+M.+French&title=A+Mouse+Model+of+Hepatocellular+Carcinoma%3A+Ectopic+Expression+of+Fibroblast+Growth+Factor+19+in+Skeletal+Muscle+of+Transgenic+Mice&doi=10.1016%2FS0002-9440%2810%2961177-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A mouse model of hepatocellular carcinoma: Ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice</span></div><div class="casAuthors">Nicholes, Katrina; Guillet, Susan; Tomlinson, Elizabeth; Hillan, Kenneth; Wright, Barbara; Frantz, Gretchen D.; Pham, Thinh A.; Dillard-Telm, Lisa; Tsai, Siao Ping; Stephan, Jean-Philippe; Stinson, Jeremy; Stewart, Timothy; French, Dorothy M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2295-2307</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Most mouse models of hepatocellular carcinoma have expressed growth factors and oncogenes under the control of a liver-specific promoter.  In contrast, the authors describe here the formation of liver tumors in transgenic mice overexpressing human fibroblast growth factor 19 (FGF19) in skeletal muscle.  FGF19 transgenic mice had elevated hepatic α-fetoprotein mRNA as early as 2 mo of age, and hepatocellular carcinomas were evident by 10 mo of age.  Increased proliferation of pericentral hepatocytes was demonstrated by 5-bromo-2'-deoxyuridine incorporation in the FGF19 transgenic mice before tumor formation and in nontransgenic mice injected with recombinant FGF19 protein.  Areas of small cell dysplasia were initially evident pericentrally, and dysplastic/neoplastic foci throughout the hepatic lobule were glutamine synthetase-pos., suggestive of a pericentral origin.  Consistent with chronic activation of the Wingless/Wnt pathway, 44% of the hepatocellular tumors from FGF19 transgenic mice had nuclear staining for β-catenin.  Sequencing of the tumor DNA encoding β-catenin revealed point mutations that resulted in amino acid substitutions.  These findings suggest a previously unknown role for FGF19 in hepatocellular carcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9ekQaICJqerVg90H21EOLACvtfcHk0li6j_7v7cwWMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltFOrsbs%253D&md5=c3355b5f65fea242cfb7ee357e2dd4a7</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2961177-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252961177-7%26sid%3Dliteratum%253Aachs%26aulast%3DNicholes%26aufirst%3DK.%26aulast%3DGuillet%26aufirst%3DS.%26aulast%3DTomlinson%26aufirst%3DE.%26aulast%3DHillan%26aufirst%3DK.%26aulast%3DWright%26aufirst%3DB.%26aulast%3DFrantz%26aufirst%3DG.%2BD.%26aulast%3DPham%26aufirst%3DT.%2BA.%26aulast%3DDillard-Telm%26aufirst%3DL.%26aulast%3DTsai%26aufirst%3DS.%2BP.%26aulast%3DStephan%26aufirst%3DJ.-P.%26aulast%3DStinson%26aufirst%3DJ.%26aulast%3DStewart%26aufirst%3DT.%26aulast%3DFrench%26aufirst%3DD.%2BM.%26atitle%3DA%2520Mouse%2520Model%2520of%2520Hepatocellular%2520Carcinoma%253A%2520Ectopic%2520Expression%2520of%2520Fibroblast%2520Growth%2520Factor%252019%2520in%2520Skeletal%2520Muscle%2520of%2520Transgenic%2520Mice%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2002%26volume%3D160%26issue%3D6%26spage%3D2295%26epage%3D2307%26doi%3D10.1016%2FS0002-9440%2810%2961177-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonderfecht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiszmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecht, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupte, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">FGF19-Induced Hepatocyte Proliferation Is Mediated through FGFR4 Activation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>285</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">5165</span>– <span class="NLM_lpage">5170</span>, <span class="refDoi"> DOI: 10.1074/jbc.M109.068783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1074%2Fjbc.M109.068783" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=5165-5170&issue=8&author=X.+Wuauthor=H.+Geauthor=B.+Lemonauthor=S.+Vonderfechtauthor=J.+Weiszmannauthor=R.+Hechtauthor=J.+Gupteauthor=T.+Hagerauthor=Z.+Wangauthor=R.+Lindbergauthor=Y.+Li&title=FGF19-Induced+Hepatocyte+Proliferation+Is+Mediated+through+FGFR4+Activation&doi=10.1074%2Fjbc.M109.068783"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.068783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.068783%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DGe%26aufirst%3DH.%26aulast%3DLemon%26aufirst%3DB.%26aulast%3DVonderfecht%26aufirst%3DS.%26aulast%3DWeiszmann%26aufirst%3DJ.%26aulast%3DHecht%26aufirst%3DR.%26aulast%3DGupte%26aufirst%3DJ.%26aulast%3DHager%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLindberg%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DFGF19-Induced%2520Hepatocyte%2520Proliferation%2520Is%2520Mediated%2520through%2520FGFR4%2520Activation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26issue%3D8%26spage%3D5165%26epage%3D5170%26doi%3D10.1074%2Fjbc.M109.068783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, Y.</span></span> <span> </span><span class="NLM_article-title">FGF19 Promotes Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma Cells by Modulating the GSK3β/β-Catenin Signaling Cascade Via FGFR4 Activation</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">13575</span>– <span class="NLM_lpage">13586</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.6185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.18632%2Foncotarget.6185" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13575-13586&issue=12&author=H.+Zhaoauthor=F.+Lvauthor=G.+Liangauthor=X.+Huangauthor=G.+Wuauthor=W.+Zhangauthor=L.+Yuauthor=L.+Shiauthor=Y.+Teng&title=FGF19+Promotes+Epithelial-Mesenchymal+Transition+in+Hepatocellular+Carcinoma+Cells+by+Modulating+the+GSK3%CE%B2%2F%CE%B2-Catenin+Signaling+Cascade+Via+FGFR4+Activation&doi=10.18632%2Foncotarget.6185"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.6185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.6185%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLv%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DTeng%26aufirst%3DY.%26atitle%3DFGF19%2520Promotes%2520Epithelial-Mesenchymal%2520Transition%2520in%2520Hepatocellular%2520Carcinoma%2520Cells%2520by%2520Modulating%2520the%2520GSK3%25CE%25B2%252F%25CE%25B2-Catenin%2520Signaling%2520Cascade%2520Via%2520FGFR4%2520Activation%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D12%26spage%3D13575%26epage%3D13586%26doi%3D10.18632%2Foncotarget.6185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gauglhofer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paur, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrottmaier, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wingelhofer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naegelen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinzle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulte-Hermann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krupitza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grusch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasl-Kraupp, B.</span></span> <span> </span><span class="NLM_article-title">Fibroblast Growth Factor Receptor 4: A Putative Key Driver for the Aggressive Phenotype of Hepatocellular Carcinoma</span>. <i>Carcinogenesis</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2331</span>– <span class="NLM_lpage">2338</span>, <span class="refDoi"> DOI: 10.1093/carcin/bgu151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1093%2Fcarcin%2Fbgu151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=25031272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtF2ltLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=2331-2338&issue=10&author=C.+Gauglhoferauthor=J.+Paurauthor=W.+C.+Schrottmaierauthor=B.+Wingelhoferauthor=D.+Huberauthor=I.+Naegelenauthor=C.+Pirkerauthor=T.+Mohrauthor=C.+Heinzleauthor=K.+Holzmannauthor=B.+Marianauthor=R.+Schulte-Hermannauthor=W.+Bergerauthor=G.+Krupitzaauthor=M.+Gruschauthor=B.+Grasl-Kraupp&title=Fibroblast+Growth+Factor+Receptor+4%3A+A+Putative+Key+Driver+for+the+Aggressive+Phenotype+of+Hepatocellular+Carcinoma&doi=10.1093%2Fcarcin%2Fbgu151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma</span></div><div class="casAuthors">Gauglhofer, Christine; Paur, Jakob; Schrottmaier, Waltraud C.; Wingelhofer, Bettina; Huber, Daniela; Naegelen, Isabelle; Pirker, Christine; Mohr, Thomas; Heinzle, Christine; Holzmann, Klaus; Marian, Brigitte; Schulte-Hermann, Rolf; Berger, Walter; Krupitza, Georg; Grusch, Michael; Grasl-Kraupp, Bettina</div><div class="citationInfo"><span class="NLM_cas:title">Carcinogenesis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2331-2338</span>CODEN:
                <span class="NLM_cas:coden">CRNGDP</span>;
        ISSN:<span class="NLM_cas:issn">0143-3334</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Recently, we found upregulation of fibroblast growth factor receptor 4 (FGFR4) in a subset of hepatocellular carcinoma (HCC).  Here, we provide mechanistic insight into the role of FGFR4-mediated signalling for the aggressive behavior of HCC cells.  To overexpress FGFR4, hepatoma/hepatocarcinoma cells were transfected with a construct coding for FGFR4.  For downmodulation of endogenous FGFR4, we used small interfering RNA or adenoviral infection with dominant-neg. FGFR4 constructs being either kinase dead (kdFGFR4) or coding for the autoinhibitory sol. domain (solFGFR4).  FGFR4 overexpression in non-tumorigenic hepatocarcinoma cells significantly reduced cell-matrix adhesion, enabled cells to grow anchorage-independently in soft agar, to disintegrate the lymph-/blood-endothelial barrier for intra-/extravasation of tumor cells and to form tumors in SCID mice.  Transcriptome anal. revealed altered expression of genes involved in cell-matrix interactions.  Conversely, in highly tumorigenic cell lines, kdFGFR4 or solFGFR4 lowered the proportion of cells in S phase of the cell cycle, enhanced the G0/G1 and G2/M-phase proportions, reduced anchorage-independent growth in vitro and attenuated disintegration of the lymph-/blood-endothelium and tumor formation in vivo.  These findings were confirmed by altered expression profiles of genes being important for late stages of cell division.  Deregulated FGFR4 expression appears to be one of the key drivers of the malignant phenotype of HCC cells.  Accordingly, blockade of FGFR4-mediated signalling by sol. dominant-neg. constructs, like solFGFR4, may be a feasible and promising therapeutic approach to antagonize aggressive behavior of hepatoma/hepatocarcinoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM2s006KqFlrVg90H21EOLACvtfcHk0lh5C3RzOC-5qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtF2ltLfF&md5=4703b05e6584d855dbf2eace3ab07a47</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgu151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgu151%26sid%3Dliteratum%253Aachs%26aulast%3DGauglhofer%26aufirst%3DC.%26aulast%3DPaur%26aufirst%3DJ.%26aulast%3DSchrottmaier%26aufirst%3DW.%2BC.%26aulast%3DWingelhofer%26aufirst%3DB.%26aulast%3DHuber%26aufirst%3DD.%26aulast%3DNaegelen%26aufirst%3DI.%26aulast%3DPirker%26aufirst%3DC.%26aulast%3DMohr%26aufirst%3DT.%26aulast%3DHeinzle%26aufirst%3DC.%26aulast%3DHolzmann%26aufirst%3DK.%26aulast%3DMarian%26aufirst%3DB.%26aulast%3DSchulte-Hermann%26aufirst%3DR.%26aulast%3DBerger%26aufirst%3DW.%26aulast%3DKrupitza%26aufirst%3DG.%26aulast%3DGrusch%26aufirst%3DM.%26aulast%3DGrasl-Kraupp%26aufirst%3DB.%26atitle%3DFibroblast%2520Growth%2520Factor%2520Receptor%25204%253A%2520A%2520Putative%2520Key%2520Driver%2520for%2520the%2520Aggressive%2520Phenotype%2520of%2520Hepatocellular%2520Carcinoma%26jtitle%3DCarcinogenesis%26date%3D2014%26volume%3D35%26issue%3D10%26spage%3D2331%26epage%3D2338%26doi%3D10.1093%2Fcarcin%2Fbgu151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Sola, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uriarte, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latasa, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urtasun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bárcena-Varela, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elizalde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Ortigosa, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corrales, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Barrena, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berasain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, M. A.</span></span> <span> </span><span class="NLM_article-title">Fibroblast Growth Factor 15/19 in Hepatocarcinogenesis</span>. <i>Dig. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1159/000450905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1159%2F000450905" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=28249259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A280%3ADC%252BC1czhslymtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=158-165&issue=3&author=G.+Alvarez-Solaauthor=I.+Uriarteauthor=M.+U.+Latasaauthor=R.+Urtasunauthor=M.+B%C3%A1rcena-Varelaauthor=M.+Elizaldeauthor=M.+Jim%C3%A9nezauthor=C.+M.+Rodriguez-Ortigosaauthor=F.+J.+Corralesauthor=M.+G.+Fern%C3%A1ndez-Barrenaauthor=C.+Berasainauthor=M.+A.+Avila&title=Fibroblast+Growth+Factor+15%2F19+in+Hepatocarcinogenesis&doi=10.1159%2F000450905"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast Growth Factor 15/19 in Hepatocarcinogenesis</span></div><div class="casAuthors">Alvarez-Sola Gloria; Uriarte Iker; Latasa M Ujue; Urtasun Raquel; Barcena-Varela Marina; Elizalde Maria; Jimenez Maddalen; Rodriguez-Ortigosa Carlos M; Corrales Fernando J; Fernandez-Barrena Maite G; Berasain Carmen; Avila Matias A</div><div class="citationInfo"><span class="NLM_cas:title">Digestive diseases (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">158-165</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Advanced hepatocellular carcinoma (HCC) is a neoplastic disease with a very bad prognosis and increasing worldwide incidence.  HCCs are resistant to conventional chemotherapy and the multikinase inhibitor sorafenib is the only agent that has shown some clinical efficacy.  It is therefore important to identify key molecular mechanisms driving hepatocarcinogenesis for the development of more efficacious therapies.  However, HCCs are heterogeneous tumors and different molecular subclasses have been characterized.  This heterogeneity may underlie the poor performance of most of the targeted therapies so far tested in HCC patients.  The fibroblast growth factor 15/19 (FGF15/19), FGF receptor 4 (FGFR4) and beta-Klotho (KLB) correceptor signaling system, a key regulator of bile acids (BA) synthesis and intermediary metabolism, is emerging as an important player in hepatocarcinogenesis.  Key Messages: Aberrant signaling through the FGF15/19-FGFR4 pathway participates in the neoplastic behavior of HCC cells, promotes HCC development in mice and its overexpression has been characterized in a subset of HCC tumors from patients with poorer prognosis.  Pharmacological interference with FGF15/19-FGFR4 signaling inhibits experimental hepatocarcinogenesis, and specific FGFR4 inhibitors are currently being tested in selected HCC patients with tumoral FGF19-FGFR4/KLB expression.  CONCLUSIONS:  Interference with FGF19-FGFR4 signaling represents a novel strategy in HCC therapy.  Selection of candidate patients based on tumoral FGF19-FGFR4/KLB levels as biomarkers may result in increased efficacy of FGFR4-targeted drugs.  Nevertheless, attention should be paid to the potential on target toxic effects of FGFR4 inhibitors due to the key role of this signaling system in BA metabolism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSocD_7LO2XS669lAbTj9rGfW6udTcc2eZWGW7LPN_7Sbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czhslymtQ%253D%253D&md5=ad9215978bb9194257a33f74ffdcc881</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1159%2F000450905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000450905%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez-Sola%26aufirst%3DG.%26aulast%3DUriarte%26aufirst%3DI.%26aulast%3DLatasa%26aufirst%3DM.%2BU.%26aulast%3DUrtasun%26aufirst%3DR.%26aulast%3DB%25C3%25A1rcena-Varela%26aufirst%3DM.%26aulast%3DElizalde%26aufirst%3DM.%26aulast%3DJim%25C3%25A9nez%26aufirst%3DM.%26aulast%3DRodriguez-Ortigosa%26aufirst%3DC.%2BM.%26aulast%3DCorrales%26aufirst%3DF.%2BJ.%26aulast%3DFern%25C3%25A1ndez-Barrena%26aufirst%3DM.%2BG.%26aulast%3DBerasain%26aufirst%3DC.%26aulast%3DAvila%26aufirst%3DM.%2BA.%26atitle%3DFibroblast%2520Growth%2520Factor%252015%252F19%2520in%2520Hepatocarcinogenesis%26jtitle%3DDig.%2520Dis.%26date%3D2017%26volume%3D35%26issue%3D3%26spage%3D158%26epage%3D165%26doi%3D10.1159%2F000450905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahimi, O. A.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for Fibroblast Growth Factor Receptor Activation</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1016/j.cytogfr.2005.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1016%2Fj.cytogfr.2005.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=15863029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVOns7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=107-137&issue=2&author=M.+Mohammadiauthor=S.+K.+Olsenauthor=O.+A.+Ibrahimi&title=Structural+Basis+for+Fibroblast+Growth+Factor+Receptor+Activation&doi=10.1016%2Fj.cytogfr.2005.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for fibroblast growth factor receptor activation</span></div><div class="casAuthors">Mohammadi, Moosa; Olsen, Shaun K.; Ibrahimi, Omar A.</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-137</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  FGF signaling plays a ubiquitous role in human biol. as a regulator of embryonic development, homeostasis and regenerative processes.  In addn., aberrant FGF signaling leads to diverse human pathologies including skeletal, olfactory, and metabolic disorders as well as cancer.  FGFs execute their pleiotropic biol. actions by binding, dimerizing and activating cell surface FGF receptors (FGFRs).  Proper regulation of FGF-FGFR binding specificity is essential for the regulation of FGF signaling and is achieved through primary sequence variations among the 18 FGFs and seven FGFRs.  The severity of human skeletal syndromes arising from mutations that violate FGF-FGFR specificity is a testament to the importance of maintaining precision in FGF-FGFR specificity.  The discovery that heparin/heparan sulfate (HS) proteoglycans are required for FGF signaling led to numerous models for FGFR dimerization and heralded one of the most controversial issues in FGF signaling.  Recent crystallog. analyses have led to two fundamentally different models for FGFR dimerization.  These models differ in both the stoichiometry and minimal length of heparin required for dimerization, the quaternary arrangement of FGF, FGFR and heparin in the dimer, and in the mechanism of 1:1 FGF-FGFR recognition and specificity.  In this review, we provide an overview of recent structural and biochem. studies used to differentiate between the two crystallog. models.  Interestingly, the structural and biophys. analyses of naturally occurring pathogenic FGFR mutations have provided the most compelling and unbiased evidences for the correct mechanisms for FGF-FGFR dimerization and binding specificity.  The structural analyses of different FGF-FGFR complexes have also shed light on the intricate mechanisms detg. FGF-FGFR binding specificity and promiscuity and also provide a plausible explanation for the mol. basis of a large no. craniosynostosis mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7MZ4mx8ZrHrVg90H21EOLACvtfcHk0li2x564zBACFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVOns7g%253D&md5=746ae413058ad52c77d77a553003746c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2005.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2005.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DOlsen%26aufirst%3DS.%2BK.%26aulast%3DIbrahimi%26aufirst%3DO.%2BA.%26atitle%3DStructural%2520Basis%2520for%2520Fibroblast%2520Growth%2520Factor%2520Receptor%2520Activation%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2005%26volume%3D16%26issue%3D2%26spage%3D107%26epage%3D137%26doi%3D10.1016%2Fj.cytogfr.2005.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeehan, W. L.</span></span> <span> </span><span class="NLM_article-title">Alternately Spliced NH2-Terminal Immunoglobulin-Like Loop I in the Ectodomain of the Fibroblast Growth Factor (FGF) Receptor 1 Lowers Affinity for Both Heparin and FGF-1</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">10231</span>– <span class="NLM_lpage">10235</span>, <span class="refDoi"> DOI: 10.1074/jbc.270.17.10231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1074%2Fjbc.270.17.10231" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=10231-10235&issue=17&author=F.+Wangauthor=M.+Kanauthor=G.+Yanauthor=J.+Xuauthor=W.+L.+McKeehan&title=Alternately+Spliced+NH2-Terminal+Immunoglobulin-Like+Loop+I+in+the+Ectodomain+of+the+Fibroblast+Growth+Factor+%28FGF%29+Receptor+1+Lowers+Affinity+for+Both+Heparin+and+FGF-1&doi=10.1074%2Fjbc.270.17.10231"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.17.10231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.17.10231%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKan%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DMcKeehan%26aufirst%3DW.%2BL.%26atitle%3DAlternately%2520Spliced%2520NH2-Terminal%2520Immunoglobulin-Like%2520Loop%2520I%2520in%2520the%2520Ectodomain%2520of%2520the%2520Fibroblast%2520Growth%2520Factor%2520%2528FGF%2529%2520Receptor%25201%2520Lowers%2520Affinity%2520for%2520Both%2520Heparin%2520and%2520FGF-1%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26issue%3D17%26spage%3D10231%26epage%3D10235%26doi%3D10.1074%2Fjbc.270.17.10231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breeze, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span> <span> </span><span class="NLM_article-title">Structural Insights into FGFR Kinase Isoform Selectivity: Diverse Binding Modes of AZD4547 and Ponatinib in Complex with FGFR1 and FGFR4</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1764</span>– <span class="NLM_lpage">1774</span>, <span class="refDoi"> DOI: 10.1016/j.str.2014.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1016%2Fj.str.2014.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=25465127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVWrsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=1764-1774&issue=12&author=J.+A.+Tuckerauthor=T.+Kleinauthor=J.+Breedauthor=A.+L.+Breezeauthor=R.+Overmanauthor=C.+Phillipsauthor=R.+A.+Norman&title=Structural+Insights+into+FGFR+Kinase+Isoform+Selectivity%3A+Diverse+Binding+Modes+of+AZD4547+and+Ponatinib+in+Complex+with+FGFR1+and+FGFR4&doi=10.1016%2Fj.str.2014.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Insights into FGFR Kinase Isoform Selectivity: Diverse Binding Modes of AZD4547 and Ponatinib in Complex with FGFR1 and FGFR4</span></div><div class="casAuthors">Tucker, Julie A.; Klein, Tobias; Breed, Jason; Breeze, Alexander L.; Overman, Ross; Phillips, Chris; Norman, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1764-1774</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The fibroblast growth factor receptor (FGFR) family of receptor tyrosine kinases has been implicated in a wide variety of cancers.  Despite a high level of sequence homol. in the ATP-binding site, the majority of reported inhibitors are selective for the FGFR1-3 isoforms and display much reduced potency toward FGFR4, an exception being the Bcr-Abl inhibitor ponatinib.  Here we present the crystal structure of the FGFR4 kinase domain and show that both FGFR1 and FGFR4 kinase domains in complex with ponatinib adopt a DFG-out activation loop conformation.  Comparison with the structure of FGFR1 in complex with the candidate drug AZD4547, combined with kinetic characterization of the binding of ponatinib and AZD4547 to FGFR1 and FGFR4, sheds light on the obsd. differences in selectivity profiles and provides a rationale for developing FGFR4-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAm8d8S6VMy7Vg90H21EOLACvtfcHk0li2x564zBACFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVWrsb3K&md5=575188359fec7b4e586233a5585c259a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2014.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2014.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DTucker%26aufirst%3DJ.%2BA.%26aulast%3DKlein%26aufirst%3DT.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DBreeze%26aufirst%3DA.%2BL.%26aulast%3DOverman%26aufirst%3DR.%26aulast%3DPhillips%26aufirst%3DC.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26atitle%3DStructural%2520Insights%2520into%2520FGFR%2520Kinase%2520Isoform%2520Selectivity%253A%2520Diverse%2520Binding%2520Modes%2520of%2520AZD4547%2520and%2520Ponatinib%2520in%2520Complex%2520with%2520FGFR1%2520and%2520FGFR4%26jtitle%3DStructure%26date%3D2014%26volume%3D22%26issue%3D12%26spage%3D1764%26epage%3D1774%26doi%3D10.1016%2Fj.str.2014.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eliseenkova, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubert, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span> <span> </span><span class="NLM_article-title">A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine Kinases</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">730</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2007.06.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1016%2Fj.molcel.2007.06.028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=717-730&issue=5&author=H.+Chenauthor=J.+Maauthor=W.+Liauthor=A.+V.+Eliseenkovaauthor=C.+Xuauthor=T.+A.+Neubertauthor=W.+T.+Millerauthor=M.+Mohammadi&title=A+Molecular+Brake+in+the+Kinase+Hinge+Region+Regulates+the+Activity+of+Receptor+Tyrosine+Kinases&doi=10.1016%2Fj.molcel.2007.06.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2007.06.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2007.06.028%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DEliseenkova%26aufirst%3DA.%2BV.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DNeubert%26aufirst%3DT.%2BA.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DMohammadi%26aufirst%3DM.%26atitle%3DA%2520Molecular%2520Brake%2520in%2520the%2520Kinase%2520Hinge%2520Region%2520Regulates%2520the%2520Activity%2520of%2520Receptor%2520Tyrosine%2520Kinases%26jtitle%3DMol.%2520Cell%26date%3D2007%26volume%3D27%26issue%3D5%26spage%3D717%26epage%3D730%26doi%3D10.1016%2Fj.molcel.2007.06.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miduturu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stransky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifulco, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodous, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooijmans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shutes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzi, T.</span></span> <span> </span><span class="NLM_article-title">First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-1029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F2159-8290.CD-14-1029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=25776529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsVSrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=424-437&issue=4&author=M.+Hagelauthor=C.+Miduturuauthor=M.+Sheetsauthor=N.+Rubinauthor=W.+Wengauthor=N.+Stranskyauthor=N.+Bifulcoauthor=J.+L.+Kimauthor=B.+Hodousauthor=N.+Brooijmansauthor=A.+Shutesauthor=C.+Winterauthor=C.+Lengauerauthor=N.+E.+Kohlauthor=T.+Guzi&title=First+Selective+Small+Molecule+Inhibitor+of+FGFR4+for+the+Treatment+of+Hepatocellular+Carcinomas+with+an+Activated+FGFR4+Signaling+Pathway&doi=10.1158%2F2159-8290.CD-14-1029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway</span></div><div class="casAuthors">Hagel, Margit; Miduturu, Chandra; Sheets, Michael; Rubin, Nooreen; Weng, Weifan; Stransky, Nicolas; Bifulco, Neil; Kim, Joseph L.; Hodous, Brian; Brooijmans, Natasja; Shutes, Adam; Winter, Christopher; Lengauer, Christoph; Kohl, Nancy E.; Guzi, Timothy</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">424-437</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HCC cells with FGF19 gene amplification or overexpression and an intact FGFR4 signaling pathway are sensitive to potent and selective FGFR4 inhibition by the small mol. BLU9931 in vitro and in xenograft models.  Aberrant signaling through the fibroblast growth factor 19 (FGF19)/fibroblast growth factor receptor 4 (FGFR 4) signaling complex has been shown to cause hepatocellular carcinoma (HCC) in mice and has been implicated to play a similar role in humans.  We have developed BLU9931, a potent and irreversible small-mol. inhibitor of FGFR4, as a targeted therapy to treat patients with HCC whose tumors have an activated FGFR4 signaling pathway.  BLU9931 is exquisitely selective for FGFR4 vs. other FGFR family members and all other kinases.  BLU9931 shows remarkable antitumor activity in mice bearing an HCC tumor xenograft that overexpresses FGF19 due to amplification as well as a liver tumor xenograft that overexpresses FGF19 mRNA but lacks FGF19 amplification.  Approx. one third of patients with HCC whose tumors express FGF19 together with FGFR4 and its coreceptor klotho β (KLB) could potentially respond to treatment with an FGFR4 inhibitor.  These findings are the first demonstration of a therapeutic strategy that targets a subset of patients with HCC.  Significance: This article documents the discovery of BLU9931, a novel irreversible kinase inhibitor that specifically targets FGFR4 while sparing all other FGFR paralogs and demonstrates exquisite kinome selectivity.  BLU9931 is efficacious in tumors with an intact FGFR4 signaling pathway that includes FGF19, FGFR4, and KLB.  BLU9931 is the first FGFR4-selective mol. for the treatment of patients with HCC with aberrant FGFR4 signaling.  Cancer Discov; 5(4); 424-37. cpr2015 AACR.  See related commentary by Packer and Pollock, p. 355 This article is highlighted in the In This Issue feature, p.  333.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqcHNr-1ZnG7Vg90H21EOLACvtfcHk0ljK1irNaYwAhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsVSrtL8%253D&md5=4a69439aee01a3c090c14851a785362e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-1029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-1029%26sid%3Dliteratum%253Aachs%26aulast%3DHagel%26aufirst%3DM.%26aulast%3DMiduturu%26aufirst%3DC.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DRubin%26aufirst%3DN.%26aulast%3DWeng%26aufirst%3DW.%26aulast%3DStransky%26aufirst%3DN.%26aulast%3DBifulco%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DHodous%26aufirst%3DB.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DShutes%26aufirst%3DA.%26aulast%3DWinter%26aufirst%3DC.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DKohl%26aufirst%3DN.%2BE.%26aulast%3DGuzi%26aufirst%3DT.%26atitle%3DFirst%2520Selective%2520Small%2520Molecule%2520Inhibitor%2520of%2520FGFR4%2520for%2520the%2520Treatment%2520of%2520Hepatocellular%2520Carcinomas%2520with%2520an%2520Activated%2520FGFR4%2520Signaling%2520Pathway%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26issue%3D4%26spage%3D424%26epage%3D437%26doi%3D10.1158%2F2159-8290.CD-14-1029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gozgit, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span> <span> </span><span class="NLM_article-title">Ponatinib (AP24534), a Multi-Targeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">690</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F1535-7163.MCT-11-0450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=22238366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=690-699&issue=3&author=J.+M.+Gozgitauthor=M.+J.+Wongauthor=L.+Moranauthor=S.+Wardwellauthor=Q.+K.+Mohemmadauthor=N.+I.+Narasimhanauthor=W.+C.+Shakespeareauthor=F.+Wangauthor=T.+Clacksonauthor=V.+M.+Rivera&title=Ponatinib+%28AP24534%29%2C+a+Multi-Targeted+Pan-FGFR+Inhibitor+with+Activity+in+Multiple+FGFR-Amplified+or+Mutated+Cancer+Models&doi=10.1158%2F1535-7163.MCT-11-0450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models</span></div><div class="casAuthors">Gozgit, Joseph M.; Wong, Matthew J.; Moran, Lauren; Wardwell, Scott; Mohemmad, Qurish K.; Narasimhan, Narayana I.; Shakespeare, William C.; Wang, Frank; Clackson, Tim; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">690-699</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Members of the fibroblast growth factor receptor family of kinases (FGFR1-4) are dysregulated in multiple cancers.  Ponatinib (AP24534) is an oral multitargeted tyrosine kinase inhibitor being explored in a pivotal phase II trial in patients with chronic myelogenous leukemia due to its potent activity against BCR-ABL.  Ponatinib has also been shown to inhibit the in vitro kinase activity of all four FGFRs, prompting us to examine its potential as an FGFR inhibitor.  In Ba/F3 cells engineered to express activated FGFR1-4, ponatinib potently inhibited FGFR-mediated signaling and viability with IC50 values <40 nmol/L, with substantial selectivity over parental Ba/F3 cells.  In a panel of 14 cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon) and contg. FGFRs dysregulated by a variety of mechanisms, ponatinib inhibited FGFR-mediated signaling with IC50 values <40 nmol/L and inhibited cell growth with GI50 (concn. needed to reduce the growth of treated cells to half that of untreated cells) values of 7 to 181 nmol/L.  Daily oral dosing of ponatinib (10-30 mg/kg) to mice reduced tumor growth and inhibited signaling in all three tumor models examd.  Importantly, the potency of ponatinib in these models is similar to that previously obsd. in BCR-ABL-driven models and plasma levels of ponatinib that exceed the IC50 values for FGFR1-4 inhibition can be sustained in patients.  These results show that ponatinib is a potent pan-FGFR inhibitor and provide strong rationale for its evaluation in patients with FGFR-driven cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4-w5b7EPxLLVg90H21EOLACvtfcHk0livhu2AsOunKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKis70%253D&md5=771979af1fba727510e073d19335ef5a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0450%26sid%3Dliteratum%253Aachs%26aulast%3DGozgit%26aufirst%3DJ.%2BM.%26aulast%3DWong%26aufirst%3DM.%2BJ.%26aulast%3DMoran%26aufirst%3DL.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DPonatinib%2520%2528AP24534%2529%252C%2520a%2520Multi-Targeted%2520Pan-FGFR%2520Inhibitor%2520with%2520Activity%2520in%2520Multiple%2520FGFR-Amplified%2520or%2520Mutated%2520Cancer%2520Models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D3%26spage%3D690%26epage%3D699%26doi%3D10.1158%2F1535-7163.MCT-11-0450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hilberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krssak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kautschitsch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommergruber, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tontsch-Grunt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garin-Chesa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettig, W. J.</span></span> <span> </span><span class="NLM_article-title">BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4774</span>– <span class="NLM_lpage">4782</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-6307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F0008-5472.CAN-07-6307" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=4774-4782&issue=12&author=F.+Hilbergauthor=G.+J.+Rothauthor=M.+Krssakauthor=S.+Kautschitschauthor=W.+Sommergruberauthor=U.+Tontsch-Gruntauthor=P.+Garin-Chesaauthor=G.+Baderauthor=A.+Zoephelauthor=J.+Quantauthor=A.+Heckelauthor=W.+J.+Rettig&title=BIBF+1120%3A+Triple+Angiokinase+Inhibitor+with+Sustained+Receptor+Blockade+and+Good+Antitumor+Efficacy&doi=10.1158%2F0008-5472.CAN-07-6307"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-6307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-6307%26sid%3Dliteratum%253Aachs%26aulast%3DHilberg%26aufirst%3DF.%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26aulast%3DKrssak%26aufirst%3DM.%26aulast%3DKautschitsch%26aufirst%3DS.%26aulast%3DSommergruber%26aufirst%3DW.%26aulast%3DTontsch-Grunt%26aufirst%3DU.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DQuant%26aufirst%3DJ.%26aulast%3DHeckel%26aufirst%3DA.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26atitle%3DBIBF%25201120%253A%2520Triple%2520Angiokinase%2520Inhibitor%2520with%2520Sustained%2520Receptor%2520Blockade%2520and%2520Good%2520Antitumor%2520Efficacy%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26issue%3D12%26spage%3D4774%26epage%3D4782%26doi%3D10.1158%2F0008-5472.CAN-07-6307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachelot, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalenc, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Garcia, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurvitz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deudon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yovine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3693</span>– <span class="NLM_lpage">3702</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F1078-0432.CCR-13-0190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=23658459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtValt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=3693-3702&issue=13&author=F.+Andreauthor=T.+Bachelotauthor=M.+Camponeauthor=F.+Dalencauthor=J.+M.+Perez-Garciaauthor=S.+A.+Hurvitzauthor=N.+Turnerauthor=H.+Rugoauthor=J.+W.+Smithauthor=S.+Deudonauthor=M.+Shiauthor=Y.+Zhangauthor=A.+Kayauthor=D.+G.+Portaauthor=A.+Yovineauthor=J.+Baselga&title=Targeting+FGFR+with+Dovitinib+%28TKI258%29%3A+Preclinical+and+Clinical+Data+in+Breast+Cancer&doi=10.1158%2F1078-0432.CCR-13-0190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer</span></div><div class="casAuthors">Andre, Fabrice; Bachelot, Thomas; Campone, Mario; Dalenc, Florence; Perez-Garcia, Jose M.; Hurvitz, Sara A.; Turner, Nicholas; Rugo, Hope; Smith, John W.; Deudon, Stephanie; Shi, Michael; Zhang, Yong; Kay, Andrea; Graus Porta, Diana; Yovine, Alejandro; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3693-3702</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Fibroblast growth factor receptor 1 (FGFR1) and FGFR2 amplifications are obsd. in approx. 10% of breast cancers and are related to poor outcomes.  We evaluated whether dovitinib (TKI258), an inhibitor of FGFR1, FGFR2, and FGFR3, presented antitumor activity in FGFR-amplified breast cancers.  Exptl. Design: Preclin. activity of dovitinib was evaluated in both breast cancer cell lines and an FGFR1-amplified xenograft model (HBCx2).  Dovitinib was then evaluated in a phase II trial that included 4 groups of patients with human EGF receptor 2-neg. metastatic breast cancer on the basis of FGFR1 amplification and hormone receptor (HR) status.  FGFR1 amplification was assessed by silver in situ hybridization.  Preplanned retrospective analyses assessed predictive value of FGFR1, FGFR2, and FGF3 amplifications by quant. PCR (qPCR).  Results: Dovitinib monotherapy inhibits proliferation in FGFR1- and FGFR2-amplified, but not FGFR-normal, breast cancer cell lines.  Dovitinib also inhibits tumor growth in FGFR1-amplified breast cancer xenografts.  Eighty-one patients were enrolled in the trial.  Unconfirmed response or stable disease for more than 6 mo was obsd. in 5 (25%) and 1 (3%) patient(s) with FGFR1-amplified/HR-pos. and FGFR1-nonamplified/HR-pos. breast cancer.  When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-pos. patients, the mean redn. in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.  Conclusion: Dovitinib showed antitumor activity in FGFR-amplified breast cancer cell lines and may have activity in breast cancers with FGF pathway amplification.  Clin Cancer Res; 19(13); 3693-702. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqsUkPK9d9YrVg90H21EOLACvtfcHk0livhu2AsOunKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtValt7fK&md5=8c6e6a67540e15a67ea71c93eeda92a9</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0190%26sid%3Dliteratum%253Aachs%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DBachelot%26aufirst%3DT.%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DDalenc%26aufirst%3DF.%26aulast%3DPerez-Garcia%26aufirst%3DJ.%2BM.%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DRugo%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DJ.%2BW.%26aulast%3DDeudon%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKay%26aufirst%3DA.%26aulast%3DPorta%26aufirst%3DD.%2BG.%26aulast%3DYovine%26aufirst%3DA.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DTargeting%2520FGFR%2520with%2520Dovitinib%2520%2528TKI258%2529%253A%2520Preclinical%2520and%2520Clinical%2520Data%2520in%2520Breast%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26issue%3D13%26spage%3D3693%26epage%3D3702%26doi%3D10.1158%2F1078-0432.CCR-13-0190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBraud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahleda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dientsmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delmonte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cereda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litten, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Phase I/IIa Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Lucitanib in Advanced Solid Tumors</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2244</span>– <span class="NLM_lpage">2251</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdu390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1093%2Fannonc%2Fmdu390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=25193991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252Fos1Ohtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=2244-2251&issue=11&author=J.-C.+Soriaauthor=F.+DeBraudauthor=R.+Bahledaauthor=B.+Adamoauthor=F.+Andreauthor=R.+Dientsmannauthor=A.+Delmonteauthor=R.+Ceredaauthor=J.+Isaacsonauthor=J.+Litten&title=Phase+I%2FIIa+Study+Evaluating+the+Safety%2C+Efficacy%2C+Pharmacokinetics%2C+and+Pharmacodynamics+of+Lucitanib+in+Advanced+Solid+Tumors&doi=10.1093%2Fannonc%2Fmdu390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors</span></div><div class="casAuthors">Soria J-C; Bahleda R; Andre F; DeBraud F; Delmonte A; Adamo B; Tabernero J; Dienstmann R; Dientsmann R; Cereda R; Isaacson J; Litten J; Allen A; Camboni M G; Dubois F; Saba C; Robert R; D'Incalci M; Zucchetti M</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2244-51</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lucitanib is a potent, oral inhibitor fibroblast growth factor receptor types 1 and 2 (FGFR), vascular endothelial growth factor receptor types 1, 2, and 3 (VEGFR), platelet-derived growth factor receptor types α and β (PGFRα/β), which are essential kinases for tumor growth, survival, migration, and angiogenesis.  Several tumor types, including breast carcinoma, demonstrate amplification of fibroblast growth factor (FGF)-related genes.  There are no approved drugs for molecularly defined FGF-aberrant (FGFR1- or FGF3/4/19-amplified) tumors.  METHODS:  This open-label phase I/IIa study involved a dose-escalation phase to determine maximum tolerated dose (MTD), recommended dose (RD), and pharmacokinetics of lucitanib in patients with advanced solid tumors, followed by a dose-expansion phase to obtain preliminary evidence of efficacy in patients who could potentially benefit from treatment (i.e. with tumors harboring FGF-aberrant pathway or considered angiogenesis-sensitive).  RESULTS:  Doses from 5 to 30 mg were evaluated with dose-limiting toxic effects dominated by vascular endothelial growth factor (VEGF) inhibition-related toxic effects at the 30 mg dose level (one case of grade 4 depressed level of consciousness and two cases of grade 3 thrombotic microangiopathy).  The most common adverse events (all grades, all cohorts) were hypertension (91%), asthenia (42%), and proteinuria (57%).  Exposure increased with dose and t1/2 was 31-40 h, suitable for once daily administration.  Seventy-six patients were included.  All but one had stage IV; 42% had >3 lines of previous chemotherapy.  Sixty-four patients were assessable for response; 58 had measurable disease.  Clinical activity was observed at all doses tested with durable Response Evaluation Criteria In Solid Tumors (RECIST) partial responses in a variety of tumor types.  In the angiogenesis-sensitive group, objective RECIST response rate (complete response + partial response) was 26% (7 of 27) and progression-free survival (PFS) was 25 weeks.  In assessable FGF-aberrant breast cancer patients, 50% (6 of 12) achieved RECIST partial response with a median PFS of 40.4 weeks for all treated patients.  CONCLUSION:  Lucitanib has promising efficacy and a manageable side-effect profile.  The spectrum of activity observed demonstrates clinical benefit in both FGF-aberrant and angiogenesis-sensitive populations.  A comprehensive phase II program is planned.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSuRYQ_A4HkTGlSCSgBhwJFfW6udTcc2eYv3JwS9Fccm7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252Fos1Ohtg%253D%253D&md5=d63e6b7930eb5562b56fb4cd02900844</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu390%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.-C.%26aulast%3DDeBraud%26aufirst%3DF.%26aulast%3DBahleda%26aufirst%3DR.%26aulast%3DAdamo%26aufirst%3DB.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DDientsmann%26aufirst%3DR.%26aulast%3DDelmonte%26aufirst%3DA.%26aulast%3DCereda%26aufirst%3DR.%26aulast%3DIsaacson%26aufirst%3DJ.%26aulast%3DLitten%26aufirst%3DJ.%26atitle%3DPhase%2520I%252FIIa%2520Study%2520Evaluating%2520the%2520Safety%252C%2520Efficacy%252C%2520Pharmacokinetics%252C%2520and%2520Pharmacodynamics%2520of%2520Lucitanib%2520in%2520Advanced%2520Solid%2520Tumors%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26issue%3D11%26spage%3D2244%26epage%3D2251%26doi%3D10.1093%2Fannonc%2Fmdu390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Hare, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2009.09.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1016%2Fj.ccr.2009.09.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=19878872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFKltb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=401-412&issue=5&author=T.+O%E2%80%99Hareauthor=W.+C.+Shakespeareauthor=X.+Zhuauthor=C.+A.+Eideauthor=V.+M.+Riveraauthor=F.+Wangauthor=L.+T.+Adrianauthor=T.+Zhouauthor=W.-S.+Huangauthor=Q.+Xu&title=AP24534%2C+a+Pan-BCR-ABL+Inhibitor+for+Chronic+Myeloid+Leukemia%2C+Potently+Inhibits+the+T315I+Mutant+and+Overcomes+Mutation-Based+Resistance&doi=10.1016%2Fj.ccr.2009.09.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</span></div><div class="casAuthors">O'Hare, Thomas; Shakespeare, William C.; Zhu, Xiaotian; Eide, Christopher A.; Rivera, Victor M.; Wang, Frank; Adrian, Lauren T.; Zhou, Tianjun; Huang, Wei-Sheng; Xu, Qihong; Metcalf, Chester A., III; Tyner, Jeffrey W.; Loriaux, Marc M.; Corbin, Amie S.; Wardwell, Scott; Ning, Yaoyu; Keats, Jeffrey A.; Wang, Yihan; Sundaramoorthi, Raji; Thomas, Mathew; Zhou, Dong; Snodgrass, Joseph; Commodore, Lois; Sawyer, Tomi K.; Dalgarno, David C.; Deininger, Michael W. N.; Druker, Brian J.; Clackson, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">401-412</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to relapse and a switch to second-line therapy with nilotinib or dasatinib.  Despite three approved therapeutic options, the cross-resistant BCR-ABLT315I mutation and compd. mutants selected on sequential inhibitor therapy remain major clin. challenges.  We report design and preclin. evaluation of AP24534, a potent, orally available multitargeted kinase inhibitor active against T315I and other BCR-ABL mutants.  AP24534 inhibited all tested BCR-ABL mutants in cellular and biochem. assays, suppressed BCR-ABLT315I-driven tumor growth in mice, and completely abrogated resistance in cell-based mutagenesis screens.  Our work supports clin. evaluation of AP24534 as a pan-BCR-ABL inhibitor for treatment of CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox3g7ZYNXwLbVg90H21EOLACvtfcHk0lhowPQype539w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFKltb3N&md5=62a383734fc345b97647ba71aa7aee04</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2009.09.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2009.09.028%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DXu%26aufirst%3DQ.%26atitle%3DAP24534%252C%2520a%2520Pan-BCR-ABL%2520Inhibitor%2520for%2520Chronic%2520Myeloid%2520Leukemia%252C%2520Potently%2520Inhibits%2520the%2520T315I%2520Mutant%2520and%2520Overcomes%2520Mutation-Based%2520Resistance%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26issue%3D5%26spage%3D401%26epage%3D412%26doi%3D10.1016%2Fj.ccr.2009.09.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lesca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustin, M.</span></span> <span> </span><span class="NLM_article-title">Structural Analysis of the Human Fibroblast Growth Factor Receptor 4 Kinase</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>426</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">3744</span>– <span class="NLM_lpage">3756</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2014.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1016%2Fj.jmb.2014.09.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2014&pages=3744-3756&issue=22&author=E.+Lescaauthor=A.+Lammensauthor=R.+Huberauthor=M.+Augustin&title=Structural+Analysis+of+the+Human+Fibroblast+Growth+Factor+Receptor+4+Kinase&doi=10.1016%2Fj.jmb.2014.09.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2014.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2014.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DLesca%26aufirst%3DE.%26aulast%3DLammens%26aufirst%3DA.%26aulast%3DHuber%26aufirst%3DR.%26aulast%3DAugustin%26aufirst%3DM.%26atitle%3DStructural%2520Analysis%2520of%2520the%2520Human%2520Fibroblast%2520Growth%2520Factor%2520Receptor%25204%2520Kinase%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D426%26issue%3D22%26spage%3D3744%26epage%3D3756%26doi%3D10.1016%2Fj.jmb.2014.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zia-Ebrahimi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloem, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huss, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.-b.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, D. J.</span></span> <span> </span><span class="NLM_article-title">A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2200</span>– <span class="NLM_lpage">2210</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F1535-7163.MCT-11-0306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=21900693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2200-2210&issue=11&author=G.+Zhaoauthor=W.-Y.+Liauthor=D.+Chenauthor=J.+R.+Henryauthor=H.-Y.+Liauthor=Z.+Chenauthor=M.+Zia-Ebrahimiauthor=L.+Bloemauthor=Y.+Zhaiauthor=K.+Hussauthor=S.-b.+Pengauthor=D.+J.+McCann&title=A+Novel%2C+Selective+Inhibitor+of+Fibroblast+Growth+Factor+Receptors+That+Shows+a+Potent+Broad+Spectrum+of+Antitumor+Activity+in+Several+Tumor+Xenograft+Models&doi=10.1158%2F1535-7163.MCT-11-0306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models</span></div><div class="casAuthors">Zhao, Genshi; Li, Wei-ying; Chen, Daohong; Henry, James R.; Li, Hong-Yu; Chen, Zhaogen; Zia-Ebrahimi, Mohammad; Bloem, Laura; Zhai, Yan; Huss, Karen; Peng, Sheng-bin; McCann, Denis J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2200-2210</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor receptors (FGFR) are tyrosine kinases that are present in many types of endothelial and tumor cells and play an important role in tumor cell growth, survival, and migration as well as in maintaining tumor angiogenesis.  Overexpression of FGFRs or aberrant regulation of their activities has been implicated in many forms of human malignancies.  Therefore, targeting FGFRs represents an attractive strategy for development of cancer treatment options by simultaneously inhibiting tumor cell growth, survival, and migration as well as tumor angiogenesis.  Here, we describe a potent, selective, small-mol. FGFR inhibitor, (R)-(E)-2-(4-(2-(5-(1-(3,5-Dichloropyridin-4-yl)ethoxy)-1H-indazol-3yl)vinyl)-1H-pyrazol-1-yl)ethanol, designated as LY2874455.  This mol. is active against all 4 FGFRs, with a similar potency in biochem. assays.  It exhibits a potent activity against FGF/FGFR-mediated signaling in several cancer cell lines and shows an excellent broad spectrum of antitumor activity in several tumor xenograft models representing the major FGF/FGFR relevant tumor histologies including lung, gastric, and bladder cancers and multiple myeloma, and with a well-defined pharmacokinetic/pharmacodynamic relationship.  LY2874455 also exhibits a 6- to 9-fold in vitro and in vivo selectivity on inhibition of FGF- over VEGF-mediated target signaling in mice.  Furthermore, LY2874455 did not show VEGF receptor 2-mediated toxicities such as hypertension at efficacious doses.  Currently, this mol. is being evaluated for its potential use in the clinic.  Mol Cancer Ther; 10(11); 2200-10.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLrzAyZQK_grVg90H21EOLACvtfcHk0ljU5RfSrHoRBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7N&md5=eaf08fd213a836f48da2055e01bd9c29</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0306%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DW.-Y.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DLi%26aufirst%3DH.-Y.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZia-Ebrahimi%26aufirst%3DM.%26aulast%3DBloem%26aufirst%3DL.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DHuss%26aufirst%3DK.%26aulast%3DPeng%26aufirst%3DS.-b.%26aulast%3DMcCann%26aufirst%3DD.%2BJ.%26atitle%3DA%2520Novel%252C%2520Selective%2520Inhibitor%2520of%2520Fibroblast%2520Growth%2520Factor%2520Receptors%2520That%2520Shows%2520a%2520Potent%2520Broad%2520Spectrum%2520of%2520Antitumor%2520Activity%2520in%2520Several%2520Tumor%2520Xenograft%2520Models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26issue%3D11%26spage%3D2200%26epage%3D2210%26doi%3D10.1158%2F1535-7163.MCT-11-0306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">e0162491</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0162491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1371%2Fjournal.pone.0162491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=27618313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFKjt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0162491&issue=9&author=D.+Wuauthor=M.+Guoauthor=M.+A.+Philipsauthor=L.+Quauthor=L.+Jiangauthor=J.+Liauthor=X.+Chenauthor=Z.+Chenauthor=L.+Chenauthor=Y.+Chen&title=Crystal+Structure+of+the+FGFR4%2FLY2874455+Complex+Reveals+Insights+into+the+Pan-FGFR+Selectivity+of+LY2874455&doi=10.1371%2Fjournal.pone.0162491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the FGFR4/LY2874455 complex reveals insights into the pan-FGFR selectivity of LY2874455</span></div><div class="casAuthors">Wu, Daichao; Guo, Ming; Philips, Michael A.; Qu, Lingzhi; Jiang, Longying; Li, Jun; Chen, Xiaojuan; Chen, Zhuchu; Chen, Lin; Chen, Yongheng</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e0162491/1-e0162491/11</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Aberrant FGFR4 signaling has been documented abundantly in various human cancers.  The majority of FGFR inhibitors display significantly reduced potency toward FGFR4 compared to FGFR1-3.  However, LY2874455 has similar inhibition potency for FGFR1-4 with IC50 less than 6.4 nM.  To date, there is no published crystal structure of LY2874455 in complex with any kinase.  To better understand the pan-FGFR selectivity of LY2874455, we have detd. the crystal structure of the FGFR4 kinase domain bound to LY2874455 at a resoln. of 2.35 Å.  LY2874455, a type I inhibitor for FGFR4, binds to the ATP-binding pocket of FGFR4 in a DFG-in active conformation with three hydrogen bonds and a no. of van derWaals contacts.  After alignment of the kinase domain sequence of 4 FGFRs, and superposition of the ATP binding pocket of 4 FGFRs, our structural analyses reveal that the interactions of LY2874455 to FGFR4 are largely conserved in 4 FGFRs, explaining at least partly, the broad inhibitory activity of LY2874455 toward 4 FGFRs.  Consequently, our studies reveal new insights into the pan-FGFR selectivity of LY2874455 and provide a structural basis for developing novel FGFR inhibitors that target FGFR1-4 broadly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquH9zGVO6xArVg90H21EOLACvtfcHk0ljU5RfSrHoRBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFKjt74%253D&md5=444e0d350dac9196672923565b10f2ba</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0162491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0162491%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DPhilips%26aufirst%3DM.%2BA.%26aulast%3DQu%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520FGFR4%252FLY2874455%2520Complex%2520Reveals%2520Insights%2520into%2520the%2520Pan-FGFR%2520Selectivity%2520of%2520LY2874455%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26issue%3D9%26spage%3De0162491%26doi%3D10.1371%2Fjournal.pone.0162491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perera, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jovcheva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mevellec, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vialard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lange, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhulst, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulussen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van De Ven, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freyne, E.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1010</span>– <span class="NLM_lpage">1020</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F1535-7163.MCT-16-0589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=28341788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=1010-1020&issue=6&author=T.+P.+Pereraauthor=E.+Jovchevaauthor=L.+Mevellecauthor=J.+Vialardauthor=D.+De+Langeauthor=T.+Verhulstauthor=C.+Paulussenauthor=K.+Van+De+Venauthor=P.+Kingauthor=E.+Freyne&title=Discovery+and+Pharmacological+Characterization+of+JNJ-42756493+%28Erdafitinib%29%2C+a+Functionally+Selective+Small-Molecule+FGFR+Family+Inhibitor&doi=10.1158%2F1535-7163.MCT-16-0589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor</span></div><div class="casAuthors">Perera, Timothy P. S.; Jovcheva, Eleonora; Mevellec, Laurence; Vialard, Jorge; De Lange, Desiree; Verhulst, Tinne; Paulussen, Caroline; Van De Ven, Kelly; King, Peter; Freyne, Eddy; Rees, David C.; Squires, Matthew; Saxty, Gordon; Page, Martin; Murray, Christopher W.; Gilissen, Ron; Ward, George; Thompson, Neil T.; Newell, David R.; Cheng, Na; Xie, Liang; Yang, Jennifer; Platero, Suso J.; Karkera, Jayaprakash D.; Moy, Christopher; Angibaud, Patrick; Laquerre, Sylvie; Lorenzi, Matthew V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1010-1020</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Fibroblast growth factor (FGF) signaling plays crit. roles in key biol. processes ranging from embryogenesis to wound healing and has strong links to several hallmarks of cancer.  Genetic alterations in FGF receptor (FGFR) family members are assocd. with increased tumor growth, metastasis, angiogenesis, and decreased survival.  JNJ-42756493, erdafitinib, is an orally active small mol. with potent tyrosine kinase inhibitory activity against all four FGFR family members and selectivity vs. other highly related kinases.  JNJ-42756493 shows rapid uptake into the lysosomal compartment of cells in culture, which is assocd. with prolonged inhibition of FGFR signaling, possibly due to sustained release of the inhibitor.  In xenografts from human tumor cell lines or patient-derived tumor tissue with activating FGFR alterations, JNJ-42756493 administration results in potent and dose-dependent antitumor activity accompanied by pharmacodynamic modulation of phospho-FGFR and phospho-ERK in tumors.  The results of the current study provide a strong rationale for the clin. investigation of JNJ-42756493 in patients with tumors harboring FGFR pathway alterations.  Mol Cancer Ther; 16(6); 1010-20. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhJZ2AgFcI6LVg90H21EOLACvtfcHk0ljU5RfSrHoRBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht7g%253D&md5=2cae21f09ad519925ab2a3c760284b02</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0589%26sid%3Dliteratum%253Aachs%26aulast%3DPerera%26aufirst%3DT.%2BP.%26aulast%3DJovcheva%26aufirst%3DE.%26aulast%3DMevellec%26aufirst%3DL.%26aulast%3DVialard%26aufirst%3DJ.%26aulast%3DDe%2BLange%26aufirst%3DD.%26aulast%3DVerhulst%26aufirst%3DT.%26aulast%3DPaulussen%26aufirst%3DC.%26aulast%3DVan%2BDe%2BVen%26aufirst%3DK.%26aulast%3DKing%26aufirst%3DP.%26aulast%3DFreyne%26aufirst%3DE.%26atitle%3DDiscovery%2520and%2520Pharmacological%2520Characterization%2520of%2520JNJ-42756493%2520%2528Erdafitinib%2529%252C%2520a%2520Functionally%2520Selective%2520Small-Molecule%2520FGFR%2520Family%2520Inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26issue%3D6%26spage%3D1010%26epage%3D1020%26doi%3D10.1158%2F1535-7163.MCT-16-0589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunney, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiyagarajan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashford, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. V.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Landscape of Activating Cancer Mutations in FGFR Kinases and Their Differential Responses to Inhibitors in Clinical Use</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">24252</span>– <span class="NLM_lpage">24268</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.8132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.18632%2Foncotarget.8132" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=24252-24268&issue=17&author=H.+Pataniauthor=T.+D.+Bunneyauthor=N.+Thiyagarajanauthor=R.+A.+Normanauthor=D.+Oggauthor=J.+Breedauthor=P.+Ashfordauthor=A.+Pottertonauthor=M.+Edwardsauthor=S.+V.+Williams&title=Landscape+of+Activating+Cancer+Mutations+in+FGFR+Kinases+and+Their+Differential+Responses+to+Inhibitors+in+Clinical+Use&doi=10.18632%2Foncotarget.8132"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.8132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.8132%26sid%3Dliteratum%253Aachs%26aulast%3DPatani%26aufirst%3DH.%26aulast%3DBunney%26aufirst%3DT.%2BD.%26aulast%3DThiyagarajan%26aufirst%3DN.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DOgg%26aufirst%3DD.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DAshford%26aufirst%3DP.%26aulast%3DPotterton%26aufirst%3DA.%26aulast%3DEdwards%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DS.%2BV.%26atitle%3DLandscape%2520of%2520Activating%2520Cancer%2520Mutations%2520in%2520FGFR%2520Kinases%2520and%2520Their%2520Differential%2520Responses%2520to%2520Inhibitors%2520in%2520Clinical%2520Use%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D17%26spage%3D24252%26epage%3D24268%26doi%3D10.18632%2Foncotarget.8132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brameld, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venetsanakos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaStant, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6516</span>– <span class="NLM_lpage">6527</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00360</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00360" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVykt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6516-6527&issue=15&author=K.+Brameldauthor=T.+Owensauthor=E.+Vernerauthor=E.+Venetsanakosauthor=J.+Bradshawauthor=V.+Phanauthor=D.+Tamauthor=K.+Leungauthor=J.+Shuauthor=J.+LaStant&title=Discovery+of+the+Irreversible+Covalent+FGFR+Inhibitor+8-%283-%284-Acryloylpiperazin-1-yl%29propyl%29-6-%282%2C6-dichloro-3%2C5-dimethoxyphenyl%29-2-%28methylamino%29pyrido%5B2%2C3-d%5Dpyrimidin-7%288H%29-one+%28PRN1371%29+for+the+Treatment+of+Solid+Tumors&doi=10.1021%2Facs.jmedchem.7b00360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors</span></div><div class="casAuthors">Brameld, Ken A.; Owens, Timothy D.; Verner, Erik; Venetsanakos, Eleni; Bradshaw, J. Michael; Phan, Vernon T.; Tam, Danny; Leung, Kwan; Shu, Jin; LaStant, Jacob; Loughhead, David G.; Ton, Tony; Karr, Dane E.; Gerritsen, Mary E.; Goldstein, David M.; Funk, Jens Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6516-6527</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aberrant signaling of the FGF/FGFR pathway occurs frequently in cancers and is an oncogenic driver in many solid tumors.  Clin. validation of FGFR as a therapeutic target has been demonstrated in bladder, liver, lung, breast, and gastric cancers.  Our goal was to develop an irreversible covalent inhibitor of FGFR1-4 for use in oncol. indications.  An irreversible covalent binding mechanism imparts many desirable pharmacol. benefits including high potency, selectivity, and prolonged target inhibition.  Herein we report the structure-based design, medicinal chem. optimization, and unique ADME assays of our irreversible covalent drug discovery program which culminated in the discovery of compd. 34 (PRN1371), a highly selective and potent FGFR1-4 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpklTuvm1niy7Vg90H21EOLACvtfcHk0lizV14URjag3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVykt7fK&md5=987069b645d5e0e36ccda5e5c81520b9</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00360%26sid%3Dliteratum%253Aachs%26aulast%3DBrameld%26aufirst%3DK.%26aulast%3DOwens%26aufirst%3DT.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DVenetsanakos%26aufirst%3DE.%26aulast%3DBradshaw%26aufirst%3DJ.%26aulast%3DPhan%26aufirst%3DV.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLeung%26aufirst%3DK.%26aulast%3DShu%26aufirst%3DJ.%26aulast%3DLaStant%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520the%2520Irreversible%2520Covalent%2520FGFR%2520Inhibitor%25208-%25283-%25284-Acryloylpiperazin-1-yl%2529propyl%2529-6-%25282%252C6-dichloro-3%252C5-dimethoxyphenyl%2529-2-%2528methylamino%2529pyrido%255B2%252C3-d%255Dpyrimidin-7%25288H%2529-one%2520%2528PRN1371%2529%2520for%2520the%2520Treatment%2520of%2520Solid%2520Tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D15%26spage%3D6516%26epage%3D6527%26doi%3D10.1021%2Facs.jmedchem.7b00360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venetsanakos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brameld, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaStant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karr, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerritsen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span> <span> </span><span class="NLM_article-title">The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2668</span>– <span class="NLM_lpage">2676</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-0309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F1535-7163.MCT-17-0309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=28978721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWhsL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=2668-2676&issue=12&author=E.+Venetsanakosauthor=K.+A.+Brameldauthor=V.+T.+Phanauthor=E.+Vernerauthor=T.+D.+Owensauthor=Y.+Xingauthor=D.+Tamauthor=J.+LaStantauthor=K.+Leungauthor=D.+E.+Karrauthor=R.+J.+Hillauthor=M.+E.+Gerritsenauthor=D.+M.+Goldsteinauthor=J.+O.+Funkauthor=J.+M.+Bradshaw&title=The+Irreversible+Covalent+Fibroblast+Growth+Factor+Receptor+Inhibitor+PRN1371+Exhibits+Sustained+Inhibition+of+FGFR+after+Drug+Clearance&doi=10.1158%2F1535-7163.MCT-17-0309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance</span></div><div class="casAuthors">Venetsanakos, Eleni; Brameld, Ken A.; Phan, Vernon T.; Verner, Erik; Owens, Timothy D.; Xing, Yan; Tam, Danny; La Stant, Jacob; Leung, Kwan; Karr, Dane E.; Hill, Ronald J.; Gerritsen, Mary E.; Goldstein, David M.; Funk, Jens Oliver; Bradshaw, J. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2668-2676</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">An increasing no. of cancers are known to harbor mutations, translocations, or amplifications in the fibroblast growth factor receptor (FGFR) family of kinases.  The FGFR inhibitors evaluated in clin. trials to date have shown promise at treating these cancers.  Here, we describe PRN1371, an irreversible covalent inhibitor of FGFR1-4 targeting a cysteine within the kinase active site.  PRN1371 demonstrated strong FGFR potency and excellent kinome-wide selectivity in a no. of biochem. and cellular assays, including in various cancer cell lines exhibiting FGFR alterations.  Furthermore, PRN1371 maintained FGFR inhibition in vivo, not only when circulating drug levels were high but also after the drug had been cleared from circulation, indicating the possibility of sustained FGFR inhibition in the clinic without the need for continuous drug exposure.  Durable tumor regression was also obtained in multiple tumor xenografts and patient-derived tumor xenograft models and was sustained even using an intermittent dosing strategy that provided drug holidays.  PRN1371 is currently under clin. investigation for treatment of patients with solid tumors.  Mol Cancer Ther; 16(12); 2668-76. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzKzxYYE-2ZbVg90H21EOLACvtfcHk0lizV14URjag3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWhsL7J&md5=72f3af90d5e9a2f4060e5d0e4c8b99f9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0309%26sid%3Dliteratum%253Aachs%26aulast%3DVenetsanakos%26aufirst%3DE.%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DPhan%26aufirst%3DV.%2BT.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DXing%26aufirst%3DY.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLaStant%26aufirst%3DJ.%26aulast%3DLeung%26aufirst%3DK.%26aulast%3DKarr%26aufirst%3DD.%2BE.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGerritsen%26aufirst%3DM.%2BE.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520Irreversible%2520Covalent%2520Fibroblast%2520Growth%2520Factor%2520Receptor%2520Inhibitor%2520PRN1371%2520Exhibits%2520Sustained%2520Inhibition%2520of%2520FGFR%2520after%2520Drug%2520Clearance%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26issue%3D12%26spage%3D2668%26epage%3D2676%26doi%3D10.1158%2F1535-7163.MCT-17-0309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knoepfel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaul, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galuba, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trappe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voshol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genick, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunet-Lefeuvre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitsch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graus-Porta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span> <span> </span><span class="NLM_article-title">Approaches to Selective Fibroblast Growth Factor Receptor 4 Inhibition through Targeting the ATP-Pocket Middle-Hinge Region</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1604</span>– <span class="NLM_lpage">1613</span>, <span class="refDoi"> DOI: 10.1039/C7MD00213K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1039%2FC7MD00213K" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1604-1613&issue=8&author=R.+A.+Fairhurstauthor=T.+Knoepfelauthor=C.+Leblancauthor=N.+Buschmannauthor=C.+Gaulauthor=J.+Blankauthor=I.+Galubaauthor=J.+Trappeauthor=C.+Zouauthor=J.+Vosholauthor=C.+Genickauthor=P.+Brunet-Lefeuvreauthor=F.+Bitschauthor=D.+Graus-Portaauthor=P.+Furet&title=Approaches+to+Selective+Fibroblast+Growth+Factor+Receptor+4+Inhibition+through+Targeting+the+ATP-Pocket+Middle-Hinge+Region&doi=10.1039%2FC7MD00213K"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1039%2FC7MD00213K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00213K%26sid%3Dliteratum%253Aachs%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DKnoepfel%26aufirst%3DT.%26aulast%3DLeblanc%26aufirst%3DC.%26aulast%3DBuschmann%26aufirst%3DN.%26aulast%3DGaul%26aufirst%3DC.%26aulast%3DBlank%26aufirst%3DJ.%26aulast%3DGaluba%26aufirst%3DI.%26aulast%3DTrappe%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DC.%26aulast%3DVoshol%26aufirst%3DJ.%26aulast%3DGenick%26aufirst%3DC.%26aulast%3DBrunet-Lefeuvre%26aufirst%3DP.%26aulast%3DBitsch%26aufirst%3DF.%26aulast%3DGraus-Porta%26aufirst%3DD.%26aulast%3DFuret%26aufirst%3DP.%26atitle%3DApproaches%2520to%2520Selective%2520Fibroblast%2520Growth%2520Factor%2520Receptor%25204%2520Inhibition%2520through%2520Targeting%2520the%2520ATP-Pocket%2520Middle-Hinge%2520Region%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26issue%3D8%26spage%3D1604%26epage%3D1613%26doi%3D10.1039%2FC7MD00213K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xian, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">A Structure-Guided Approach to Creating Covalent FGFR Inhibitors</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1016%2Fj.chembiol.2010.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=20338520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=285-295&issue=3&author=W.+Zhouauthor=W.+Hurauthor=U.+McDermottauthor=A.+Duttauthor=W.+Xianauthor=S.+B.+Ficarroauthor=J.+Zhangauthor=S.+V.+Sharmaauthor=J.+Bruggeauthor=M.+Meyersonauthor=J.+Settlemanauthor=N.+S.+Gray&title=A+Structure-Guided+Approach+to+Creating+Covalent+FGFR+Inhibitors&doi=10.1016%2Fj.chembiol.2010.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A Structure-Guided Approach to Creating Covalent FGFR Inhibitors</span></div><div class="casAuthors">Zhou, Wenjun; Hur, Wooyoung; McDermott, Ultan; Dutt, Amit; Xian, Wa; Ficarro, Scott B.; Zhang, Jianming; Sharma, Sreenath V.; Brugge, Joan; Meyerson, Matthew; Settleman, Jeffrey; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-295</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The fibroblast growth factor receptor tyrosine kinases (FGFR1, 2, 3, and 4) represent promising therapeutic targets in a no. of cancers.  We have developed the first potent and selective irreversible inhibitor of FGFR1, 2, 3, and 4, which we named FIIN-1 that forms a covalent bond with cysteine 486 located in the P loop of the FGFR1 ATP binding site.  We demonstrated that the inhibitor potently inhibits Tel-FGFR1-transformed Ba/F3 cells (EC50 = 14 nM) as well as numerous FGFR-dependent cancer cell lines.  A biotin-derivatized version of the inhibitor, FIIN-1-biotin, was shown to covalently label FGFR1 at Cys486.  FIIN-1 is a useful probe of FGFR-dependent cellular phenomena and may provide a starting point of the development of therapeutically relevant irreversible inhibitors of wild-type and drug-resistant forms of FGFR kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqxMZh8QQP47Vg90H21EOLACvtfcHk0lhB6CjwZL-Abw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D&md5=0b7b084a073b1c6f30f38565a0e4db81</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DDutt%26aufirst%3DA.%26aulast%3DXian%26aufirst%3DW.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBrugge%26aufirst%3DJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520Structure-Guided%2520Approach%2520to%2520Creating%2520Covalent%2520FGFR%2520Inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26issue%3D3%26spage%3D285%26epage%3D295%26doi%3D10.1016%2Fj.chembiol.2010.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyana-Sundaram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khazanov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ateeq, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonigro, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vats, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.-F.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Identification of Targetable FGFR Gene Fusions in Diverse Cancers</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">636</span>– <span class="NLM_lpage">647</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F2159-8290.CD-13-0050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=23558953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVOrt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=636-647&issue=6&author=Y.-M.+Wuauthor=F.+Suauthor=S.+Kalyana-Sundaramauthor=N.+Khazanovauthor=B.+Ateeqauthor=X.+Caoauthor=R.+J.+Lonigroauthor=P.+Vatsauthor=R.+Wangauthor=S.-F.+Lin&title=Identification+of+Targetable+FGFR+Gene+Fusions+in+Diverse+Cancers&doi=10.1158%2F2159-8290.CD-13-0050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Targetable FGFR Gene Fusions in Diverse Cancers</span></div><div class="casAuthors">Wu, Yi-Mi; Su, Fengyun; Kalyana-Sundaram, Shanker; Khazanov, Nickolay; Ateeq, Bushra; Cao, Xuhong; Lonigro, Robert J.; Vats, Pankaj; Wang, Rui; Lin, Su-Fang; Cheng, Ann-Joy; Kunju, Lakshmi P.; Siddiqui, Javed; Tomlins, Scott A.; Wyngaard, Peter; Sadis, Seth; Roychowdhury, Sameek; Hussain, Maha H.; Feng, Felix Y.; Zalupski, Mark M.; Talpaz, Moshe; Pienta, Kenneth J.; Rhodes, Daniel R.; Robinson, Dan R.; Chinnaiyan, Arul M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">636-647</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Through a prospective clin. sequencing program for advanced cancers, four index cases were identified which harbor gene rearrangements of FGFR2, including patients with cholangiocarcinoma, breast cancer, and prostate cancer.  After extending our assessment of FGFR rearrangements across multiple tumor cohorts, we identified addnl. FGFR fusions with intact kinase domains in lung squamous cell cancer, bladder cancer, thyroid cancer, oral cancer, glioblastoma, and head and neck squamous cell cancer.  All FGFR fusion partners tested exhibit oligomerization capability, suggesting a shared mode of kinase activation.  Overexpression of FGFR fusion proteins induced cell proliferation.  Two bladder cancer cell lines that harbor FGFR3 fusion proteins exhibited enhanced susceptibility to pharmacol. inhibition in vitro and in vivo.  Because of the combinatorial possibilities of FGFR family fusion to a variety of oligomerization partners, clin. sequencing efforts, which incorporate transcriptome anal. for gene fusions, are poised to identify rare, targetable FGFR fusions across diverse cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodvZGzChrbzrVg90H21EOLACvtfcHk0lhB6CjwZL-Abw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVOrt7s%253D&md5=efee9f36e261e9df463e598f4018f07d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0050%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-M.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DKalyana-Sundaram%26aufirst%3DS.%26aulast%3DKhazanov%26aufirst%3DN.%26aulast%3DAteeq%26aufirst%3DB.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DLonigro%26aufirst%3DR.%2BJ.%26aulast%3DVats%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DS.-F.%26atitle%3DIdentification%2520of%2520Targetable%2520FGFR%2520Gene%2520Fusions%2520in%2520Diverse%2520Cancers%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26issue%3D6%26spage%3D636%26epage%3D647%26doi%3D10.1158%2F2159-8290.CD-13-0050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahleda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dienstmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Italiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazzah, A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced Solid Tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">30</span>),  <span class="NLM_fpage">3401</span>– <span class="NLM_lpage">3408</span>, <span class="refDoi"> DOI: 10.1200/JCO.2014.60.7341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1200%2FJCO.2014.60.7341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=26324363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFGrtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=3401-3408&issue=30&author=J.+Taberneroauthor=R.+Bahledaauthor=R.+Dienstmannauthor=J.+R.+Infanteauthor=A.+Mitaauthor=A.+Italianoauthor=E.+Calvoauthor=V.+Morenoauthor=B.+Adamoauthor=A.+Gazzah&title=Phase+I+Dose-Escalation+Study+of+JNJ-42756493%2C+an+Oral+Pan-Fibroblast+Growth+Factor+Receptor+Inhibitor%2C+in+Patients+with+Advanced+Solid+Tumors&doi=10.1200%2FJCO.2014.60.7341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I dose-escalation study of JNJ-42756493, an oral Pan-Fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors</span></div><div class="casAuthors">Tabernero, Josep; Bahleda, Rastislav; Dienstmann, Rodrigo; Infante, Jeffrey R.; Mita, Alain; Italiano, Antoine; Calvo, Emiliano; Moreno, Victor; Adamo, Barbara; Gazzah, Anas; Zhong, Bob; Platero, Suso J.; Smit, Johan W.; Stuyckens, Kim; Chatterjee-Kishore, Moitreyee; Radon, Jordi; Peddareddigari, Vijay; Luo, Feng R.; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">3401-3408</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: JNJ-42756493 is an orally administered pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.  This first-in-human study evaluates the safety, pharmacokinetics, and pharmaco-dynamics and defines the recommended phase II dose (RP2D) of JNJ-42756493.  Patients and Methods: Eligible patients with advanced solid tumors received escalating doses of JNJ-42756493 from 0.5 to 12 mg administered continuously daily or JNJ-42756493 10 or 12 mg administered intermittently (7 days on/7 days off).  Results: Sixty-five patients were enrolled.  The most common treatment-emergent adverse events included hyperphosphatemia (65%), asthenia (55%), dry mouth (45%), nail toxicity (35%), constipation (34%), decreased appetite (32%), and dysgeusia (31%).  Twenty-seven patients (42%) experi- enced grade ≥ 3 treatment-emergent adverse events, and one dose-limiting toxicity of grade 3 ALT elevation was obsd. at 12 mg daily.  Maximum-tolerated dose was not defined.  Nine milligrams daily was considered as the initial RP2D; however, tolerability was improved with intermittent schedules, and 10 mg administered on a 7-days-on/7-days-off schedule was considered the final RP2D.  Pharmacokinetics were linear, dose proportional, and predictable, with a half-life of 50 to 60 h.  Dose-dependent elevations in serum phosphate, a manifestation of pharmacodynamic effect, occurred in all patients starting at 4 mg daily.  Among 23 response- evaluable patients with tumor FGFR pathway alterations, four confirmed responses and one unconfirmed partial response were obsd. in patients with glioblastoma and urothelial and endometrial cancer (all with FGFR2 or FGFR3 translocations); 16 patients had stable disease.  Conclusion: JNJ-42756493 administered at 10 mg on a 7-days-on/7-days-off schedule achieved exposures at which clin. responses were obsd., demonstrated pharmacodynamic biomarker activity, and had a manageable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo08TfKyvsabVg90H21EOLACvtfcHk0ljK4qaasMWcEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFGrtb4%253D&md5=6d4a6b3c2f06f3d5d1a490cf9ffe44c5</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.60.7341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.60.7341%26sid%3Dliteratum%253Aachs%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DBahleda%26aufirst%3DR.%26aulast%3DDienstmann%26aufirst%3DR.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DMita%26aufirst%3DA.%26aulast%3DItaliano%26aufirst%3DA.%26aulast%3DCalvo%26aufirst%3DE.%26aulast%3DMoreno%26aufirst%3DV.%26aulast%3DAdamo%26aufirst%3DB.%26aulast%3DGazzah%26aufirst%3DA.%26atitle%3DPhase%2520I%2520Dose-Escalation%2520Study%2520of%2520JNJ-42756493%252C%2520an%2520Oral%2520Pan-Fibroblast%2520Growth%2520Factor%2520Receptor%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26issue%3D30%26spage%3D3401%26epage%3D3408%26doi%3D10.1200%2FJCO.2014.60.7341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nogova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez Garcia, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delord, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassier, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Kinase Inhibitor, in Patients with Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.67.2048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1200%2FJCO.2016.67.2048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=27870574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlensr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=157-165&issue=2&author=L.+Nogovaauthor=L.+V.+Sequistauthor=J.+M.+Perez+Garciaauthor=F.+Andreauthor=J.-P.+Delordauthor=M.+Hidalgoauthor=J.+H.+Schellensauthor=P.+A.+Cassierauthor=D.+R.+Camidgeauthor=M.+Schuler&title=Evaluation+of+BGJ398%2C+a+Fibroblast+Growth+Factor+Receptor+1%E2%80%933+Kinase+Inhibitor%2C+in+Patients+with+Advanced+Solid+Tumors+Harboring+Genetic+Alterations+in+Fibroblast+Growth+Factor+Receptors%3A+Results+of+a+Global+Phase+I%2C+Dose-Escalation+and+Dose-Expansion+Study&doi=10.1200%2FJCO.2016.67.2048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study</span></div><div class="casAuthors">Nogova, Lucia; Sequist, Lecia V.; Garcia, Jose Manuel Perez; Andre, Fabrice; Delord, Jean-Pierre; Hidalgo, Manuel; Schellens, Jan H. M.; Cassier, Philippe A.; Camidge, D. Ross; Schuler, Martin; Vaishampayan, Ulka; Burris, Howard; Tian, G. Gary; Campone, Mario; Wainberg, Zev A.; Lim, Wan-Teck; Lo Russo, Patricia; Shapiro, Geoffrey I.; Parker, Katie; Chen, Xueying; Choudhury, Somesh; Ringeisen, Francois; Graus-Porta, Diana; Porter, Dale; Isaacs, Randi; Buettner, Reinhard; Wolf, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-175</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: This two-part, first-in-human study was initiated in patient swith advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors (FGFRs) to det. the max. tolerated dose (MTD), the recommended phase II dose (RP2D), and the schedule, safety, pharmacokinetics, pharmacodynamics, and antitumor activity of oral BGJ398, a selective FGFR1-3 tyrosine kinase inhibitor.  Patients and Methods: Adult patients were treated with escalating dosages of BGJ398 5 to 150 mg once daily or 50 mg twice daily continuously in 28-day cycles.  During expansion at the MTD, patients with FGFR1-amplified squamous cell non-small-cell lung cancer (sqNSCLC; arm 1) or other solid tumors with FGFR genetic alterations (mutations/amplifications/fusions) received BGJ398 daily on a continuous schedule (arm 2), or on a 3-wk-on/1-wk-off schedule (arm 3).  Results: Data in 132 patients from the escalation and expansion arms are reported (May 15, 2015, cutoff).  The MTD, 125 mg daily, was detd. on the basis of dose-limiting toxicities in four patients (100 mg, grade 3 aminotransferase elevations [n = 1]; 125 mg, hyperphosphatemia [n = 1]; 150 mg, grade 1 corneal toxicity [n = 1] and grade 3 aminotransferase elevations [n = 1]).  Common adverse events in patients treated at the MTD (n = 57) included hyperphosphatemia (82.5%), constipation (50.9%), decreased appetite (45.6%), and stomatitis (45.6%).  A similar safety profile was obsd. using the 3-wk-on/1-wk-off schedule (RP2D).  However, adverse event-related dose adjustments/interruptions were less frequent with the 3-wk-on/1-wk-off (50.0%) vs. the continuous (73.7%) schedule.  Antitumor activity (seven partial responses [six confirmed]) was demonstrated with BGJ398 doses ≥ 100 mg in patients with FGFR1-amplified sqNSCLC and FGFR3-mutant bladder/urothelial cancer.  Conclusion: BGJ398 at the MTD/RP2D had a tolerable and manageable safety profile and showed antitumor activity in several tumor types, including FGFR1-amplified sqNSCLC and FGFR3-mutant bladder/urothelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0KJ9yf2nMQrVg90H21EOLACvtfcHk0ljK4qaasMWcEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlensr0%253D&md5=b0204f7a46eeaa059fe732ad35508ca9</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.67.2048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.67.2048%26sid%3Dliteratum%253Aachs%26aulast%3DNogova%26aufirst%3DL.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DPerez%2BGarcia%26aufirst%3DJ.%2BM.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DDelord%26aufirst%3DJ.-P.%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3DCassier%26aufirst%3DP.%2BA.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DSchuler%26aufirst%3DM.%26atitle%3DEvaluation%2520of%2520BGJ398%252C%2520a%2520Fibroblast%2520Growth%2520Factor%2520Receptor%25201%25E2%2580%25933%2520Kinase%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%2520Harboring%2520Genetic%2520Alterations%2520in%2520Fibroblast%2520Growth%2520Factor%2520Receptors%253A%2520Results%2520of%2520a%2520Global%2520Phase%2520I%252C%2520Dose-Escalation%2520and%2520Dose-Expansion%2520Study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26issue%3D2%26spage%3D157%26epage%3D165%26doi%3D10.1200%2FJCO.2016.67.2048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Degirolamo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbà, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moschetta, A.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Potential of the Endocrine Fibroblast Growth Factors FGF19, FGF21 and FGF23</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1038/nrd.2015.9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1038%2Fnrd.2015.9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=26567701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVCqsbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=51-69&issue=1&author=C.+Degirolamoauthor=C.+Sabb%C3%A0author=A.+Moschetta&title=Therapeutic+Potential+of+the+Endocrine+Fibroblast+Growth+Factors+FGF19%2C+FGF21+and+FGF23&doi=10.1038%2Fnrd.2015.9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23</span></div><div class="casAuthors">Degirolamo, Chiara; Sabba, Carlo; Moschetta, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-69</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The endocrine fibroblast growth factors (FGFs), FGF19, FGF21 and FGF23, are crit. for maintaining whole-body homeostasis, with roles in bile acid, glucose and lipid metab., modulation of vitamin D and phosphate homeostasis and metabolic adaptation during fasting.  Given these functions, the endocrine FGFs have therapeutic potential in a wide array of chronic human diseases, including obesity, type 2 diabetes, cancer, and kidney and cardiovascular disease.  However, the safety and feasibility of chronic endocrine FGF administration has been challenged, and FGF analogs and mimetics are now being investigated.  Here, we discuss current knowledge of the complex biol. of the endocrine FGFs and assess how this may be harnessed therapeutically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfwCe0KoqharVg90H21EOLACvtfcHk0ljK4qaasMWcEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVCqsbjK&md5=da061de431f62ea2bc62d046905f81bb</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2015.9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2015.9%26sid%3Dliteratum%253Aachs%26aulast%3DDegirolamo%26aufirst%3DC.%26aulast%3DSabb%25C3%25A0%26aufirst%3DC.%26aulast%3DMoschetta%26aufirst%3DA.%26atitle%3DTherapeutic%2520Potential%2520of%2520the%2520Endocrine%2520Fibroblast%2520Growth%2520Factors%2520FGF19%252C%2520FGF21%2520and%2520FGF23%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26issue%3D1%26spage%3D51%26epage%3D69%26doi%3D10.1038%2Fnrd.2015.9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bifulco, N.</span>; <span class="NLM_string-name">Dipietro, L. V.</span>; <span class="NLM_string-name">Hodous, B. L.</span>; <span class="NLM_string-name">Miduturu, C. V.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the Fibroblast Growth Factor Receptor</span>. <span class="NLM_patent">WO 2015061572</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=N.+Bifulco&author=L.+V.+Dipietro&author=B.+L.+Hodous&author=C.+V.+Miduturu&title=Inhibitors+of+the+Fibroblast+Growth+Factor+Receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBifulco%26aufirst%3DN.%26atitle%3DInhibitors%2520of%2520the%2520Fibroblast%2520Growth%2520Factor%2520Receptor%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R.</span>; <span class="NLM_string-name">Sarker, D.</span>; <span class="NLM_string-name">Macarulla, T.</span>; <span class="NLM_string-name">Yau, T.</span>; <span class="NLM_string-name">Choo, S. P.</span>; <span class="NLM_string-name">Meyer, T.</span>; <span class="NLM_string-name">Hollebecque, A.</span>; <span class="NLM_string-name">Whisenant, J.</span>; <span class="NLM_string-name">Sung, M.</span>; <span class="NLM_string-name">Yoon, J.</span></span>; <span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">365O Phase 1 Safety and Clinical Activity of BLU-554 in Advanced Hepatocellular Carcinoma (HCC)</span>.  <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume">28</span> (<span class="NLM_issue">Suppl. 5</span>),<span class="refDoi"> DOI: 10.1093/annonc/mdx367</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1093%2Fannonc%2Fmdx367" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&issue=Suppl.+5&author=R.+Kim&author=D.+Sarker&author=T.+Macarulla&author=T.+Yau&author=S.+P.+Choo&author=T.+Meyer&author=A.+Hollebecque&author=J.+Whisenant&author=M.+Sung&author=J.+Yoon&title=365O+Phase+1+Safety+and+Clinical+Activity+of+BLU-554+in+Advanced+Hepatocellular+Carcinoma+%28HCC%29&doi=10.1093%2Fannonc%2Fmdx367"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx367%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DR.%26atitle%3D365O%2520Phase%25201%2520Safety%2520and%2520Clinical%2520Activity%2520of%2520BLU-554%2520in%2520Advanced%2520Hepatocellular%2520Carcinoma%2520%2528HCC%2529%26jtitle%3DAnn.%2520Oncol.%26date%3D2017%26volume%3D28%26issue%3DSuppl.%25205%26doi%3D10.1093%2Fannonc%2Fmdx367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, D.</span>; <span class="NLM_string-name">Hao, M.</span>; <span class="NLM_string-name">Wang, J.</span>; <span class="NLM_string-name">Prajapati, S.</span>; <span class="NLM_string-name">Satoh, T.</span>; <span class="NLM_string-name">Selvaraj, A.</span></span> <span> </span><span class="NLM_article-title">Pyrimidine FGFR4 Inhibitors</span>. <span class="NLM_patent">WO 2015057938</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=D.+Reynolds&author=M.+Hao&author=J.+Wang&author=S.+Prajapati&author=T.+Satoh&author=A.+Selvaraj&title=Pyrimidine+FGFR4+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DReynolds%26aufirst%3DD.%26atitle%3DPyrimidine%2520FGFR4%2520Inhibitors%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffey, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prajapati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">6999</span>– <span class="NLM_lpage">7013</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-17-1865</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F0008-5472.CAN-17-1865" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=29247039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOgur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=6999-7013&issue=24&author=J.+J.+Joshiauthor=H.+Coffeyauthor=E.+Corcoranauthor=J.+Tsaiauthor=C.-L.+Huangauthor=K.+Ichikawaauthor=S.+Prajapatiauthor=M.-H.+Haoauthor=S.+Baileyauthor=J.+Wu&title=H3B-6527+Is+a+Potent+and+Selective+Inhibitor+of+FGFR4+in+FGF19-Driven+Hepatocellular+Carcinoma&doi=10.1158%2F0008-5472.CAN-17-1865"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma</span></div><div class="casAuthors">Joshi, Jaya Julie; Coffey, Heather; Corcoran, Erik; Tsai, Jennifer; Huang, Chia-Ling; Ichikawa, Kana; Prajapati, Sudeep; Hao, Ming-Hong; Bailey, Suzanna; Wu, Jeremy; Rimkunas, Victoria; Karr, Craig; Subramanian, Vanitha; Kumar, Pavan; MacKenzie, Crystal; Hurley, Raelene; Satoh, Takashi; Yu, Kun; Park, Eunice; Rioux, Nathalie; Kim, Amy; Lai, Weidong G.; Yu, Lihua; Zhu, Ping; Buonamici, Silvia; Larsen, Nicholas; Fekkes, Peter; Wang, John; Warmuth, Markus; Reynolds, Dominic J.; Smith, Peter G.; Selvaraj, Anand</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6999-7013</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activation of the fibroblast growth factor receptor FGFR4 by FGF19 drives hepatocellular carcinoma (HCC), a disease with few, if any, effective treatment options.  While a no. of pan-FGFR inhibitors are being clin. evaluated, their application to FGF19-driven HCC may be limited by dose-limiting toxicities mediated by FGFR1-3 receptors.  To evade the potential limitations of pan-FGFR inhibitors, we generated H3B-6527, a highly selective covalent FGFR4 inhibitor, through structure-guided drug design.  Studies in a panel of 40 HCC cell lines and 30 HCC PDX models showed that FGF19 expression is a predictive biomarker for H3B-6527 response.  Moreover, coadministration of the CDK4/6 inhibitor palbociclib in combination with H3B-6527 could effectively trigger tumor regression in a xenograft model of HCC.  Overall, our results offer preclin. proof of concept for H3B-6527 as a candidate therapeutic agent for HCC cases that exhibit increased expression of FGF19.  Cancer Res; 77(24); 6999-7013. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohONN1gEpft7Vg90H21EOLACvtfcHk0lhxkAbEuOQOZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOgur%252FI&md5=9d7ea6245e3b047aa85fc6961a88e5eb</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-1865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-1865%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DJ.%2BJ.%26aulast%3DCoffey%26aufirst%3DH.%26aulast%3DCorcoran%26aufirst%3DE.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DC.-L.%26aulast%3DIchikawa%26aufirst%3DK.%26aulast%3DPrajapati%26aufirst%3DS.%26aulast%3DHao%26aufirst%3DM.-H.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DH3B-6527%2520Is%2520a%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520FGFR4%2520in%2520FGF19-Driven%2520Hepatocellular%2520Carcinoma%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D24%26spage%3D6999%26epage%3D7013%26doi%3D10.1158%2F0008-5472.CAN-17-1865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guise, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00091</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00091" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsVWhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=543-548&issue=5&author=C.+Moauthor=Z.+Zhangauthor=C.+P.+Guiseauthor=X.+Liauthor=J.+Luoauthor=Z.+Tuauthor=Y.+Xuauthor=A.+V.+Pattersonauthor=J.+B.+Smaillauthor=X.+Renauthor=X.+Luauthor=K.+Ding&title=2-Aminopyrimidine+Derivatives+as+New+Selective+Fibroblast+Growth+Factor+Receptor+4+%28FGFR4%29+Inhibitors&doi=10.1021%2Facsmedchemlett.7b00091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors</span></div><div class="casAuthors">Mo, Cheng; Zhang, Zhang; Guise, Christopher P.; Li, Xueqiang; Luo, Jinfeng; Tu, Zhengchao; Xu, Yong; Patterson, Adam V.; Smaill, Jeff B.; Ren, Xiaomei; Lu, Xiaoyun; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">543-548</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 2-aminopyrimidine derivs. were designed and synthesized as highly selective FGFR4 inhibitors.  One of the most promising compds. I tightly bound FGFR4 with a Kd value of 3.3 nM and potently inhibited its enzymic activity with an IC50 value of 2.6 nM, but completely spared FGFR1/2/3.  The compd. selectively suppressed proliferation of breast cancer cells harboring dysregulated FGFR4 signaling with an IC50 value of 0.38 μM.  Furthermore, I exhibited extraordinary target specificity in a Kinome-wide screen against 468 kinases, with S(35) and S(10) selectivity scores of 0.01 and 0.007 at 1.0 μM, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqZiLAE7lPj7Vg90H21EOLACvtfcHk0lhxkAbEuOQOZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsVWhu7s%253D&md5=63aec200353c08090a50a9c5988442bd</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00091%26sid%3Dliteratum%253Aachs%26aulast%3DMo%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DGuise%26aufirst%3DC.%2BP.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DPatterson%26aufirst%3DA.%2BV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3D2-Aminopyrimidine%2520Derivatives%2520as%2520New%2520Selective%2520Fibroblast%2520Growth%2520Factor%2520Receptor%25204%2520%2528FGFR4%2529%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D5%26spage%3D543%26epage%3D548%26doi%3D10.1021%2Facsmedchemlett.7b00091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, W.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of Selective FGFR4 Inhibitors Via Scaffold Hopping</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2420</span>– <span class="NLM_lpage">2423</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1016%2Fj.bmcl.2017.04.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2420-2423&issue=11&author=Y.+Wangauthor=Z.+Chenauthor=M.+Daiauthor=P.+Sunauthor=C.+Wangauthor=Y.+Gaoauthor=H.+Zhaoauthor=W.+Zengauthor=L.+Shenauthor=W.+Mao&title=Discovery+and+Optimization+of+Selective+FGFR4+Inhibitors+Via+Scaffold+Hopping&doi=10.1016%2Fj.bmcl.2017.04.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DDai%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DZeng%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DMao%26aufirst%3DW.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Selective%2520FGFR4%2520Inhibitors%2520Via%2520Scaffold%2520Hopping%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D11%26spage%3D2420%26epage%3D2423%26doi%3D10.1016%2Fj.bmcl.2017.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knoepfel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripoche, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graus-Porta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wartmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galuba, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. A.</span></span> <span> </span><span class="NLM_article-title">2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00485</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00485" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Srsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=215-220&issue=3&author=T.+Knoepfelauthor=P.+Furetauthor=R.+Mahauthor=N.+Buschmannauthor=C.+Leblancauthor=S.+Ripocheauthor=D.+Graus-Portaauthor=M.+Wartmannauthor=I.+Galubaauthor=R.+A.+Fairhurst&title=2-Formylpyridyl+Ureas+as+Highly+Selective+Reversible-Covalent+Inhibitors+of+Fibroblast+Growth+Factor+Receptor+4&doi=10.1021%2Facsmedchemlett.7b00485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4</span></div><div class="casAuthors">Knoepfel, Thomas; Furet, Pascal; Mah, Robert; Buschmann, Nicole; Leblanc, Catherine; Ripoche, Sebastien; Graus-Porta, Diana; Wartmann, Markus; Galuba, Inga; Fairhurst, Robin A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-220</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As part of a project to identify FGFR4 selective inhibitors, scaffold morphing of a 2-formylquinoline amide hit identified series of 2-formylpyridine ureas (2-FPUs) with improved potency and physicochem. properties.  In particular, tetrahydronaphthyridine urea analogs with cellular activities below 30 nM have been identified.  Consistent with the hypothesized reversible-covalent mechanism of inhibition, the 2-FPUs exhibited slow binding kinetics, and the aldehyde, as the putative electrophile, could be demonstrated to be a key structural element for activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA1PRltYPuWrVg90H21EOLACvtfcHk0lhFU7h9PY-bow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Srsb4%253D&md5=fd43811b8a9e5f7a02f27096569423f8</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00485%26sid%3Dliteratum%253Aachs%26aulast%3DKnoepfel%26aufirst%3DT.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DMah%26aufirst%3DR.%26aulast%3DBuschmann%26aufirst%3DN.%26aulast%3DLeblanc%26aufirst%3DC.%26aulast%3DRipoche%26aufirst%3DS.%26aulast%3DGraus-Porta%26aufirst%3DD.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DGaluba%26aufirst%3DI.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26atitle%3D2-Formylpyridyl%2520Ureas%2520as%2520Highly%2520Selective%2520Reversible-Covalent%2520Inhibitors%2520of%2520Fibroblast%2520Growth%2520Factor%2520Receptor%25204%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D3%26spage%3D215%26epage%3D220%26doi%3D10.1021%2Facsmedchemlett.7b00485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buschmann, N.</span>; <span class="NLM_string-name">Fairhurst, R. A.</span>; <span class="NLM_string-name">Furet, P.</span>; <span class="NLM_string-name">Knöpfel, T.</span>; <span class="NLM_string-name">Leblanc, C.</span>; <span class="NLM_string-name">Mah, R.</span>; <span class="NLM_string-name">Nimsgern, P.</span>; <span class="NLM_string-name">Ripoche, S.</span>; <span class="NLM_string-name">Liao, L.</span>; <span class="NLM_string-name">Xiong, J.</span>; <span class="NLM_string-name">Zhao, X.</span>; <span class="NLM_string-name">Han, B.</span>; <span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">Ring-Fused Bicyclic Pyridyl Derivatives as FGFR4 Inhibitors</span>. U.S. Patent <span class="NLM_patent">9,266,883</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=N.+Buschmann&author=R.+A.+Fairhurst&author=P.+Furet&author=T.+Kn%C3%B6pfel&author=C.+Leblanc&author=R.+Mah&author=P.+Nimsgern&author=S.+Ripoche&author=L.+Liao&author=J.+Xiong&author=X.+Zhao&author=B.+Han&author=C.+Wang&title=Ring-Fused+Bicyclic+Pyridyl+Derivatives+as+FGFR4+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBuschmann%26aufirst%3DN.%26atitle%3DRing-Fused%2520Bicyclic%2520Pyridyl%2520Derivatives%2520as%2520FGFR4%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porta, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wartmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinyamu-Akunda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span> <span> </span><span class="NLM_article-title">NVP-FGF401, a First-in-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of HCC</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">13 Suppl.</span>),  <span class="NLM_fpage">2098</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-2098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F1538-7445.AM2017-2098" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=2098&issue=13+Suppl.&author=D.+G.+Portaauthor=A.+Weissauthor=R.+A.+Fairhurstauthor=M.+Wartmannauthor=C.+Stammauthor=F.+Reimannauthor=A.+Buhlesauthor=J.+Kinyamu-Akundaauthor=D.+Sterkerauthor=M.+Murakamiauthor=Y.+Wangauthor=J.+Engelmanauthor=F.+Hofmannauthor=W.+R.+Sellers&title=NVP-FGF401%2C+a+First-in-Class+Highly+Selective+and+Potent+FGFR4+Inhibitor+for+the+Treatment+of+HCC&doi=10.1158%2F1538-7445.AM2017-2098"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-2098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-2098%26sid%3Dliteratum%253Aachs%26aulast%3DPorta%26aufirst%3DD.%2BG.%26aulast%3DWeiss%26aufirst%3DA.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DStamm%26aufirst%3DC.%26aulast%3DReimann%26aufirst%3DF.%26aulast%3DBuhles%26aufirst%3DA.%26aulast%3DKinyamu-Akunda%26aufirst%3DJ.%26aulast%3DSterker%26aufirst%3DD.%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DEngelman%26aufirst%3DJ.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26atitle%3DNVP-FGF401%252C%2520a%2520First-in-Class%2520Highly%2520Selective%2520and%2520Potent%2520FGFR4%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520HCC%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D13%2520Suppl%26spage%3D2098%26doi%3D10.1158%2F1538-7445.AM2017-2098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinyamu-Akunda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wartmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span> <span> </span><span class="NLM_article-title">NVP-FGF401: Cellular and in Vivo Profile of a Novel Highly Potent and Selective FGFR4 Inhibitor for the Treatment of FGF19/FGFR4/KLB+ Tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">13 Suppl.</span>),  <span class="NLM_fpage">2103</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-2103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1158%2F1538-7445.AM2017-2103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=2103&issue=13+Suppl.&author=A.+Weissauthor=D.+G.+Portaauthor=F.+Reimannauthor=A.+Buhlesauthor=C.+Stammauthor=R.+A.+Fairhurstauthor=J.+Kinyamu-Akundaauthor=D.+Sterkerauthor=M.+Murakamiauthor=M.+Wartmannauthor=Y.+Wangauthor=J.+A.+Engelmanauthor=F.+Hofmannauthor=W.+R.+Sellers&title=NVP-FGF401%3A+Cellular+and+in+Vivo+Profile+of+a+Novel+Highly+Potent+and+Selective+FGFR4+Inhibitor+for+the+Treatment+of+FGF19%2FFGFR4%2FKLB%2B+Tumors&doi=10.1158%2F1538-7445.AM2017-2103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-2103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-2103%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DA.%26aulast%3DPorta%26aufirst%3DD.%2BG.%26aulast%3DReimann%26aufirst%3DF.%26aulast%3DBuhles%26aufirst%3DA.%26aulast%3DStamm%26aufirst%3DC.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DKinyamu-Akunda%26aufirst%3DJ.%26aulast%3DSterker%26aufirst%3DD.%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26atitle%3DNVP-FGF401%253A%2520Cellular%2520and%2520in%2520Vivo%2520Profile%2520of%2520a%2520Novel%2520Highly%2520Potent%2520and%2520Selective%2520FGFR4%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520FGF19%252FFGFR4%252FKLB%252B%2520Tumors%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D13%2520Suppl%26spage%3D2103%26doi%3D10.1158%2F1538-7445.AM2017-2103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schadt, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahl, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuersch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couttet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emotte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C.-H.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Bile Acid Sequestration by Cholestyramine Mitigates FGFR4 Inhibition-Induced Alt Elevation</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>163</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">278</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfy031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1093%2Ftoxsci%2Fkfy031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=29432567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGksr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2018&pages=265-278&issue=1&author=H.+S.+Schadtauthor=A.+Wolfauthor=J.+A.+Mahlauthor=K.+Wuerschauthor=P.+Couttetauthor=M.+Schwaldauthor=A.+Fischerauthor=M.+Lienardauthor=C.+Emotteauthor=C.-H.+Teng&title=Bile+Acid+Sequestration+by+Cholestyramine+Mitigates+FGFR4+Inhibition-Induced+Alt+Elevation&doi=10.1093%2Ftoxsci%2Fkfy031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Bile acid sequestration by cholestyramine mitigates FGFR4 inhibition-induced ALT elevation</span></div><div class="casAuthors">Schadt, Heiko S.; Wolf, Armin; Mahl, Joerg Andreas; Wuersch, Kuno; Couttet, Philippe; Schwald, Marianne; Fischer, Audrey; Lienard, Mathilde; Emotte, Corinne; Teng, Chi-Hse; Skuba, Elizabeth; Richardson, Terrilyn A.; Manenti, Luigi; Weiss, Andreas; Porta, Diana Graus; Fairhurst, Robin A.; Kullak-Ublick, Gerd A.; Chibout, Salah-Dine; Pognan, Francois; Kluwe, William; Kinyamu-Akunda, Jacqueline</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">265-278</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The FGF19-fibroblast growth factor receptor (FGFR4)-βKlotho (KLB) pathway plays an important role in the regulation of bile acid (BA) homeostasis.  Aberrant activation of this pathway has been described in the development and progression of a subset of liver cancers including hepatocellular carcinoma, establishing FGFR4 as an attractive therapeutic target for such solid tumors.  FGF401 is a highly selective FGFR4 kinase inhibitor being developed for hepatocellular carcinoma, currently in phase I/II clin. studies.  In preclin. studies in mice and dogs, oral administration of FGF401 led to induction of Cyp7a1, elevation of its peripheral marker 7alpha-hydroxy-4-cholesten-3-one, increased BA pool size, decreased serum cholesterol and diarrhea in dogs.  FGF401 was also assocd. with increases of serum aminotransferases, primarily alanine aminotransferase (ALT), in the absence of any observable adverse histopathol. in the liver, or in any other organs.  The authors hypothesized that the increase in ALT could be secondary to increased BAs and conducted an investigative study in dogs with FGF401 and coadministration of the BA sequestrant cholestyramine (CHO).  CHO prevented and reversed FGF401-related increases in ALT in dogs in parallel to its ability to reduce BAs in the circulation.  Correlation anal. showed that FGF401-mediated increases in ALT strongly correlated with increases in taurolithocholic acid and taurodeoxycholic acid, the major secondary BAs in dog plasma, indicating a mechanistic link between ALT elevation and changes in BA pool hydrophobicity.  Thus, CHO may offer the potential to mitigate elevations in serum amtransferases in human subjects that are caused by targeted FGFR4 inhibition and elevated intracellular BA levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4tzKAwiqUR7Vg90H21EOLACvtfcHk0li4qV9WYstK3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGksr%252FF&md5=e11d415d68d5b1b326a9547d35ef727a</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfy031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfy031%26sid%3Dliteratum%253Aachs%26aulast%3DSchadt%26aufirst%3DH.%2BS.%26aulast%3DWolf%26aufirst%3DA.%26aulast%3DMahl%26aufirst%3DJ.%2BA.%26aulast%3DWuersch%26aufirst%3DK.%26aulast%3DCouttet%26aufirst%3DP.%26aulast%3DSchwald%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DA.%26aulast%3DLienard%26aufirst%3DM.%26aulast%3DEmotte%26aufirst%3DC.%26aulast%3DTeng%26aufirst%3DC.-H.%26atitle%3DBile%2520Acid%2520Sequestration%2520by%2520Cholestyramine%2520Mitigates%2520FGFR4%2520Inhibition-Induced%2520Alt%2520Elevation%26jtitle%3DToxicol.%2520Sci.%26date%3D2018%26volume%3D163%26issue%3D1%26spage%3D265%26epage%3D278%26doi%3D10.1093%2Ftoxsci%2Fkfy031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span>; <span class="NLM_string-name">Sun, G.</span>; <span class="NLM_string-name">Tan, S.</span>; <span class="NLM_string-name">Liu, L.</span>; <span class="NLM_string-name">Bao, R.</span></span> <span> </span><span class="NLM_article-title">FGFR4 Inhibitor and Preparation Method and Use Thereof</span>. <span class="NLM_patent">WO 2018028664</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=P.+Gao&author=G.+Sun&author=S.+Tan&author=L.+Liu&author=R.+Bao&title=FGFR4+Inhibitor+and+Preparation+Method+and+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DP.%26atitle%3DFGFR4%2520Inhibitor%2520and%2520Preparation%2520Method%2520and%2520Use%2520Thereof%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanizaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aref, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Development of Covalent Inhibitors That Can Overcome Resistance to First-Generation FGFR Kinase Inhibitors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span> (<span class="NLM_issue">45</span>),  <span class="NLM_fpage">4869</span>– <span class="NLM_lpage">4877</span>, <span class="refDoi"> DOI: 10.1073/pnas.1403438111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;key=10.1073%2Fpnas.1403438111" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=4869-4877&issue=45&author=L.+Tanauthor=J.+Wangauthor=J.+Tanizakiauthor=Z.+Huangauthor=A.+R.+Arefauthor=M.+Rusanauthor=S.+J.+Zhuauthor=Y.+Zhangauthor=D.+Ercanauthor=R.+G.+Liaoauthor=M.+Capellettiauthor=W.+Zhouauthor=W.+Hurauthor=N.+Kimauthor=T.+Simauthor=S.+Gaudetauthor=D.+A.+Barbieauthor=J.+R.+Yehauthor=C.+H.+Yunauthor=P.+S.+Hammermanauthor=M.+Mohammadiauthor=P.+A.+Janneauthor=N.+S.+Gray&title=Development+of+Covalent+Inhibitors+That+Can+Overcome+Resistance+to+First-Generation+FGFR+Kinase+Inhibitors&doi=10.1073%2Fpnas.1403438111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1403438111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1403438111%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTanizaki%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAref%26aufirst%3DA.%2BR.%26aulast%3DRusan%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DLiao%26aufirst%3DR.%2BG.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DGaudet%26aufirst%3DS.%26aulast%3DBarbie%26aufirst%3DD.%2BA.%26aulast%3DYeh%26aufirst%3DJ.%2BR.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDevelopment%2520of%2520Covalent%2520Inhibitors%2520That%2520Can%2520Overcome%2520Resistance%2520to%2520First-Generation%2520FGFR%2520Kinase%2520Inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26issue%3D45%26spage%3D4869%26epage%3D4877%26doi%3D10.1073%2Fpnas.1403438111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blais, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubert, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span> <span> </span><span class="NLM_article-title">DFG-out Mode of Inhibition by an Irreversible Type-1 Inhibitor Capable of Overcoming Gate-Keeper Mutations in FGF Receptors</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1021/cb500674s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500674s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=299-309&issue=1&author=Z.+Huangauthor=L.+Tanauthor=H.+Wangauthor=Y.+Liuauthor=S.+Blaisauthor=J.+Dengauthor=T.+A.+Neubertauthor=N.+S.+Grayauthor=X.+Liauthor=M.+Mohammadi&title=DFG-out+Mode+of+Inhibition+by+an+Irreversible+Type-1+Inhibitor+Capable+of+Overcoming+Gate-Keeper+Mutations+in+FGF+Receptors&doi=10.1021%2Fcb500674s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fcb500674s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500674s%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DBlais%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DJ.%26aulast%3DNeubert%26aufirst%3DT.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DMohammadi%26aufirst%3DM.%26atitle%3DDFG-out%2520Mode%2520of%2520Inhibition%2520by%2520an%2520Irreversible%2520Type-1%2520Inhibitor%2520Capable%2520of%2520Overcoming%2520Gate-Keeper%2520Mutations%2520in%2520FGF%2520Receptors%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26issue%3D1%26spage%3D299%26epage%3D309%26doi%3D10.1021%2Fcb500674s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4xcu" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4xcu','PDB','4xcu'); return false;">PDB: 4xcu</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4v04" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4v04','PDB','4v04'); return false;">PDB: 4v04</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4uxq" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4uxq','PDB','4uxq'); return false;">PDB: 4uxq</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JKG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JKG','PDB','5JKG'); return false;">PDB: 5JKG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EW8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EW8','PDB','5EW8'); return false;">PDB: 5EW8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5nwz" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5nwz','PDB','5nwz'); return false;">PDB: 5nwz</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5vnd" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5vnd','PDB','5vnd'); return false;">PDB: 5vnd</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5nud" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5nud','PDB','5nud'); return false;">PDB: 5nud</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01531&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01531%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-6%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01531" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799ea42fdfb2290","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
